A molecular marker of artemisinin-resistant Plasmodiu

Nature

505, 50-55

DOI: 10.1038/nature12876

Citation Report

#	Article	IF	Citations
1	Metabolomics in the fight against malaria. Memorias Do Instituto Oswaldo Cruz, 2014, 109, 589-597.	0.8	29
2	Development of a Transgenic Plasmodium berghei Line (Pbpfpkg) Expressing the P. falciparum cGMP-Dependent Protein Kinase, a Novel Antimalarial Drug Target. PLoS ONE, 2014, 9, e96923.	1.1	5
3	Polymorphisms in K13 and Falcipain-2 Associated with Artemisinin Resistance Are Not Prevalent in Plasmodium falciparum Isolated from Ugandan Children. PLoS ONE, 2014, 9, e105690.	1.1	101
4	Efficacy of Mobile Phone Short Message Service (SMS) Reminders on Malaria Treatment Adherence and Day 3 Post-Treatment Reviews (SMS-RES-MAL) in Kenya: A Study Protocol. Journal of Clinical Trials, 2014, 05, 217.	0.1	1
5	Malaria on the Guiana Shield: a review of the situation in French Guiana. Memorias Do Instituto Oswaldo Cruz, 2014, 109, 525-533.	0.8	59
7	Spiroindolone KAE609 for Falciparum and Vivax Malaria. New England Journal of Medicine, 2014, 371, 403-410.	13.9	197
8	Spread of Artemisinin Resistance in Plasmodium falciparum Malaria. New England Journal of Medicine, 2014, 371, 411-423.	13.9	1,753
9	High prevalence of pfmdr1 N86Y and Y184F mutations inPlasmodium falciparumisolates from Bioko island, Equatorial Guinea. Pathogens and Global Health, 2014, 108, 339-343.	1.0	23
10	Plasmodium prevalence and artemisinin-resistant falciparum malaria in Preah Vihear Province, Cambodia: a cross-sectional population-based study. Malaria Journal, 2014, 13, 394.	0.8	37
11	Artemisinin resistance â€“ modelling the potential human and economic costs. Malaria Journal, 2014, 13, 452.	0.8	102
12	Open-label, randomized, non-inferiority clinical trial of artesunate-amodiaquine versus artemether-lumefantrine fixed-dose combinations in children and adults with uncomplicated falciparum malaria in CÃ´te d'Ivoire. Malaria Journal, 2014, 13, 439.	0.8	14
13	Recent progress in the development of anti-malarial quinolones. Malaria Journal, 2014, 13, 339.	0.8	63
14	Flow Cytometry-Based Analysis of Artemisinin-Resistant Plasmodium falciparum in the Ring-Stage Survival Assay. Antimicrobial Agents and Chemotherapy, 2014, 58, 4938-4940.	1.4	43
15	The Peculiarities and Paradoxes of Plasmodium Heme Metabolism. Annual Review of Microbiology, 2014, 68, 259-278.	2.9	96
16	Whole-Genome Scans Provide Evidence of Adaptive Evolution in Malawian Plasmodium falciparum Isolates. Journal of Infectious Diseases, 2014, 210, 1991-2000.	1.9	62
17	Influence of host iron status on Plasmodium falciparum infection. Frontiers in Pharmacology, 2014, 5, 84.	1.6	58
18	Antimalarial resistance: is vivax left behind?. Lancet Infectious Diseases, The, 2014, 14, 908-909.	4.6	1
19	Challenges of drug-resistant malaria. Parasite, 2014, 21, 61.	0.8	85

#	Article	IF	Citations
20	Treatment of Malaria â€" A Continuing Challenge. New England Journal of Medicine, 2014, 371, 474-475.	13.9	24
21	Efficacy of Artemisinin-Based Combination Treatments of Uncomplicated Falciparum Malaria in Under-Five-Year-Old Nigerian Children. American Journal of Tropical Medicine and Hygiene, 2014, 91, 925-935.	0.6	36
22	Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine. American Journal of Tropical Medicine and Hygiene, 2014, 91, 833-843.	0.6	204
23	Temporal trends in prevalence of Plasmodium falciparum drug resistance alleles over two decades of changing antimalarial policy in coastal Kenya. International Journal for Parasitology: Drugs and Drug Resistance, 2014, 4, 152-163.	1.4	34
24	Role of Pfmdr1 in In Vitro Plasmodium falciparum Susceptibility to Chloroquine, Quinine, Monodesethylamodiaquine, Mefloquine, Lumefantrine, and Dihydroartemisinin. Antimicrobial Agents and Chemotherapy, 2014, 58, 7032-7040.	1.4	65
25	Directional Selection at the pfmdr1, pfcrt, pfubp1, and pfap2mu Loci of Plasmodium falciparum in Kenyan Children Treated With ACT. Journal of Infectious Diseases, 2014, 210, 2001-2008.	1.9	108
26	Fighting the good fight: the role of militaries in malaria elimination in Southeast Asia. Trends in Parasitology, 2014, 30, 571-581.	1.5	16
27	Historical Patterns of Malaria Transmission in China. Advances in Parasitology, 2014, 86, 1-19.	1.4	58
28	Operational Research Needs Toward Malaria Elimination in China. Advances in Parasitology, 2014, 86, 109-133.	1.4	14
29	Analogs of natural aminoacyl-tRNA synthetase inhibitors clear malaria in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5508-17.	3.3	69
30	From the Genome to the Phenome: Tools to Understand the Basic Biology of Plasmodium falciparum. Journal of Eukaryotic Microbiology, 2014, 61, 655-671.	0.8	8
31	Estimation of malaria haplotype and genotype frequencies: a statistical approach to overcome the challenge associated with multiclonal infections. Malaria Journal, 2014, 13, 102.	0.8	23
32	Plasmodium falciparum Founder Populations in Western Cambodia Have Reduced Artemisinin Sensitivity In Vitro. Antimicrobial Agents and Chemotherapy, 2014, 58, 4935-4937.	1.4	47
33	Analysis of polymorphisms in Plasmodium falciparum genes related to drug resistance: a survey over four decades under different treatment policies in Brazil. Malaria Journal, 2014, 13, 372.	0.8	11
34	The diminishing returns of atovaquone-proguanil for elimination of Plasmodium falciparum malaria: modelling mass drug administration and treatment. Malaria Journal, 2014, 13, 380.	0.8	33
35	Mutations in Plasmodium falciparum K13 propeller gene from Bangladesh (2009â€"2013). Malaria Journal, 2014, 13, 431.	0.8	78
36	Limited polymorphisms in k13 gene in Plasmodium falciparum isolates from Dakar, Senegal in 2012â€"2013. Malaria Journal, 2014, 13, 472.	0.8	79
37	A genomic and evolutionary approach reveals non-genetic drug resistance in malaria. Genome Biology, 2014, 15, 511.	3.8	37

#	Article	IF	Citations
38	Drug resistance genomics of the antimalarial drug artemisinin. Genome Biology, 2014, 15, 544.	3.8	66
39	The contribution of mass drug administration to global health: past, present and future. Philosophical Transactions of the Royal Society B: Biological Sciences, 2014, 369, 20130434.	1.8	206
40	Chloroquine Remains Effective for Treating Plasmodium vivax Malaria in Pursat Province, Western Cambodia. Antimicrobial Agents and Chemotherapy, 2014, 58, 6270-6272.	1.4	13
41	Ex Vivo Activity of Endoperoxide Antimalarials, Including Artemisone and Arterolane, against Multidrug-Resistant Plasmodium falciparum Isolates from Cambodia. Antimicrobial Agents and Chemotherapy, 2014, 58, 5831-5840.	1.4	21
42	Effects of Mefloquine Use onPlasmodium vivaxMultidrug Resistance. Emerging Infectious Diseases, 2014, 20, 1629-1636.	2.0	23
43	Ecotope-Based Entomological Surveillance and Molecular Xenomonitoring of Multidrug Resistant Malaria Parasites inAnophelesVectors. Interdisciplinary Perspectives on Infectious Diseases, 2014, 2014, 1-17.	0.6	10
44	Malaria: a molecular marker of artemisinin resistance. Lancet, The, 2014, 383, 1439-1440.	6.3	22
45	Semi-synthetic artemisinin: a model for the use of synthetic biology in pharmaceutical development. Nature Reviews Microbiology, 2014, 12, 355-367.	13.6	556
46	Drug repurposing and human parasitic protozoan diseases. International Journal for Parasitology: Drugs and Drug Resistance, 2014, 4, 95-111.	1.4	286
47	Fluorine Modulates Species Selectivity in the Triazolopyrimidine Class of Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 5381-5394.	2.9	98
49	Tetraoxaneâ€“Pyrimidine Nitrile Hybrids as Dual Stage Antimalarials. Journal of Medicinal Chemistry, 2014, 57, 4916-4923.	2.9	43
50	Resistance nailed. Nature, 2014, 505, 30-31.	13.7	15
51	Cloudy with a chance of dustballs. Nature, 2014, 505, 31-32.	13.7	2
52	K13-Propeller Polymorphisms in Plasmodium falciparum Parasites From Sub-Saharan Africa. Journal of Infectious Diseases, 2015, 211, 1352-5.	1.9	203
53	Monitoring parasite diversity for malaria elimination in sub-Saharan Africa. Science, 2014, 345, 1297-1298.	6.0	39
54	Orally Bioavailable 6-Chloro-7-methoxy-4(1H)-quinolones Efficacious against Multiple Stages of Plasmodium. Journal of Medicinal Chemistry, 2014, 57, 8860-8879.	2.9	32
55	â€œRecyclingâ€•Classical Drugs for Malaria. Chemical Reviews, 2014, 114, 11164-11220.	23.0	104
56	Delayed Parasite Clearance after Treatment with Dihydroartemisinin-Piperaquine in Plasmodium falciparum Malaria Patients in Central Vietnam. Antimicrobial Agents and Chemotherapy, 2014, 58, 7049-7055.	1.4	88

#	Article	IF	Citations
57	Preliminary Investigation of the Contribution of CYP2A6, CYP2B6, and UGT1A9 Polymorphisms on Artesunate-Mefloquine Treatment Response in Burmese Patients with Plasmodium falciparum Malaria. American Journal of Tropical Medicine and Hygiene, 2014, 91, 361-366.	0.6	8
58	Artemisinin Combination Therapies and Malaria Parasite Drug Resistance: The Game Is Afoot. Journal of Infectious Diseases, 2014, 210, 335-337.	1.9	18
59	Chemical Interrogation of the Malaria Kinome. ChemBioChem, 2014, 15, 1920-1930.	1.3	29
60	Genomics illuminates parasite biology. Nature Reviews Microbiology, 2014, 12, 727-727.	13.6	2
61	Crystallographic and Receptor Binding Characterization of Plasmodium falciparum Macrophage Migration Inhibitory Factor Complexed to Two Potent Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 8652-8656.	2.9	18
62	Biochemical and Antiparasitic Properties of Inhibitors of the Plasmodium falciparum Calcium-Dependent Protein Kinase PfCDPK1. Antimicrobial Agents and Chemotherapy, 2014, 58, 6032-6043.	1.4	35
63	Molecular surveillance for artemisinin resistance in Africa. Lancet Infectious Diseases, The, 2014, 14, 668-670.	4.6	25
64	Genetic polymorphisms of candidate markers and in vitro susceptibility of Plasmodium falciparum isolates from Thai-Myanmar border in relation to clinical response to artesunateâ€“mefloquine combination. Acta Tropica, 2014, 139, 77-83.	0.9	6
65	Methyl-methoxylpyrrolinone and flavinium nucleus binding signatures on falcipain-2 active site. Journal of Molecular Modeling, 2014, 20, 2386.	0.8	15
66	Supergenomic Network Compression and the Discovery of EXP1 as a Glutathione Transferase Inhibited by Artesunate. Cell, 2014, 158, 916-928.	13.5	113
67	Malaria: an update on current chemotherapy. Expert Opinion on Pharmacotherapy, 2014, 15, 2219-2254.	0.9	53
68	Defining the biology component of the drug discovery strategy for malaria eradication. Trends in Parasitology, 2014, 30, 478-490.	1.5	41
69	A microarray platform and novel SNP calling algorithm to evaluate Plasmodium falciparum field samples of low DNA quantity. BMC Genomics, 2014, 15, 719.	1.2	18
70	Malaria control in Nepal 1963â€“2012: challenges on the path towards elimination. Malaria Journal, 2014, 13, 241.	0.8	32
71	Surveillance of artemether-lumefantrine associated Plasmodium falciparum multidrug resistance protein-1 gene polymorphisms in Tanzania. Malaria Journal, 2014, 13, 264.	0.8	27
72	Declining efficacy of artesunate plus sulphadoxine-pyrimethamine in northeastern India. Malaria Journal, 2014, 13, 284.	0.8	63
73	The challenge of artemisinin resistance can only be met by eliminating Plasmodium falciparum malaria across the Greater Mekong subregion. Malaria Journal, 2014, 13, 286.	0.8	31
74	Prevalence of pfmdr1 alleles associated with artemether-lumefantrine tolerance/resistance in Maputo before and after the implementation of artemisinin-based combination therapy. Malaria Journal, 2014, 13, 300.	0.8	31

#	Article	IF	Citations
75	N-Aryl-2-aminobenzimidazoles: Novel, Efficacious, Antimalarial Lead Compounds. Journal of Medicinal Chemistry, 2014, 57, 6642-6652.	2.9	37
76	DNA Repair Mechanisms and Their Biological Roles in the Malaria Parasite Plasmodium falciparum. Microbiology and Molecular Biology Reviews, 2014, 78, 469-486.	2.9	88
77	Plasmodium falciparum multidrug resistance protein 1 (pfmrp1) gene and its association with in vitro drug susceptibility of parasite isolates from north-east Myanmar. Journal of Antimicrobial Chemotherapy, 2014, 69, 2110-2117.	1.3	24
78	Plasmodium falciparum clearance in clinical studies of artesunate-amodiaquine and comparator treatments in sub-Saharan Africa, 1999â€“2009. Malaria Journal, 2014, 13, 114.	0.8	25
79	Optimal assay design for determining the in vitro sensitivity of ring stage Plasmodium falciparum to artemisinins. International Journal for Parasitology, 2014, 44, 893-899.	1.3	23
80	Single-cell genomics for dissection of complex malaria infections. Genome Research, 2014, 24, 1028-1038.	2.4	83
81	Genome editing in the human malaria parasite Plasmodium falciparum using the CRISPR-Cas9 system. Nature Biotechnology, 2014, 32, 819-821.	9.4	546
82	A better resolution for integrating methods for monitoring Plasmodium falciparum resistance to antimalarial drugs. Acta Tropica, 2014, 137, 44-57.	0.9	16
83	Aminoazabenzimidazoles, a Novel Class of Orally Active Antimalarial Agents. Journal of Medicinal Chemistry, 2014, 57, 5702-5713.	2.9	24
84	A barcode of organellar genome polymorphisms identifies the geographic origin of Plasmodium falciparum strains. Nature Communications, 2014, 5, 4052.	5.8	130
85	Understanding drug resistance in malaria parasites: Basic science for public health. Molecular and Biochemical Parasitology, 2014, 195, 107-114.	0.5	24
86	DNA sequence polymorphisms of the pfmdr1 gene and association of mutations with the pfcrt gene in Indian Plasmodium falciparum isolates. Infection, Genetics and Evolution, 2014, 26, 213-222.	1.0	9
87	Artemisinin resistance in Plasmodium falciparum. Lancet Infectious Diseases, The, 2014, 14, 449-450.	4.6	68
88	Prevailing Plasmodium falciparum dihydrofolate reductase 108-asparagine in Hodeidah, Yemen: A questionable sulfadoxineâ€“pyrimethamine partner within the artemisinin-based combination therapy. Acta Tropica, 2014, 132, 39-44.	0.9	5
89	Narrow-spectrum antimicrobials. , 2015, , 433-434.		0
90	Antiprotozoal agents derived from natural soil and aquatic actinobacteria: Fighting one microbe with another. , 2015, , 457-478.		0
91	Chemogenomic profiling of Plasmodium falciparum as a tool to aid antimalarial drug discovery. Scientific Reports, 2015, 5, 15930.	1.6	34
92	An outbreak of artemisinin resistant falciparum malaria in Eastern Thailand. Scientific Reports, 2015, 5, 17412.	1.6	50

#	Article	IF	Citations
93	Falciparum malaria molecular drug resistance in the Democratic Republic of Congo: a systematic review. Malaria Journal, 2015, 14, 354.	0.8	26
94	High-level Plasmodium falciparum sulfadoxine-pyrimethamine resistance with the concomitant occurrence of septuple haplotype in Tanzania. Malaria Journal, 2015, 14, 439.	0.8	30
95	Artemisinin (Qinghaosu): a mesmerizing drug that still puzzles. Science China Life Sciences, 2015, 58, 1151-1153.	2.3	6
96	Plasmodium parasites mount an arrest response to dihydroartemisinin, as revealed by whole transcriptome shotgun sequencing (RNA-seq) and microarray study. BMC Genomics, 2015, 16, 830.	1.2	29
97	Past and new challenges for malaria control and elimination: the role of operational research for innovation in designing interventions. Malaria Journal, 2015, 14, 279.	0.8	46
98	A molecular survey of acute febrile illnesses reveals Plasmodium vivax infections in Kedougou, southeastern Senegal. Malaria Journal, 2015, 14, 281.	0.8	34
99	Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis. Malaria Journal, 2015, 14, 359.	0.8	47
100	Network-based gene prediction for Plasmodium falciparum malaria towards genetics-based drug discovery. BMC Genomics, 2015, 16, S9.	1.2	26
101	Teaching old drugs new tricks to stop malaria invasion in its tracks. BMC Biology, 2015, 13, 72.	1.7	5
102	Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data. BMC Medicine, 2015, 13, 212.	2.3	61
103	Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigations. BMC Medicine, 2015, 13, 305.	2.3	143
104	Monitoring of efficacy and safety of artemisinin-based anti-malarials for treatment of uncomplicated malaria: a review of evidence of implementation of anti-malarial therapeutic efficacy trials in Tanzania. Malaria Journal, 2015, 14, 135.	0.8	35
105	Identification of large variation in pfcrt, pfmdr-1 and pfubp-1 markers in Plasmodium falciparum isolates from Ethiopia and Tanzania. Malaria Journal, 2015, 14, 264.	0.8	12
106	Inhibition by stabilization: targeting the Plasmodium falciparum aldolaseâ€“TRAP complex. Malaria Journal, 2015, 14, 324.	0.8	20
107	Significant geographical differences in prevalence of mutations associated with Plasmodium falciparum and Plasmodium vivax drug resistance in two regions from Papua New Guinea. Malaria Journal, 2015, 14, 399.	0.8	18
108	Tetracyclines in malaria. Malaria Journal, 2015, 14, 445.	0.8	84
109	An improved SYBR Green-1-based fluorescence method for the routine monitoring of Plasmodium falciparum resistance to anti-malarial drugs. Malaria Journal, 2015, 14, 481.	0.8	29
110	Evaluation of artemether-lumefantrine efficacy in the treatment of uncomplicated malaria and its association with pfmdr1, pfatpase6 and K13-propeller polymorphisms in Luanda, Angola. Malaria Journal, 2015, 14, 504.	0.8	34

#	Article	IF	Citations
111	Polymorphisms of the artemisinin resistant marker (K13) in Plasmodium falciparum parasite populations of Grande Comore Island 10Âyears after artemisinin combination therapy. Parasites and Vectors, 2015, 8, 634.	1.0	29
112	Balancing drug resistance and growth rates via compensatory mutations in the <scp>P</scp>lasmodium falciparum chloroquine resistance transporter. Molecular Microbiology, 2015, 97, 381-395.	1.2	47
113	Haemoglobin degradation underpins the sensitivity of early ring stage Plasmodium falciparum to artemisinins. Journal of Cell Science, 2016, 129, 406-16.	1.2	78
114	Understanding artemisinin-resistant malaria. Current Opinion in Infectious Diseases, 2015, 28, 417-425.	1.3	78
115	High Antimalarial Efficacy of Dihydroartemisininâ€“Piperaquine on the Chinaâ€“Myanmar Border: The Calm Before the Storm. American Journal of Tropical Medicine and Hygiene, 2015, 93, 436-437.	0.6	5
116	Artesunate Treatment of Severe Pediatric Malaria: A Review of Parasite Clearance Kinetics and Clinical Implications. Canadian Journal of Infectious Diseases and Medical Microbiology, 2015, 26, 237-240.	0.7	4
117	Polymorphism of Pfatpase6 in Cte dIvoire: Detection of a four new point mutations. African Journal of Biotechnology, 2015, 14, 304-309.	0.3	0
118	Novel Mutations in K13 Propeller Gene of Artemisinin-ResistantPlasmodium falciparum. Emerging Infectious Diseases, 2015, 21, 490-492.	2.0	65
119	Slow Clearance ofPlasmodium falciparumin Severe Pediatric Malaria, Uganda, 2011â€“2013. Emerging Infectious Diseases, 2015, 21, 1237-1239.	2.0	43
120	Induction of Multidrug Tolerance inPlasmodium falciparumby Extended Artemisinin Pressure. Emerging Infectious Diseases, 2015, 21, 1733-1741.	2.0	40
121	Role and Regulation of Glutathione Metabolism in Plasmodium falciparum. Molecules, 2015, 20, 10511-10534.	1.7	56
122	Polymorphisms in Plasmodium falciparum K13-Propeller in Angola and Mozambique after the Introduction of the ACTs. PLoS ONE, 2015, 10, e0119215.	1.1	36
123	Screening the Medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum Aminopeptidases, M1, M17 and M18. PLoS ONE, 2015, 10, e0115859.	1.1	34
124	The Stapled AKAP Disruptor Peptide STAD-2 Displays Antimalarial Activity through a PKA-Independent Mechanism. PLoS ONE, 2015, 10, e0129239.	1.1	13
125	Genetic Analysis and Species Specific Amplification of the Artemisinin Resistance-Associated Kelch Propeller Domain in P. falciparum and P. vivax. PLoS ONE, 2015, 10, e0136099.	1.1	37
126	Identification and Validation of a Potent Dual Inhibitor of the P. falciparum M1 and M17 Aminopeptidases Using Virtual Screening. PLoS ONE, 2015, 10, e0138957.	1.1	17
127	No Polymorphism inPlasmodium falciparum K13Propeller Gene in Clinical Isolates from Kolkata, India. Journal of Pathogens, 2015, 2015, 1-4.	0.9	13
128	The Impact of Pharmacokinetic Mismatched Antimalarial Drug Combinations on the Emergence and Spread of Drug Resistant Parasites. , 2015, , .		4

#	Article	IF	Citations
129	Antimalarial Drugs. , 2015, , 495-509.e5.		3
130	Malaria (Plasmodium Species). , 2015, , 3070-3090.e9.		9
131	Artemisinin Resistance: The More We Know, the More Complicated It Appears. Journal of Infectious Diseases, 2015, 211, 667-669.	1.9	3
132	Plasmodium falciparum genetic crosses in a humanized mouse model. Nature Methods, 2015, 12, 631-633.	9.0	74
133	Impact of Antimalarial Treatment and Chemoprevention on the Drug Sensitivity of Malaria Parasites Isolated from Ugandan Children. Antimicrobial Agents and Chemotherapy, 2015, 59, 3018-3030.	1.4	48
134	Three-dimensional structures in the design of therapeutics targeting parasitic protozoa: reflections on the past, present and future. Acta Crystallographica Section F, Structural Biology Communications, 2015, 71, 485-499.	0.4	6
135	Malaria medicines: a glass half full?. Nature Reviews Drug Discovery, 2015, 14, 424-442.	21.5	367
136	Modelling the Effects of Mass Drug Administration on the Molecular Epidemiology of Schistosomes. Advances in Parasitology, 2015, 87, 293-327.	1.4	8
137	Prevalence of K13-propeller polymorphisms in Plasmodium falciparum from China-Myanmar border in 2007â€“2012. Malaria Journal, 2015, 14, 168.	0.8	71
138	Evidence of Plasmodium falciparum Malaria Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical Assessment. Antimicrobial Agents and Chemotherapy, 2015, 59, 4719-4726.	1.4	254
139	Ex Vivo Drug Susceptibility Testing and Molecular Profiling of Clinical Plasmodium falciparum Isolates from Cambodia from 2008 to 2013 Suggest Emerging Piperaquine Resistance. Antimicrobial Agents and Chemotherapy, 2015, 59, 4631-4643.	1.4	63
140	Artemisinin Resistance-Associated Polymorphisms at the K13-Propeller Locus are Absent in Plasmodium falciparum Isolates from Haiti. American Journal of Tropical Medicine and Hygiene, 2015, 92, 552-554.	0.6	14
141	The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs. Science Translational Medicine, 2015, 7, 288ra77.	5.8	82
142	The X-ray structure ofPlasmodium falciparumdihydroorotate dehydrogenase bound to a potent and selectiveN-phenylbenzamide inhibitor reveals novel binding-site interactions. Acta Crystallographica Section F, Structural Biology Communications, 2015, 71, 553-559.	0.4	22
143	Lack of Artemisinin Resistance in Plasmodium falciparum in Uganda Based on Parasitological and Molecular Assays. Antimicrobial Agents and Chemotherapy, 2015, 59, 5061-5064.	1.4	55
144	Artemisinin, a miracle of traditional Chinese medicine. Natural Product Reports, 2015, 32, 1617-1621.	5.2	137
146	Parasite clearance after malaria therapy: staying a step ahead of drug resistance. BMC Medicine, 2015, 13, 251.	2.3	13
147	Profile of William C. Campbell, Satoshi ÅŒmura, and Youyou Tu, 2015 Nobel Laureates in Physiology or Medicine. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15773-15776.	3.3	32

#	Article	IF	Citations
148	Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum. Nature Communications, 2015, 6, 10111.	5.8	486
149	Clinical Efficacy of Dihydroartemisininâ€“Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria at the Chinaâ€“Myanmar Border. American Journal of Tropical Medicine and Hygiene, 2015, 93, 577-583.	0.6	29
150	From within host dynamics to the epidemiology of infectious disease: Scientific overview and challenges. Mathematical Biosciences, 2015, 270, 143-155.	0.9	33
151	Optimum population-level use of artemisinin combination therapies: a modelling study. The Lancet Global Health, 2015, 3, e758-e766.	2.9	62
152	Advances in genetics and genomics: use and limitations in achieving malaria elimination goals. Pathogens and Global Health, 2015, 109, 123-141.	1.0	5
153	Molecular markers of anti-malarial drug resistance in southwest Ethiopia over time: regional surveillance from 2006 to 2013. Malaria Journal, 2015, 14, 208.	0.8	18
154	Bayesian models trained with HTS data for predicting Î²-haematin inhibition and in vitro antimalarial activity. Bioorganic and Medicinal Chemistry, 2015, 23, 5210-5217.	1.4	20
155	Molecular Assessment of Artemisinin Resistance Markers, Polymorphisms in the K13 Propeller, and a Multidrug-Resistance Gene in the Eastern and Western Border Areas of Myanmar. Clinical Infectious Diseases, 2015, 60, 1208-1215.	2.9	71
156	Host-based Prophylaxis Successfully Targets Liver Stage Malaria Parasites. Molecular Therapy, 2015, 23, 857-865.	3.7	33
157	Synthesis and in vitro evaluation of novel 8-aminoquinolineâ€“pyrazolopyrimidine hybrids as potent antimalarial agents. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1100-1103.	1.0	26
158	Histone Methyltransferase Inhibitors Are Orally Bioavailable, Fast-Acting Molecules with Activity against Different Species Causing Malaria in Humans. Antimicrobial Agents and Chemotherapy, 2015, 59, 950-959.	1.4	43
159	Yeast-Based High-Throughput Screen Identifies Plasmodium falciparum Equilibrative Nucleoside Transporter 1 Inhibitors That Kill Malaria Parasites. ACS Chemical Biology, 2015, 10, 775-783.	1.6	21
160	Toward the development of effective transmission-blocking vaccines for malaria. Expert Review of Vaccines, 2015, 14, 653-680.	2.0	95
161	Pooled Sequencing and Rare Variant Association Tests for Identifying the Determinants of Emerging Drug Resistance in Malaria Parasites. Molecular Biology and Evolution, 2015, 32, 1080-1090.	3.5	34
162	Malaria PCR Detection in Cambodian Low-Transmission Settings: Dried Blood Spots Versus Venous Blood Samples. American Journal of Tropical Medicine and Hygiene, 2015, 92, 573-577.	0.6	34
163	Plasmodium falciparum field isolates from areas of repeated emergence of drug resistant malaria show no evidence of hypermutator phenotype. Infection, Genetics and Evolution, 2015, 30, 318-322.	1.0	18
164	Understanding artemisinin resistance. Science, 2015, 347, 373-374.	6.0	30
165	Synthesis and biological evaluation of adamantane-based aminophenols as a novel class of antiplasmodial agents. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 952-955.	1.0	5

#	Article	IF	Citations
166	Absence of Putative Artemisinin Resistance Mutations Among Plasmodium falciparum in Sub-Saharan Africa: A Molecular Epidemiologic Study. Journal of Infectious Diseases, 2015, 211, 680-688.	1.9	235
167	Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nature Genetics, 2015, 47, 226-234.	9.4	515
168	Plasmodium falciparum susceptibility to standard and potential anti-malarial drugs in Dakar, Senegal, during the 2013â€“2014 malaria season. Malaria Journal, 2015, 14, 60.	0.8	26
169	Towards real-time monitoring of artemisinin resistance. Lancet Infectious Diseases, The, 2015, 15, 367-368.	4.6	19
170	In vivo monitoring of dihydroartemisinin-piperaquine sensitivity in Plasmodium falciparum along the China-Myanmar border of Yunnan Province, China from 2007 to 2013. Malaria Journal, 2015, 14, 47.	0.8	31
171	Temporal changes in Plasmodium falciparum anti-malarial drug sensitivity in vitro and resistance-associated genetic mutations in isolates from Papua New Guinea. Malaria Journal, 2015, 14, 37.	0.8	17
172	A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature, 2015, 522, 315-320.	13.7	353
173	Strand-specific RNA sequencing in Plasmodium falciparum malaria identifies developmentally regulated long non-coding RNA and circular RNA. BMC Genomics, 2015, 16, 454.	1.2	160
174	The emerging threat of artemisinin resistance in malaria: focus on artemether-lumefantrine. Expert Review of Anti-Infective Therapy, 2015, 13, 1031-1045.	2.0	13
175	From genome-scale data to models of infectious disease: A Bayesian network-based strategy to drive model development. Mathematical Biosciences, 2015, 270, 156-168.	0.9	8
176	Malaria resistance to non-artemisinin partner drugs: how to reACT. Lancet Infectious Diseases, The, 2015, 15, 621-623.	4.6	16
177	Temporal trends in prevalence of Plasmodium falciparum molecular markers selected for by artemetherâ€“lumefantrine treatment in pre-ACT and post-ACT parasites in western Kenya. International Journal for Parasitology: Drugs and Drug Resistance, 2015, 5, 92-99.	1.4	35
178	Drug-resistant Plasmodium falciparum: are recent advances a cause for optimism?. Future Microbiology, 2015, 10, 1261-1263.	1.0	2
179	The Mu Subunit of Plasmodium falciparum Clathrin-Associated Adaptor Protein 2 Modulates In Vitro Parasite Response to Artemisinin and Quinine. Antimicrobial Agents and Chemotherapy, 2015, 59, 2540-2547.	1.4	42
180	Reversible Conformational Change in the Plasmodium falciparum Circumsporozoite Protein Masks Its Adhesion Domains. Infection and Immunity, 2015, 83, 3771-3780.	1.0	59
181	Fitness of artemisinin-resistantPlasmodium falciparum in vitro. Journal of Antimicrobial Chemotherapy, 2015, 70, 2787-2796.	1.3	26
182	Exploring the 3-piperidin-4-yl-1H-indole scaffold as a novel antimalarial chemotype. European Journal of Medicinal Chemistry, 2015, 102, 320-333.	2.6	31
183	Analysis of Major Genome Loci Underlying Artemisinin Resistance and pfmdr1 Copy Number in pre- and post-ACTs in Western Kenya. Scientific Reports, 2015, 5, 8308.	1.6	26

#	Article	IF	Citations
184	Global distribution of polymorphisms associated with delayed Plasmodium falciparum parasite clearance following artemisinin treatment: Genotyping of archive blood samples. Parasitology International, 2015, 64, 267-273.	0.6	6
185	Screening and Treating UN Peacekeepers to Prevent the Introduction of Artemisinin-Resistant Malaria into Africa. PLoS Medicine, 2015, 12, e1001822.	3.9	7
186	Evolution of insecticide resistance diagnostics in malaria vectors. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2015, 109, 291-293.	0.7	34
187	Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms. Nature Reviews Genetics, 2015, 16, 459-471.	7.7	201
188	JA-mediated transcriptional regulation of secondary metabolism in medicinal plants. Science Bulletin, 2015, 60, 1062-1072.	4.3	77
189	Defining the In Vivo Phenotype of Artemisinin-Resistant Falciparum Malaria: A Modelling Approach. PLoS Medicine, 2015, 12, e1001823.	3.9	36
190	Benzoxaborole Antimalarial Agents. Part 4. Discovery of Potent 6-(2-(Alkoxycarbonyl)pyrazinyl-5-oxy)-1,3-dihydro-1-hydroxy-2,1-benzoxaboroles. Journal of Medicinal Chemistry, 2015, 58, 5344-5354.	2.9	31
191	Imputation-Based Population Genetics Analysis of Plasmodium falciparum Malaria Parasites. PLoS Genetics, 2015, 11, e1005131.	1.5	53
192	Antimalarial activity of kinase inhibitor, nilotinib, in vitro and in vivo. Journal of Antibiotics, 2015, 68, 469-472.	1.0	5
193	A crucial piece in the puzzle of the artemisinin resistance mechanism in Plasmodium falciparum. Trends in Parasitology, 2015, 31, 345-346.	1.5	6
194	Identification and Deconvolution of Cross-Resistance Signals from Antimalarial Compounds Using Multidrug-Resistant Plasmodium falciparum Strains. Antimicrobial Agents and Chemotherapy, 2015, 59, 1110-1118.	1.4	34
195	Monitoring artemisinin resistance in Plasmodium falciparum: comparison of parasite clearance time by microscopy and real-time PCR and evaluation of mutations in Pfatpase6 gene in Odisha state of India. Parasitology Research, 2015, 114, 3487-3496.	0.6	4
196	In silico attempt for adduct agent(s) against malaria: Combination of chloroquine with alkaloids of Adhatoda vasica. Computer Methods and Programs in Biomedicine, 2015, 122, 16-25.	2.6	14
197	Targeting the Cell Stress Response of Plasmodium falciparum to Overcome Artemisinin Resistance. PLoS Biology, 2015, 13, e1002132.	2.6	254
198	Selection and Spread of Artemisinin-Resistant Alleles in Thailand Prior to the Global Artemisinin Resistance Containment Campaign. PLoS Pathogens, 2015, 11, e1004789.	2.1	85
200	Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infectious Diseases, The, 2015, 15, 683-691.	4.6	213
201	Malaria genomics: tracking a diverse and evolving parasite population. International Health, 2015, 7, 82-84.	0.8	18
202	Amplification ofpfmdr1,pfcrt,pvmdr1, and K13 Propeller Polymorphisms Associated with Plasmodium falciparum and Plasmodium vivax Isolates from the China-Myanmar Border. Antimicrobial Agents and Chemotherapy, 2015, 59, 2554-2559.	1.4	40

#	Article	IF	Citations
203	Malaria runs rings round artemisinin. Nature, 2015, 520, 628-630.	13.7	12
204	A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature, 2015, 520, 683-687.	13.7	485
205	How genomics is contributing to the fight against artemisinin-resistant malaria parasites. Acta Tropica, 2015, 148, 1-7.	0.9	21
206	Observing in real time the evolution of artemisinin resistance in Plasmodium falciparum. BMC Medicine, 2015, 13, 67.	2.3	8
207	PfMDR2 and PfMDR5 are dispensable for Plasmodium falciparum asexual parasite multiplication but change in vitro susceptibility to anti-malarial drugs. Malaria Journal, 2015, 14, 76.	0.8	17
208	Assessing anti-malarial drug effects ex vivo using the haemozoin detection assay. Malaria Journal, 2015, 14, 140.	0.8	5
209	Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infectious Diseases, The, 2015, 15, 415-421.	4.6	363
210	Artemisinin-Resistant Plasmodium falciparum Parasites Exhibit Altered Patterns of Development in Infected Erythrocytes. Antimicrobial Agents and Chemotherapy, 2015, 59, 3156-3167.	1.4	97
211	Surveillance of Artemisinin Resistance in Plasmodium falciparum in India Using the kelch13 Molecular Marker. Antimicrobial Agents and Chemotherapy, 2015, 59, 2548-2553.	1.4	65
212	Decreasing pfmdr1 Copy Number Suggests that Plasmodium falciparum in Western Cambodia Is Regaining In Vitro Susceptibility to Mefloquine. Antimicrobial Agents and Chemotherapy, 2015, 59, 2934-2937.	1.4	29
213	Polymorphisms in the K13-Propeller Gene in Artemisinin-Susceptible Plasmodium falciparum Parasites from Bougoula-Hameau and Bandiagara, Mali. American Journal of Tropical Medicine and Hygiene, 2015, 92, 1202-1206.	0.6	89
214	Resistance to antimalarial drugs: An endless world war against Plasmodium that we risk losing. Journal of Global Antimicrobial Resistance, 2015, 3, 58-63.	0.9	24
215	Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate. Nature Communications, 2015, 6, 6715.	5.8	55
217	Do hypnozoites cause relapse in malaria?. Trends in Parasitology, 2015, 31, 239-245.	1.5	38
218	Fighting fire with fire: mass antimalarial drug administrations in an era of antimalarial resistance. Expert Review of Anti-Infective Therapy, 2015, 13, 715-730.	2.0	78
219	K13-Propeller Polymorphisms in Plasmodium falciparum Isolates from Patients in Mayotte in 2013 and 2014. Antimicrobial Agents and Chemotherapy, 2015, 59, 7878-7881.	1.4	23
220	Population Genetics, Evolutionary Genomics, and Genome-Wide Studies of Malaria: A View Across the International Centers of Excellence for Malaria Research. American Journal of Tropical Medicine and Hygiene, 2015, 93, 87-98.	0.6	22
221	A Single Mutation in K13 Predominates in Southern China and Is Associated With Delayed Clearance ofPlasmodium falciparumFollowing Artemisinin Treatment. Journal of Infectious Diseases, 2015, 212, 1629-1635.	1.9	125

#	Article	IF	Citations
222	In Vitro and Molecular Surveillance for Antimalarial Drug Resistance in Plasmodium falciparum Parasites in Western Kenya Reveals Sustained Artemisinin Sensitivity and Increased Chloroquine Sensitivity. Antimicrobial Agents and Chemotherapy, 2015, 59, 7540-7547.	1.4	25
223	The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. BMC Medicine, 2015, 13, 66.	2.3	37
224	Maximizing antimalarial efficacy and the importance of dosing strategies. BMC Medicine, 2015, 13, 110.	2.3	8
225	Whole genome capture of vector-borne pathogens from mixed DNA samples: a case study of Borrelia burgdorferi. BMC Genomics, 2015, 16, 434.	1.2	38
226	Antimalarial drug resistance in Africa: key lessons for the future. Annals of the New York Academy of Sciences, 2015, 1342, 62-67.	1.8	83
227	How Robust Are Malaria Parasite Clearance Rates as Indicators of Drug Effectiveness and Resistance?. Antimicrobial Agents and Chemotherapy, 2015, 59, 6428-6436.	1.4	59
228	Topoisomerase II from Human Malaria Parasites. Journal of Biological Chemistry, 2015, 290, 20313-20324.	1.6	18
229	Artemisinin-resistant Plasmodium falciparum clinical isolates can infect diverse mosquito vectors of Southeast Asia and Africa. Nature Communications, 2015, 6, 8614.	5.8	55
230	Comparison of genomic signatures of selection on Plasmodium falciparum between different regions of a country with high malaria endemicity. BMC Genomics, 2015, 16, 527.	1.2	34
231	Malaria eradication and elimination: views on how to translate a vision into reality. BMC Medicine, 2015, 13, 167.	2.3	101
232	Hit and lead criteria in drug discovery for infectious diseases of the developing world. Nature Reviews Drug Discovery, 2015, 14, 751-758.	21.5	437
233	Structureâ€“Activity Relationship Studies of Orally Active Antimalarial 2,4-Diamino-thienopyrimidines. Journal of Medicinal Chemistry, 2015, 58, 7572-7579.	2.9	14
234	Next-Generation Sequencing of Plasmodium vivax Patient Samples Shows Evidence of Direct Evolution in Drug-Resistance Genes. ACS Infectious Diseases, 2015, 1, 367-379.	1.8	30
235	Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles. Vaccine, 2015, 33, 5064-5071.	1.7	75
236	Artemisinin Resistance at the China-Myanmar Border and Association with Mutations in the K13 Propeller Gene. Antimicrobial Agents and Chemotherapy, 2015, 59, 6952-6959.	1.4	84
237	Exploring clotrimazole-based pharmacophore: 3D-QSAR studies and synthesis of novel antiplasmodial agents. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5412-5418.	1.0	15
238	Fusion of field studies and the laboratory solves a puzzle in antimalarial resistance. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11432-11433.	3.3	1
239	Antimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR Network. American Journal of Tropical Medicine and Hygiene, 2015, 93, 57-68.	0.6	250

#	Article	IF	Citations
240	Artemisinin resistance in Myanmar â€“ Authors' reply. Lancet Infectious Diseases, The, 2015, 15, 1002-1003.	4.6	0
241	Genetic Investigation of Tricarboxylic Acid Metabolism during the Plasmodium falciparum Life Cycle. Cell Reports, 2015, 11, 164-174.	2.9	134
242	Plasmodium evasion of mosquito immunity and global malaria transmission: The lock-and-key theory. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15178-15183.	3.3	106
243	K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science, 2015, 347, 428-431.	6.0	563
244	Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science, 2015, 347, 431-435.	6.0	362
245	The impact of genomics on population genetics of parasitic diseases. Current Opinion in Microbiology, 2015, 23, 49-54.	2.3	16
246	Antiplasmodial constituents from the stem bark of Polyalthia longifolia var pendula. Phytochemistry Letters, 2015, 11, 28-31.	0.6	19
247	Synthetic spirocyclic endoperoxides: new antimalarial scaffolds. MedChemComm, 2015, 6, 357-362.	3.5	39
248	Synthetic chemistry fuels interdisciplinary approaches to the production of artemisinin. Natural Product Reports, 2015, 32, 359-366.	5.2	48
249	Antimalarial Action of Artesunate Involves DNA Damage Mediated by Reactive Oxygen Species. Antimicrobial Agents and Chemotherapy, 2015, 59, 317-325.	1.4	120
250	Synthesis and inÂvitro biological evaluation of dihydroartemisinyl-chalcone esters. European Journal of Medicinal Chemistry, 2015, 90, 33-44.	2.6	48
251	New insight-guided approaches to detect, cure, prevent and eliminate malaria. Protoplasma, 2015, 252, 717-753.	1.0	17
252	Reduced Polymorphism in the Kelch Propeller Domain in Plasmodium vivax Isolates from Cambodia. Antimicrobial Agents and Chemotherapy, 2015, 59, 730-733.	1.4	25
253	Independent Emergence of Artemisinin Resistance Mutations Among Plasmodium falciparum in Southeast Asia. Journal of Infectious Diseases, 2015, 211, 670-679.	1.9	368
254	Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Malaria in Children in Zaire and UÃge Provinces, Angola. Antimicrobial Agents and Chemotherapy, 2015, 59, 437-443.	1.4	79
255	Evaluation of Antimalarial Resistance Marker Polymorphism in Returned Migrant Workers in China. Antimicrobial Agents and Chemotherapy, 2015, 59, 326-330.	1.4	35
256	Malaria parasite genetics: doing something useful. Parasitology International, 2015, 64, 244-253.	0.6	7
257	RÃ©sistance de lâ€™agent du paludisme, Plasmodium falciparum aux combinaisons thÃ©rapeutiques Ã base dâ€™artÃ©misinine (ACTs) : Craintes dâ€™une chimiorÃ©sistance gÃ©nÃ©ralisÃ©e. Bulletin De L'Academie Nationale De Medecine, 2016, 200, 477-490.	0.0	2

#	Article	IF	Citations
258	In vitro sensitivity pattern of chloroquine and artemisinin in Plasmodium falciparum. Indian Journal of Medical Microbiology, 2016, 34, 509-512.	0.3	2
259	Artemisinin-Resistant Plasmodium falciparum Malaria. , 0, , 409-429.		8
261	Incomplete reversal of genotypic resistance of Plasmodium falciparum to chloroquine after a decade of change in malaria treatment policy in Uganda. Reports in Parasitology, 2016, , 15.	0.5	0
262	Reply to Meshnick and Hastings et al. Clinical Infectious Diseases, 2016, 63, 1528-1529.	2.9	7
263	The molecular and cellular action properties of artemisinins: what has yeast told us?. Microbial Cell, 2016, 3, 196-205.	1.4	19
264	Protection after Malaria Therapy: A Step-up to Immunity. Malaria Control & Elimination, 2016, 5, .	1.0	0
265	Malaria Hyperendemicity and Risk for Artemisinin Resistance among Illegal Gold Miners, French Guiana. Emerging Infectious Diseases, 2016, 22, 903-906.	2.0	35
267	Plasmodium falciparumIn Vitro Resistance to Monodesethylamodiaquine, Dakar, Senegal, 2014. Emerging Infectious Diseases, 2016, 22, 841-845.	2.0	15
268	IASM: A System for the Intelligent Active Surveillance of Malaria. Computational and Mathematical Methods in Medicine, 2016, 2016, 1-11.	0.7	4
269	Artemisinin-ResistantPlasmodium falciparumK13 Mutant Alleles, Thailandâ€“Myanmar Border. Emerging Infectious Diseases, 2016, 22, 1503-1505.	2.0	37
270	In Vivo Efficacy of Artesunate/Sulphadoxine-Pyrimethamine versus Artesunate/Amodiaquine in the Treatment of Uncomplicated P. falciparum Malaria in Children around the Slope of Mount Cameroon: A Randomized Controlled Trial. Biomedicines, 2016, 4, 5.	1.4	6
271	Failure of dihydroartemisinin plus piperaquine treatment of falciparum malaria by under-dosing in an overweight patient. Malaria Journal, 2016, 15, 479.	0.8	8
272	Asymptomatic Plasmodium infections in 18 villages of southern Savannakhet Province, Lao PDR (Laos). Malaria Journal, 2016, 15, 296.	0.8	45
273	Prevalence of anti-malarial resistance genes in Dakar, Senegal from 2013 to 2014. Malaria Journal, 2016, 15, 347.	0.8	15
274	Therapeutic efficacy trial of artemisinin-based combination therapy for the treatment of uncomplicated malaria and investigation of mutations in k13 propeller domain in Togo, 2012â€“2013. Malaria Journal, 2016, 15, 331.	0.8	32
275	Assessing the asymptomatic reservoir and dihydroartemisininâ€“piperaquine effectiveness in a low transmission setting threatened by artemisinin resistant Plasmodium falciparum. Malaria Journal, 2016, 15, 446.	0.8	8
276	Selection of N86F184D1246 haplotype of Pfmrd1 gene by artemetherâ€“lumefantrine drug pressure on Plasmodium falciparum populations in Senegal. Malaria Journal, 2016, 15, 433.	0.8	33
277	Limited genetic diversity in the PvK12 Kelch protein in Plasmodium vivax isolates from Southeast Asia. Malaria Journal, 2016, 15, 537.	0.8	21

#	Article	IF	Citations
278	Genetic diversity of the Pvk12 gene in Plasmodium vivax from the China-Myanmar border area. Malaria Journal, 2016, 15, 528.	0.8	16
279	Intramuscular Artesunate for Severe Malaria in African Children: A Multicenter Randomized Controlled Trial. PLoS Medicine, 2016, 13, e1001938.	3.9	44
280	Inhibition of an Erythrocyte Tyrosine Kinase with Imatinib Prevents Plasmodium falciparum Egress and Terminates Parasitemia. PLoS ONE, 2016, 11, e0164895.	1.1	39
281	Methylene Homologues of Artemisone: An Unexpected Structureâ€“Activity Relationship and a Possible Implication for the Design of C10â€Substituted Artemisinins. ChemMedChem, 2016, 11, 1469-1479.	1.6	20
282	Molecular markers associated with resistance to commonly used antimalarial drugs among Plasmodium falciparum isolates from a malaria-endemic area in Taiz governorateâ€”Yemen during the transmission season. Acta Tropica, 2016, 162, 174-179.	0.9	6
283	Comparison of the Exposure Time Dependence of the Activities of Synthetic Ozonide Antimalarials and Dihydroartemisinin against K13 Wild-Type and Mutant Plasmodium falciparum Strains. Antimicrobial Agents and Chemotherapy, 2016, 60, 4501-4510.	1.4	49
284	Limited Polymorphism of the Kelch Propeller Domain in Plasmodium malariae and P. ovale Isolates from Thailand. Antimicrobial Agents and Chemotherapy, 2016, 60, 4055-4062.	1.4	4
285	CRISPRâ€Cas9â€modified pfmdr1 protects Plasmodium falciparum asexual blood stages and gametocytes against a class of piperazineâ€containing compounds but potentiates artemisininâ€based combination therapy partner drugs. Molecular Microbiology, 2016, 101, 381-393.	1.2	56
286	A Method for Amplicon Deep Sequencing of Drug Resistance Genes in Plasmodium falciparum Clinical Isolates from India. Journal of Clinical Microbiology, 2016, 54, 1500-1511.	1.8	41
287	The threat of antimalarial drug resistance. Tropical Diseases, Travel Medicine and Vaccines, 2016, 2, 10.	0.9	65
288	Organism-like formation of Schistosoma hemozoin and its function suggest a mechanism for anti-malarial action of artemisinin. Scientific Reports, 2016, 6, 34463.	1.6	9
289	Plasmodium falciparum parasite population structure and gene flow associated to anti-malarial drugs resistance in Cambodia. Malaria Journal, 2016, 15, 319.	0.8	17
291	An optimised age-based dosing regimen for single low-dose primaquine for blocking malaria transmission in Cambodia. BMC Medicine, 2016, 14, 171.	2.3	15
292	The role of early detection and treatment in malaria elimination. Malaria Journal, 2016, 15, 363.	0.8	82
293	Gametocyte clearance dynamics following oral artesunate treatment of uncomplicatedfalciparummalaria in Malian children. Parasite, 2016, 23, 3.	0.8	14
294	Distinctive origin of artemisinin-resistant Plasmodium falciparum on the China-Myanmar border. Scientific Reports, 2016, 6, 20100.	1.6	72
295	DNA damage regulation and its role in drug-related phenotypes in the malaria parasites. Scientific Reports, 2016, 6, 23603.	1.6	54
296	Phenotypic Screens Identify Parasite Genetic Factors Associated with Malarial Fever Response in Plasmodium falciparum piggyBac Mutants. MSphere, 2016, 1, .	1.3	18

#	Article	IF	Citations
297	Prevalence of crt and mdr-1 mutations in Plasmodium falciparum isolates from Grande Comore island after withdrawal of chloroquine. Malaria Journal, 2016, 15, 414.	0.8	20
298	Extreme mutation bias and high AT content inPlasmodium falciparum. Nucleic Acids Research, 2017, 45, gkw1259.	6.5	89
299	Polymorphisms inK13, pfcrt, pfmdr1, pfdhfr, andpfdhpsin parasites isolated from symptomatic malaria patients in Burkina Faso. Parasite, 2016, 23, 60.	0.8	25
300	Parasite Clearance and Artemether Pharmacokinetics Parameters Over the Course of Artemether-Lumefantrine Treatment for Malaria in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Ugandan Children. Open Forum Infectious Diseases, 2016, 3, ofw217.	0.4	6
301	Whole genome sequencing of Plasmodium falciparum from dried blood spots using selective whole genome amplification. Malaria Journal, 2016, 15, 597.	0.8	129
302	Changing antimalarial drug resistance patterns identified by surveillance at three sites in Uganda. Journal of Infectious Diseases, 2017, 215, jiw614.	1.9	41
303	Artemisinin-Resistant Plasmodium falciparum Malaria. Microbiology Spectrum, 2016, 4, .	1.2	225
304	Alternatives to currently used antimalarial drugs: in search of a magic bullet. Infectious Diseases of Poverty, 2016, 5, 103.	1.5	22
305	Plasmodium falciparum proteins involved in cytoadherence of infected erythrocytes to chemokine CX3CL1. Scientific Reports, 2016, 6, 33786.	1.6	32
306	Application of multi-target phytotherapeutic concept in malaria drug discovery: a systems biology approach in biomarker identification. Biomarker Research, 2016, 4, 25.	2.8	25
308	In vitro selection of Plasmodium falciparum Pfcrt and Pfmdr1 variants by artemisinin. Malaria Journal, 2016, 15, 381.	0.8	20
309	Lack of artemisinin resistance inPlasmodium falciparumin northwest Benin after 10 years of use of artemisinin-based combination therapy. Parasite, 2016, 23, 28.	0.8	10
310	Therapeutic efficacy of artemetherâ€“lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria from three highly malarious states in India. Malaria Journal, 2016, 15, 498.	0.8	20
311	Little Polymorphism at the K13 Propeller Locus in Worldwide Plasmodium falciparum Populations Prior to the Introduction of Artemisinin Combination Therapies. Antimicrobial Agents and Chemotherapy, 2016, 60, 3340-3347.	1.4	18
312	Pharmacodynamics of Antimalarial Agents. Methods in Pharmacology and Toxicology, 2016, , 415-439.	0.1	0
313	Antimalarial qinghaosu/artemisinin: The therapy worthy of a Nobel Prize. Asian Pacific Journal of Tropical Biomedicine, 2016, 6, 371-375.	0.5	21
314	A deep sequencing tool for partitioning clearance rates following antimalarial treatment in polyclonal infections. Evolution, Medicine and Public Health, 2016, 2016, 21-36.	1.1	38
315	Sustained efficacy of artesunate-sulfadoxine-pyrimethamine against Plasmodium falciparum in Yemen and a renewed call for an adjunct single dose primaquine to clear gametocytes. Malaria Journal, 2016, 15, 295.	0.8	6

#	Article	IF	Citations
316	Back on TRAC: New trial launched in bid to outpace multidrug-resistant malaria. Nature Medicine, 2016, 22, 220-221.	15.2	11
317	Efficacy and Safety of Pyronaridine-Artesunate for Treatment of Uncomplicated Plasmodium falciparum Malaria in Western Cambodia. Antimicrobial Agents and Chemotherapy, 2016, 60, 3884-3890.	1.4	39
318	Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL), a Resistance Mechanism for Two Distinct Compound Classes. ACS Infectious Diseases, 2016, 2, 816-826.	1.8	34
319	Malaria: global challenges for malaria eradication. Microbiology Australia, 2016, 37, 34.	0.1	9
320	The population genetics of drug resistance evolution inÂnatural populations of viral, bacterial and eukaryotic pathogens. Molecular Ecology, 2016, 25, 42-66.	2.0	41
322	Plasmodium falciparum malaria: Convergent evolutionary trajectories towards delayed clearance following artemisinin treatment. Medical Hypotheses, 2016, 90, 19-22.	0.8	12
323	Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study. Malaria Journal, 2016, 15, 185.	0.8	43
324	Identifying antimalarial compounds targeting dihydrofolate reductase-thymidylate synthase (DHFR-TS) by chemogenomic profiling. International Journal for Parasitology, 2016, 46, 527-535.	1.3	23
326	The Institut Pasteur International Network: a century-old global public health powerhouse. Lancet, The, 2016, 387, 2181-2183.	6.3	1
327	No Clinical or Molecular Evidence of Plasmodium falciparum Resistance to Artesunateâ€“Mefloquine in Northwestern Brazil. American Journal of Tropical Medicine and Hygiene, 2016, 95, 148-154.	0.6	21
328	Artemisinin Resistanceâ€“Associated K13 Polymorphisms of Plasmodium falciparum in Southern Rwanda, 2010â€“2015. American Journal of Tropical Medicine and Hygiene, 2016, 95, 1090-1093.	0.6	68
329	National Malaria Prevalence in Cambodia: Microscopy Versus Polymerase Chain Reaction Estimates. American Journal of Tropical Medicine and Hygiene, 2016, 95, 588-594.	0.6	9
330	Declining Efficacy of Artemisinin Combination Therapy AgainstP. FalciparumMalaria on the Thaiâ€“Myanmar Border (2003â€“2013): The Role of Parasite Genetic Factors. Clinical Infectious Diseases, 2016, 63, 784-791.	2.9	178
331	Diversity-oriented synthesis yields novel multistage antimalarial inhibitors. Nature, 2016, 538, 344-349.	13.7	214
332	Recent advances in malaria genomics and epigenomics. Genome Medicine, 2016, 8, 92.	3.6	37
333	Endoperoxide Drug Cross-Resistance Patterns for Plasmodium falciparum Exhibiting an Artemisinin Delayed-Clearance Phenotype. Antimicrobial Agents and Chemotherapy, 2016, 60, 6952-6956.	1.4	29
334	Sexual Selection and the Evolution of Mating Systems in Mosquitoes. Advances in Insect Physiology, 2016, 51, 67-92.	1.1	7
335	Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria. New England Journal of Medicine, 2016, 375, 1152-1160.	13.9	89

#	Article	IF	Citations
336	Efficacy of artemisinin-based combination therapies for the treatment of falciparum malaria in Pakistan (2007â€“2015): In vivo response and dhfr and dhps mutations. Acta Tropica, 2016, 164, 17-22.	0.9	7
338	Transcriptomic Analysis of Chloroquine-Sensitive and Chloroquine-Resistant Strains ofPlasmodium falciparum: Toward Malaria Diagnostics and Therapeutics for Global Health. OMICS A Journal of Integrative Biology, 2016, 20, 424-432.	1.0	12
340	Indels, structural variation, and recombination drive genomic diversity in Plasmodium falciparum. Genome Research, 2016, 26, 1288-1299.	2.4	180
341	Immunoglobulin response to the low polymorphic Pf113 antigen in children from Lastoursville, South-East of Gabon. Acta Tropica, 2016, 163, 149-156.	0.9	3
342	PfCRT and PfMDR1 modulate interactions of artemisinin derivatives and ion channel blockers. Scientific Reports, 2016, 6, 25379.	1.6	15
343	Quantitative insertion-site sequencing (QIseq) for high throughput phenotyping of transposon mutants. Genome Research, 2016, 26, 980-989.	2.4	39
344	Insight into k13-propeller gene polymorphism and ex vivo DHA-response profiles from Cameroonian isolates. Malaria Journal, 2016, 15, 572.	0.8	23
345	Continued Sensitivity of Plasmodium falciparum to Artemisinin in Guyana, With Absence of Kelch Propeller Domain Mutant Alleles. Open Forum Infectious Diseases, 2016, 3, ofw185.	0.4	9
346	Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies. Nature Communications, 2016, 7, 11553.	5.8	208
347	Impact of exposure to mosquito transmission-blocking antibodies on Plasmodium falciparum population genetic structure. Infection, Genetics and Evolution, 2016, 45, 138-144.	1.0	9
348	Intermittent Preventive Treatment with Dihydroartemisinin-Piperaquine in Ugandan Schoolchildren Selects for Plasmodium falciparum Transporter Polymorphisms That Modify Drug Sensitivity. Antimicrobial Agents and Chemotherapy, 2016, 60, 5649-5654.	1.4	25
349	Artemisinin-based antimalarial research: application of biotechnology to the production of artemisinin, its mode of action, and the mechanism of resistance of Plasmodium parasites. Journal of Natural Medicines, 2016, 70, 318-334.	1.1	42
350	Mosquito Vectors and the Globalization ofPlasmodium falciparumMalaria. Annual Review of Genetics, 2016, 50, 447-465.	3.2	51
351	Longitudinal Pooled Deep Sequencing of the Plasmodium vivax K12 Kelch Gene in Cambodia Reveals a Lack of Selection by Artemisinin. American Journal of Tropical Medicine and Hygiene, 2016, 95, 1409-1412.	0.6	11
352	Plasmodium falciparum Resistance to Artemisinin Derivatives and Piperaquine: A Major Challenge for Malaria Elimination in Cambodia. American Journal of Tropical Medicine and Hygiene, 2016, 95, 1228-1238.	0.6	57
353	Plasmodium. , 2016, , 241-284.		0
354	Genome-wide association analysis identifies genetic loci associated with resistance to multiple antimalarials in Plasmodium falciparum from China-Myanmar border. Scientific Reports, 2016, 6, 33891.	1.6	100
355	Malaria: Biology and Disease. Cell, 2016, 167, 610-624.	13.5	576

#	Article	IF	Citations
356	Drug resistance in eukaryotic microorganisms. Nature Microbiology, 2016, 1, 16092.	5.9	118
357	Rapid Point-of-Care Isothermal Amplification Assay for the Detection of Malaria without Nucleic Acid Purification. Infectious Diseases: Research and Treatment, 2016, 9, IDRT.S32162.	0.7	29
358	Altered drug susceptibility during host adaptation of a Plasmodium falciparum strain in a non-human primate model. Scientific Reports, 2016, 6, 21216.	1.6	1
359	Malaria control along China-Myanmar Border during 2007â€“2013: an integrated impact evaluation. Infectious Diseases of Poverty, 2016, 5, 75.	1.5	42
360	Prevalence of K13-propeller gene polymorphisms among Plasmodium falciparum parasites isolated from adult symptomatic patients in northern Uganda. BMC Infectious Diseases, 2016, 16, 428.	1.3	14
361	Emerging polymorphisms in falciparum Kelch 13 gene in Northeastern region of India. Malaria Journal, 2016, 15, 583.	0.8	51
362	Optimal health and disease management using spatial uncertainty: a geographic characterization of emergent artemisinin-resistant Plasmodium falciparum distributions in Southeast Asia. International Journal of Health Geographics, 2016, 15, 37.	1.2	13
363	<scp>MRP</scp>1 mediates folate transport and antifolate sensitivity in Plasmodium falciparum. FEBS Letters, 2016, 590, 482-492.	1.3	13
364	Comparative genome-wide analysis and evolutionary history of haemoglobin-processing and haem detoxification enzymes in malarial parasites. Malaria Journal, 2016, 15, 51.	0.8	11
365	Plasmodium copy number variation scan: gene copy numbers evaluation in haploid genomes. Malaria Journal, 2016, 15, 206.	0.8	20
366	Artesunate/Amodiaquine Versus Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria in Uganda: A Randomized Trial. Journal of Infectious Diseases, 2016, 213, 1134-1142.	1.9	63
367	Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials. Journal of Medicinal Chemistry, 2016, 59, 6101-6120.	2.9	13
368	Population genomics studies identify signatures of global dispersal and drug resistance in Plasmodium vivax. Nature Genetics, 2016, 48, 953-958.	9.4	194
369	K13-Propeller Mutations and Malaria Resistance. New England Journal of Medicine, 2016, 374, 2492-2493.	13.9	8
370	A Worldwide Map ofPlasmodium falciparumK13-Propeller Polymorphisms. New England Journal of Medicine, 2016, 374, 2453-2464.	13.9	449
371	Comparison of methods probing the intracellular redox milieu in Plasmodium falciparum. Molecular and Biochemical Parasitology, 2016, 206, 75-83.	0.5	19
372	Evaluation of DISCOVAR de novo using a mosquito sample for cost-effective short-read genome assembly. BMC Genomics, 2016, 17, 187.	1.2	60
373	Assessing the potential impact of artemisinin and partner drug resistance in sub-Saharan Africa. Malaria Journal, 2016, 15, 10.	0.8	48

#	Article	IF	Citations
374	Malaria in pregnancy: a passive surveillance study of pregnant women in low transmission areas of Colombia, Latin America. Malaria Journal, 2016, 15, 66.	0.8	20
375	Population pharmacokinetic properties of artemisinin in healthy male Vietnamese volunteers. Malaria Journal, 2016, 15, 90.	0.8	21
376	Alternative methods for the Plasmodium falciparum artemisinin ring-stage survival assay with increased simplicity and parasite stage-specificity. Malaria Journal, 2016, 15, 94.	0.8	25
377	Plasmodium falciparum: multifaceted resistance to artemisinins. Malaria Journal, 2016, 15, 149.	0.8	91
378	Persistent Plasmodium falciparum and Plasmodium vivax infections in a western Cambodian population: implications for prevention, treatment and elimination strategies. Malaria Journal, 2016, 15, 181.	0.8	54
379	Cysteamine broadly improves the anti-plasmodial activity of artemisinins against murine blood stage and cerebral malaria. Malaria Journal, 2016, 15, 260.	0.8	10
380	Investigation and control of a Plasmodium falciparum malaria outbreak in Shan Special Region II of Myanmar along the China-Myanmar Border from June to December 2014. Infectious Diseases of Poverty, 2016, 5, 32.	1.5	14
381	The Spiroindolone KAE609 Does Not Induce Dormant Ring Stages in Plasmodium falciparum Parasites. Antimicrobial Agents and Chemotherapy, 2016, 60, 5167-5174.	1.4	14
382	In Vivo Efficacy and Tolerability of Artesunateâ€“Azithromycin for the Treatment of Falciparum Malaria in Vietnam. American Journal of Tropical Medicine and Hygiene, 2016, 95, 164-167.	0.6	8
383	Substrate and Inhibitor Specificity of thePlasmodium bergheiEquilibrative Nucleoside Transporter Type 1. Molecular Pharmacology, 2016, 89, 678-685.	1.0	8
384	Artemisinin Action and Resistance in Plasmodium falciparum. Trends in Parasitology, 2016, 32, 682-696.	1.5	271
385	Lack of K13 mutations in Plasmodium falciparum persisting after artemisinin combination therapy treatment of Kenyan children. Malaria Journal, 2016, 15, 36.	0.8	54
386	Evaluation of intensified behaviour change communication strategies in an artemisinin resistance setting. Malaria Journal, 2016, 15, 249.	0.8	17
387	Can new treatment developments combat resistance in malaria?. Expert Opinion on Pharmacotherapy, 2016, 17, 1303-1307.	0.9	32
388	Efficacy of OZ439 (artefenomel) against earlyPlasmodium falciparumblood-stage malaria infection in healthy volunteers. Journal of Antimicrobial Chemotherapy, 2016, 71, 2620-2627.	1.3	64
389	Complete telomere-to-telomerede novoassembly of thePlasmodium falciparumgenome through long-read (>11â€‰kb), single molecule, real-time sequencing. DNA Research, 2016, 23, 339-351.	1.5	47
390	Reappraising the effects of artemisinin on the ATPase activity of PfATP6 and SERCA1a E255L expressed in Xenopus laevis oocytes. Nature Structural and Molecular Biology, 2016, 23, 1-2.	3.6	29
391	Defining the targets of antiparasitic compounds. Drug Discovery Today, 2016, 21, 725-739.	3.2	25

#	Article	IF	Citations
392	Sensitive DNA detection and SNP discrimination using ultrabright SERS nanorattles and magnetic beads for malaria diagnostics. Biosensors and Bioelectronics, 2016, 81, 8-14.	5.3	111
393	Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development. International Journal for Parasitology: Drugs and Drug Resistance, 2016, 6, 1-11.	1.4	16
394	Limited artemisinin resistance-associated polymorphisms in Plasmodium falciparum K13-propeller and PfATPase6 gene isolated from Bioko Island, Equatorial Guinea. International Journal for Parasitology: Drugs and Drug Resistance, 2016, 6, 54-59.	1.4	29
395	Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines and Tetraoxanes Potential Two-Stage Antimalarials?. Journal of Medicinal Chemistry, 2016, 59, 264-281.	2.9	32
396	Natural selection of K13 mutants of Plasmodium falciparum in response to artemisinin combination therapies in Thailand. Clinical Microbiology and Infection, 2016, 22, 285.e1-285.e8.	2.8	24
397	Can the experimental evolution programme help us elucidate the genetic basis of adaptation in nature?. Molecular Ecology, 2016, 25, 203-218.	2.0	73
398	Molecular surveillance of antimalarial drug resistance related genes in Plasmodium falciparum isolates from Eritrea. Acta Tropica, 2016, 157, 158-161.	0.9	10
399	A Unique Plasmodium falciparum K13 Gene Mutation in Northwest Ethiopia. American Journal of Tropical Medicine and Hygiene, 2016, 94, 132-135.	0.6	44
400	In Vivo Efficacy and Parasite Clearance of Artesunate + Sulfadoxineâ€“Pyrimethamine Versus Artemetherâ€“Lumefantrine in Mali. American Journal of Tropical Medicine and Hygiene, 2016, 94, 634-639.	0.6	18
401	Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites Plasmodium falciparum 3D7. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 2080-2085.	3.3	209
402	Combinatorial Genetic Modeling ofpfcrt-Mediated Drug Resistance Evolution inPlasmodium falciparum. Molecular Biology and Evolution, 2016, 33, 1554-1570.	3.5	51
403	K13 mutations and pfmdr1 copy number variation in Plasmodium falciparum malaria in Myanmar. Malaria Journal, 2016, 15, 110.	0.8	27
404	Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction. Malaria Journal, 2016, 15, 121.	0.8	8
405	Imidazopyridazine Inhibitors of Plasmodium falciparum Calcium-Dependent Protein Kinase 1 Also Target Cyclic GMP-Dependent Protein Kinase and Heat Shock Protein 90 To Kill the Parasite at Different Stages of Intracellular Development. Antimicrobial Agents and Chemotherapy, 2016, 60, 1464-1475.	1.4	52
406	Malaria Vaccine Development: Focusing Field Erythrocyte Invasion Studies on Phenotypic Diversity. Trends in Parasitology, 2016, 32, 274-283.	1.5	12
407	Independent Emergence of thePlasmodium falciparumKelch Propeller Domain Mutant Allele C580Y in Guyana. Journal of Infectious Diseases, 2016, 213, 1472-1475.	1.9	110
408	Dihydroartemisininâ€“piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infectious Diseases, The, 2016, 16, 357-365.	4.6	381
409	Plasmodium falciparum kelch 13: a potential molecular marker for tackling artemisinin-resistant malaria parasites. Expert Review of Anti-Infective Therapy, 2016, 14, 125-135.	2.0	21

#	Article	IF	Citations
410	Is the A578S Single-Nucleotide Polymorphism inK13-propellera Marker of Emerging Resistance to Artemisinin AmongPlasmodium falciparumin Africa?: Table 1.. Journal of Infectious Diseases, 2016, 213, 165-166.	1.9	20
411	Genetic variability and population structure of Plasmodium falciparum parasite populations from different malaria ecological regions of Kenya. Infection, Genetics and Evolution, 2016, 39, 372-380.	1.0	21
412	Emergence of Mutations in the K13 Propeller Gene of Plasmodium falciparum Isolates from Dakar, Senegal, in 2013-2014. Antimicrobial Agents and Chemotherapy, 2016, 60, 624-627.	1.4	51
413	Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial. Lancet Infectious Diseases, The, 2016, 16, 61-69.	4.6	147
414	Updates on artemisinin: an insight to mode of actions and strategies for enhanced global production. Protoplasma, 2016, 253, 15-30.	1.0	39
415	Development of whole sporozoite malaria vaccines. Expert Review of Vaccines, 2017, 16, 45-54.	2.0	32
416	Microbial genomics and antimicrobial susceptibility testing. Expert Review of Molecular Diagnostics, 2017, 17, 257-269.	1.5	36
417	Determination of glutathione redox potential and pH value in subcellular compartments of malaria parasites. Free Radical Biology and Medicine, 2017, 104, 104-117.	1.3	32
418	Establishment and application of a novel isothermal amplification assay for rapid detection of chloroquine resistance (K76T) in Plasmodium falciparum. Scientific Reports, 2017, 7, 41119.	1.6	18
419	pfk13 -Independent Treatment Failure in Four Imported Cases of Plasmodium falciparum Malaria Treated with Artemether-Lumefantrine in the United Kingdom. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	91
420	K13 Propeller Mutations in Plasmodium falciparum Populations in Regions of Malaria Endemicity in Vietnam from 2009 to 2016. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	41
421	Molecular Epidemiology of Plasmodium falciparum kelch13 Mutations in Senegal Determined by Using Targeted Amplicon Deep Sequencing. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	35
422	Design, synthesis and antimalarial activity of novel bis{N-[(pyrrolo[1,2-a]quinoxalin-4-yl)benzyl]-3-aminopropyl}amine derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 547-563.	2.5	51
423	Molecular surveillance of artemisinin resistance falciparum malaria among migrant goldmine workers in Myanmar. Malaria Journal, 2017, 16, 97.	0.8	13
424	The Malaria TaqMan Array Card Includes 87 Assays for Plasmodium falciparum Drug Resistance, Identification of Species, and Genotyping in a Single Reaction. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	13
425	Quantification of labile heme in live malaria parasites using a genetically encoded biosensor. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E2068-E2076.	3.3	56
426	Genomics of apicomplexan parasites. Critical Reviews in Biochemistry and Molecular Biology, 2017, 52, 254-273.	2.3	26
427	Malaria parasite clearance. Malaria Journal, 2017, 16, 88.	0.8	138

#	Article	IF	Citations
428	Evidence of a hard selective sweep for artemisinin resistant Plasmodium falciparum. Lancet Infectious Diseases, The, 2017, 17, 462-463.	4.6	1
429	New developments in anti-malarial target candidate and product profiles. Malaria Journal, 2017, 16, 26.	0.8	360
430	Whole-genome sequencing of a Plasmodium vivax clinical isolate exhibits geographical characteristics and high genetic variation in China-Myanmar border area. BMC Genomics, 2017, 18, 131.	1.2	32
431	DNA detection and single nucleotide mutation identification using SERS for molecular diagnostics and global health. Proceedings of SPIE, 2017, , .	0.8	1
432	How to Contain Artemisinin- and Multidrug-Resistant Falciparum Malaria. Trends in Parasitology, 2017, 33, 353-363.	1.5	71
433	Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria. Journal of Medicinal Chemistry, 2017, 60, 1994-2005.	2.9	51
434	Efficacy and safety of artemetherâ€“lumefantrine for the treatment of uncomplicated falciparum malaria at sentinel sites in Mozambique, 2015. Acta Tropica, 2017, 171, 146-150.	0.9	12
435	<scp>Clear</scp>: Composition of Likelihoods for Evolve and Resequence Experiments. Genetics, 2017, 206, 1011-1023.	1.2	32
436	Plasmodium falciparum K13 Mutations Differentially Impact Ozonide Susceptibility and Parasite Fitness In Vitro. MBio, 2017, 8, .	1.8	103
437	Total Synthesis of Penicinoline E, Marinamide, Methyl Marinamide and their Antimalarial Activity. ChemistrySelect, 2017, 2, 3256-3261.	0.7	9
438	A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine. MBio, 2017, 8, .	1.8	82
439	Artemisinin resistance without pfkelch13 mutations in Plasmodium falciparum isolates from Cambodia. Malaria Journal, 2017, 16, 195.	0.8	99
440	Longitudinal genomic surveillance of Plasmodium falciparum malaria parasites reveals complex genomic architecture of emerging artemisinin resistance. Genome Biology, 2017, 18, 78.	3.8	120
441	Absence of association between polymorphisms in the K13 gene and the presence of Plasmodium falciparum parasites at day 3 after treatment with artemisinin derivatives in Senegal. International Journal of Antimicrobial Agents, 2017, 49, 754-756.	1.1	42
442	Baseline in vivo, ex vivo and molecular responses of Plasmodium falciparum to artemether and lumefantrine in three endemic zones for malaria in Colombia. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2017, 111, 71-80.	0.7	13
443	Oxidative stress in malaria and artemisinin combination therapy: Pros and Cons. FEBS Journal, 2017, 284, 2579-2591.	2.2	73
444	Unpacking â€˜Artemisinin Resistanceâ€™. Trends in Pharmacological Sciences, 2017, 38, 506-511.	4.0	44
445	Susceptibility Testing of Medically Important Parasites. Clinical Microbiology Reviews, 2017, 30, 647-669.	5.7	9

#	Article	IF	Citations
446	Discovery and Development of Artemisinin and Related Compounds. Chinese Herbal Medicines, 2017, 9, 101-114.	1.2	35
447	Modern day population, pathogen and pest dispersals. , 0, , 521-534.		1
448	Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate. Journal of Medicinal Chemistry, 2017, 60, 5889-5908.	2.9	52
449	The Plasmodium PI(4)K inhibitor KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites. Scientific Reports, 2017, 7, 2325.	1.6	21
450	Artemisinin the Nobel Molecule. Studies in Natural Products Chemistry, 2017, 52, 193-229.	0.8	6
451	Clinical and molecular monitoring of Plasmodium falciparum resistance to antimalarial drug (artesunate+sulphadoxine-pyrimethamine) in two highly malarious district of Madhya Pradesh, Central India from 2012â€“2014. Pathogens and Global Health, 2017, 111, 186-194.	1.0	17
452	High throughput resistance profiling of Plasmodium falciparum infections based on custom dual indexing and Illumina next generation sequencing-technology. Scientific Reports, 2017, 7, 2398.	1.6	57
453	The within-host population dynamics of Mycobacterium tuberculosis vary with treatment efficacy. Genome Biology, 2017, 18, 71.	3.8	95
454	Multi-omics Based Identification of Specific Biochemical Changes Associated With PfKelch13-Mutant Artemisinin-Resistant Plasmodium falciparum. Journal of Infectious Diseases, 2017, 215, 1435-1444.	1.9	84
455	Genetic diversity of next generation antimalarial targets: A baseline for drug resistance surveillance programmes. International Journal for Parasitology: Drugs and Drug Resistance, 2017, 7, 174-180.	1.4	12
456	What is a vector?. Philosophical Transactions of the Royal Society B: Biological Sciences, 2017, 372, 20160085.	1.8	47
457	pfmdr1 (Plasmodium falciparum multidrug drug resistance gene 1): a pivotal factor in malaria resistance to artemisinin combination therapies. Expert Review of Anti-Infective Therapy, 2017, 15, 527-543.	2.0	43
458	Pharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration. Scientific Reports, 2017, 7, 502.	1.6	30
459	A genetic system to study Plasmodium falciparum protein function. Nature Methods, 2017, 14, 450-456.	9.0	249
460	Host immunity to Plasmodium falciparum and the assessment of emerging artemisinin resistance in a multinational cohort. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3515-3520.	3.3	78
461	Antimalarial Drug Resistance: A Threat to Malaria Elimination. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a025619.	2.9	301
462	Overlap Extension Barcoding for the Next Generation Sequencing and Genotyping of Plasmodium falciparum in Individual Patients in Western Kenya. Scientific Reports, 2017, 7, 41108.	1.6	20
463	Population Parameters Underlying an Ongoing Soft Sweep in Southeast Asian Malaria Parasites. Molecular Biology and Evolution, 2017, 34, 131-144.	3.5	87

#	Article	IF	Citations
464	Last parasite standing. Nature Reviews Microbiology, 2017, 15, 4-4.	13.6	1
465	Synthesis of an organo-ruthenium aminoquinoline-trioxane hybrid and evaluation of its activity against Plasmodium falciparum and its toxicity toward normal mammalian cells. Medicinal Chemistry Research, 2017, 26, 473-483.	1.1	15
466	Potential of marine natural products against drug-resistant fungal, viral, and parasitic infections. Lancet Infectious Diseases, The, 2017, 17, e30-e41.	4.6	113
467	Malaria Epidemiology at the Clone Level. Trends in Parasitology, 2017, 33, 974-985.	1.5	48
468	Sustained Ex Vivo Susceptibility of Plasmodium falciparum to Artemisinin Derivatives but Increasing Tolerance to Artemisinin Combination Therapy Partner Quinolines in The Gambia. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	16
469	Changing Antimalarial Drug Sensitivities in Uganda. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	52
470	Population Pharmacokinetic and Pharmacodynamic Modeling of Artemisinin Resistance in Southeast Asia. AAPS Journal, 2017, 19, 1842-1854.	2.2	12
471	K13 Propeller Alleles, mdr1 Polymorphism, and Drug Effectiveness at Day 3 after Artemether-Lumefantrine Treatment for Plasmodium falciparum Malaria in Colombia, 2014-2015. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	6
472	Discovery of new antimalarial agents: Second-generation dual inhibitors against FP-2 and PfDHFR via fragments assembely. Bioorganic and Medicinal Chemistry, 2017, 25, 6467-6478.	1.4	12
473	A Dynamic Stress Model Explains the Delayed Drug Effect in Artemisinin Treatment of Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	9
474	Impact of Intermittent Preventive Treatment During Pregnancy on Plasmodium falciparum Drug Resistanceâ€“Mediating Polymorphisms in Uganda. Journal of Infectious Diseases, 2017, 216, 1008-1017.	1.9	25
475	A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue. Nature Communications, 2017, 8, 14574.	5.8	110
476	Hydrogen peroxide dynamics in subcellular compartments of malaria parasites using genetically encoded redox probes. Scientific Reports, 2017, 7, 10449.	1.6	24
477	Heterologous Expression, Purification, and Functional Analysis of Plasmodium falciparum Phosphatidylinositol 3â€²-Kinase. Biochemistry, 2017, 56, 4335-4345.	1.2	21
478	Plasmodium falciparum inÂvitro continuous culture conditions: A comparison of parasite susceptibility and tolerance to anti-malarial drugs throughout the asexual intra-erythrocytic life cycle. International Journal for Parasitology: Drugs and Drug Resistance, 2017, 7, 295-302.	1.4	24
479	Synthesis of a Bicyclic Azetidine with In Vivo Antimalarial Activity Enabled by Stereospecific, Directed C(sp³)â€“H Arylation. Journal of the American Chemical Society, 2017, 139, 11300-11306.	6.6	104
480	A mechanistic model quantifies artemisinin-induced parasite growth retardation in blood-stage Plasmodium falciparum infection. Journal of Theoretical Biology, 2017, 430, 117-127.	0.8	9
481	Association of a Novel Mutation in the Plasmodium falciparum Chloroquine Resistance Transporter With Decreased Piperaquine Sensitivity. Journal of Infectious Diseases, 2017, 216, 468-476.	1.9	102

#	Article	IF	Citations
482	Adaptive immunity is essential in preventing recrudescence ofPlasmodium yoeliimalaria parasites after artesunate treatment. Cellular Microbiology, 2017, 19, e12763.	1.1	7
483	An in silico strategy for identification of novel drug targets against Plasmodium falciparum. Parasitology Research, 2017, 116, 2539-2559.	0.6	7
484	Malaria. Nature Reviews Disease Primers, 2017, 3, 17050.	18.1	423
485	Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic. Nature Medicine, 2017, 23, 917-928.	15.2	384
486	Plasmodium P47 : a key gene for malaria transmission by mosquito vectors. Current Opinion in Microbiology, 2017, 40, 168-174.	2.3	51
487	Activities of 11â€Azaartemisinin and Nâ€Sulfonyl Derivatives against Asexual and Transmissible Malaria Parasites. ChemMedChem, 2017, 12, 2086-2093.	1.6	17
488	Prevalence of mutations linked to antimalarial resistance in Plasmodium falciparum from Chhattisgarh, Central India: A malaria elimination point of view. Scientific Reports, 2017, 7, 16690.	1.6	32
489	Enantioselective Synthesis and in Vivo Evaluation of Regioisomeric Analogues of the Antimalarial Arterolane. Journal of Medicinal Chemistry, 2017, 60, 6400-6407.	2.9	17
490	Development of a Potent Inhibitor of the Plasmodium Proteasome with Reduced Mammalian Toxicity. Journal of Medicinal Chemistry, 2017, 60, 6721-6732.	2.9	70
491	Protein Degradation Systems as Antimalarial Therapeutic Targets. Trends in Parasitology, 2017, 33, 731-743.	1.5	46
492	Absence of in vivo selection for K13 mutations after artemetherâ€“lumefantrine treatment in Uganda. Malaria Journal, 2017, 16, 23.	0.8	24
493	Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisininâ€“piperaquine in the south of Vietnam. Malaria Journal, 2017, 16, 27.	0.8	130
494	In vitro activity of anti-malarial ozonides against an artemisinin-resistant isolate. Malaria Journal, 2017, 16, 45.	0.8	23
495	Reduced ex vivo susceptibility of Plasmodium falciparum after oral artemetherâ€“lumefantrine treatment in Mali. Malaria Journal, 2017, 16, 59.	0.8	27
496	Efficacy of artemetherâ€“lumefantrine, artesunateâ€“amodiaquine, and dihydroartemisininâ€“piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015. Malaria Journal, 2017, 16, 62.	0.8	60
497	Confirmation of Plasmodium falciparum in vitro resistance to monodesethylamodiaquine and chloroquine in Dakar, Senegal, in 2015. Malaria Journal, 2017, 16, 118.	0.8	10
498	Therapeutic efficacy and artemisinin resistance in northern Myanmar: evidence from in vivo and molecular marker studies. Malaria Journal, 2017, 16, 143.	0.8	19
499	Characterization of Plasmodium falciparum genes associated with drug resistance in Hodh Elgharbi, a malaria hotspot near Malianâ€“Mauritanian border. Malaria Journal, 2017, 16, 140.	0.8	9

#	Article	IF	Citations
500	An intricate case of multidrug resistant Plasmodium falciparum isolate imported from Cambodia. Malaria Journal, 2017, 16, 149.	0.8	7
501	High resolution melting: a useful field-deployable method to measure dhfr and dhps drug resistance in both highly and lowly endemic Plasmodium populations. Malaria Journal, 2017, 16, 153.	0.8	9
502	Molecular surveillance of Plasmodium falciparum drug resistance in the Republic of Congo: four and nine years after the introduction of artemisinin-based combination therapy. Malaria Journal, 2017, 16, 155.	0.8	22
503	Molecular markers of anti-malarial drug resistance in Central, West and East African children with severe malaria. Malaria Journal, 2017, 16, 217.	0.8	20
504	Longitudinal study of Plasmodium pathogens identifies new loci associated with artemisinin resistance. Genome Biology, 2017, 18, 79.	3.8	4
505	Detection of the Plasmodium falciparum Kelch-13 gene P553L mutation in sporozoites isolated from mosquito salivary glands in South-Central Vietnam. Parasites and Vectors, 2017, 10, 308.	1.0	6
506	Domestic trends in malaria research and development in China and its global influence. Infectious Diseases of Poverty, 2017, 6, 4.	1.5	6
507	Hidden reservoir of resistant parasites: the missing link in the elimination of falciparum malaria. Infectious Diseases of Poverty, 2017, 6, 12.	1.5	10
508	Knockout of the peroxiredoxin 5 homologue PFAOP does not affect the artemisinin susceptibility of Plasmodium falciparum. Scientific Reports, 2017, 7, 4410.	1.6	8
509	New genetic marker for piperaquine resistance in Plasmodium falciparum. Lancet Infectious Diseases, The, 2017, 17, 119-121.	4.6	8
510	Dissecting malaria biology and epidemiology using population genetics and genomics. International Journal for Parasitology, 2017, 47, 77-85.	1.3	56
511	High Rate of Treatment Failures in Nonimmune Travelers Treated With Artemether-Lumefantrine for UncomplicatedPlasmodium falciparumMalaria in Sweden: Retrospective Comparative Analysis of Effectiveness and Case Series. Clinical Infectious Diseases, 2017, 64, 199-206.	2.9	41
512	Genome-Wide Association Studies of Drug-Resistance Determinants. Trends in Parasitology, 2017, 33, 214-230.	1.5	16
513	Genetic markers associated with dihydroartemisininâ€“piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotypeâ€“phenotype association study. Lancet Infectious Diseases, The, 2017, 17, 164-173.	4.6	301
514	Plasmodium falciparum Genetic Diversity in Continental Equatorial Guinea before and after Introduction of Artemisinin-Based Combination Therapy. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	17
515	A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotypeâ€“genotype association study. Lancet Infectious Diseases, The, 2017, 17, 174-183.	4.6	302
516	Antiparasitic Agents. , 2017, , 1345-1372.e2.		15
517	A Redox-Active Fluorescent pH Indicator for Detecting Plasmodium falciparum Strains with Reduced Responsiveness to Quinoline Antimalarial Drugs. ACS Infectious Diseases, 2017, 3, 119-131.	1.8	7

#	Article	IF	Citations
518	Development of replication-deficient adenovirus malaria vaccines. Expert Review of Vaccines, 2017, 16, 261-271.	2.0	14
519	The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. FEMS Microbiology Reviews, 2017, 41, 34-48.	3.9	171
520	Elimination of malaria: halfway there. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2017, 111, 1-2.	0.7	7
521	Molecular markers for artemisinin and partner drug resistance in natural Plasmodium falciparum populations following increased insecticide treated net coverage along the slope of mount Cameroon: cross-sectional study. Infectious Diseases of Poverty, 2017, 6, 136.	1.5	32
522	Randomised controlled trial of two sequential artemisinin-based combination therapy regimens to treat uncomplicated falciparum malaria in African children: a protocol to investigate safety, efficacy and adherence. BMJ Global Health, 2017, 2, e000371.	2.0	23
523	Correlation of in vitro Sensitivity of Chloroquine and other Antimalarials with the Partner Drug Resistance to Plasmodium falciparum Malaria in Selected Sites of India. Indian Journal of Medical Microbiology, 2017, 35, 485-490.	0.3	4
524	PageRank influence analysis of protein-protein association networks in the malaria parasite Plasmodium falciparum. International Journal of Computational Biology and Drug Design, 2017, 10, 137.	0.3	3
525	Transmission dynamics of co-endemic Plasmodium vivax and P. falciparum in Ethiopia and prevalence of antimalarial resistant genotypes. PLoS Neglected Tropical Diseases, 2017, 11, e0005806.	1.3	57
526	Progress in the Optimization of 4(1H)-Quinolone Derivatives as Antimalarials Targeting the Erythrocytic, the Exoerythrocytic and the Transmitting Stages of the Malaria Parasite. Chimia, 2017, 71, 213.	0.3	2
527	Genetic markers of artemisinin resistance in Plasmodium spp. parasites. Emerging Topics in Life Sciences, 2017, 1, 525-531.	1.1	5
528	Infectious Disease Genomics. , 2017, , 211-225.		2
529	Drug-Resistant Polymorphisms and Copy Numbers inPlasmodium falciparum, Mozambique, 2015. Emerging Infectious Diseases, 2017, 24, 40-48.	2.0	42
530	Fortilin: A Potential Target for the Prevention and Treatment of Human Diseases. Advances in Clinical Chemistry, 2017, 82, 265-300.	1.8	16
531	Bibliometric Analysis of Worldwide Publications on Antimalarial Drug Resistance (2006â€“2015). Malaria Research and Treatment, 2017, 2017, 1-13.	2.0	27
532	Sustained Effectiveness of a Fixed-Dose Combination of Artesunate and Amodiaquine in 480 Patients with Uncomplicated Plasmodium falciparum Malaria in CÃ´te dâ€™Ivoire. Malaria Research and Treatment, 2017, 2017, 1-8.	2.0	1
533	Treatment Failure of Dihydroartemisinin/Piperaquine for Plasmodium falciparum Malaria, Vietnam. Emerging Infectious Diseases, 2017, 23, 715-717.	2.0	76
534	Drug resistance in protozoan parasites. Emerging Topics in Life Sciences, 2017, 1, 627-632.	1.1	37
535	Declining Transmission and Immunity to Malaria and Emerging Artemisinin Resistance in Thailand: A Longitudinal Study. Journal of Infectious Diseases, 2017, 216, 723-731.	1.9	15

#	Article	IF	Citations
536	Profiling molecular factors associated with pyknosis and developmental arrest induced by an opioid receptor antagonist and dihydroartemisinin in Plasmodium falciparum. PLoS ONE, 2017, 12, e0184874.	1.1	4
537	malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication. PLoS Medicine, 2017, 14, e1002455.	3.9	87
538	A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria. BMC Medicine, 2017, 15, 181.	2.3	49
539	Malaria epidemiology in central Myanmar: identification of a multi-species asymptomatic reservoir of infection. Malaria Journal, 2017, 16, 16.	0.8	48
540	Malaria in Brazil, Colombia, Peru and Venezuela: current challenges in malaria control and elimination. Malaria Journal, 2017, 16, 273.	0.8	173
541	Clinical and molecular surveillance of artemisinin resistant falciparum malaria in Myanmar (2009â€“2013). Malaria Journal, 2017, 16, 333.	0.8	18
542	Molecular analysis demonstrates high prevalence of chloroquine resistance but no evidence of artemisinin resistance in Plasmodium falciparum in the Chittagong Hill Tracts of Bangladesh. Malaria Journal, 2017, 16, 335.	0.8	12
543	Prevalence of K13 mutation and Day-3 positive parasitaemia in artemisinin-resistant malaria endemic area of Cambodia: a cross-sectional study. Malaria Journal, 2017, 16, 372.	0.8	18
544	Plasmodium falciparum Kelch 13 mutations and treatment response in patients in Hpa-Pun District, Northern Kayin State, Myanmar. Malaria Journal, 2017, 16, 480.	0.8	20
545	Functional characterization of Plasmodium berghei PSOP25 during ookinete development and as a malaria transmission-blocking vaccine candidate. Parasites and Vectors, 2017, 10, 8.	1.0	29
546	Plasmodium falciparum uses vitamin E to avoid oxidative stress. Parasites and Vectors, 2017, 10, 461.	1.0	31
547	Functional analysis of Plasmodium falciparum subpopulations associated with artemisinin resistance in Cambodia. Malaria Journal, 2017, 16, 493.	0.8	17
548	Partner-Drug Resistance and Population Substructuring of Artemisinin-Resistant Plasmodium falciparum in Cambodia. Genome Biology and Evolution, 2017, 9, 1673-1686.	1.1	45
549	Polymorphisms of Plasmodium falciparum k13-propeller gene among migrant workers returning to Henan Province, China from Africa. BMC Infectious Diseases, 2017, 17, 560.	1.3	28
550	Severe Plasmodium falciparum malaria in a traveller returning from Mozambique. Jammi, 2017, 2, 97-101.	0.3	0
551	Molecular Evidence of Drug Resistance in Asymptomatic Malaria Infections, Myanmar, 2015. Emerging Infectious Diseases, 2017, 23, 517-520.	2.0	22
552	Plasmodium falciparum. Emerging Topics in Life Sciences, 2017, 1, 517-523.	1.1	3
553	Novel Plasmodium falciparum metabolic network reconstruction identifies shifts associated with clinical antimalarial resistance. BMC Genomics, 2017, 18, 543.	1.2	36

#	Article	IF	Citations
554	Methods for monitoring artemisinin-based combination therapies efficacy. Clinical Reviews and Opinions, 2017, 8, 1-13.	1.0	4
555	Capacity Development through the US Presidentâ€™s Malaria Initiativeâ€“Supported Antimalarial Resistance Monitoring in Africa Network. Emerging Infectious Diseases, 2017, 23, .	2.0	23
556	Bioavailability and Pharmacokinetics of Dihydroartemisinin (DHA) and its Analogsâ€”Mechanistic Studies on its ADME. Current Pharmacology Reports, 2018, 4, 33-44.	1.5	2
557	Rocaglates as dual-targeting agents for experimental cerebral malaria. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2366-E2375.	3.3	24
558	Antimalarial activity of phytol derivatives: in vitro and in vivo study. Medicinal Chemistry Research, 2018, 27, 1345-1354.	1.1	9
559	A Novel Single-Nucleotide Polymorphism Loop Mediated Isothermal Amplification Assay for Detection of Artemisinin-Resistant Plasmodium falciparum Malaria. Open Forum Infectious Diseases, 2018, 5, ofy011.	0.4	20
560	The prevalence of molecular markers of drug resistance in Plasmodium vivax from the border regions of Thailand in 2008 and 2014. International Journal for Parasitology: Drugs and Drug Resistance, 2018, 8, 229-237.	1.4	30
561	Plasmodium falciparum resistance to artemisinin-based combination therapies: A sword of Damocles in the path toward malaria elimination. Parasite, 2018, 25, 24.	0.8	111
562	Plasmodium falciparum Falcipain-2a Polymorphisms in Southeast Asia and Their Association With Artemisinin Resistance. Journal of Infectious Diseases, 2018, 218, 434-442.	1.9	32
563	Predictive Model for the Sequence-Dependent Fluorogenic Response of Forced-Intercalation Peptide Nucleic Acid. ACS Omega, 2018, 3, 3813-3818.	1.6	3
564	Malaria. Lancet, The, 2018, 391, 1608-1621.	6.3	374
565	Genetic diversity of the Plasmodium vivax phosphatidylinositol 3-kinase gene in two regions of the China-Myanmar border. Infection, Genetics and Evolution, 2018, 61, 45-52.	1.0	4
566	Origins of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective genetic study. Lancet Infectious Diseases, The, 2018, 18, 337-345.	4.6	161
567	Evolutionary ARMS Race: Antimalarial Resistance Molecular Surveillance. Trends in Parasitology, 2018, 34, 322-334.	1.5	9
568	Contribution to Malaria Transmission of Symptomatic and Asymptomatic Parasite Carriers in Cambodia. Journal of Infectious Diseases, 2018, 217, 1561-1568.	1.9	43
569	Recent updates in the discovery and development of novel antimalarial drug candidates. MedChemComm, 2018, 9, 437-453.	3.5	52
570	Multidrug-resistant Plasmodium falciparum malaria in the Greater Mekong subregion. Lancet Infectious Diseases, The, 2018, 18, 238-239.	4.6	11
571	Immune Responses in Malaria Transmission. Current Clinical Microbiology Reports, 2018, 5, 38-44.	1.8	4

#	Article	IF	Citations
572	Artemisinin Therapy for Malaria in Hemoglobinopathies: A Systematic Review. Clinical Infectious Diseases, 2018, 66, 799-804.	2.9	7
573	Emergence and Spread of kelch13 Mutations Associated with Artemisinin Resistance in Plasmodium falciparum Parasites in 12 Thai Provinces from 2007 to 2016. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	19
574	Endoperoxide-based compounds: cross-resistance with artemisinins and selection of a Plasmodium falciparum lineage with a K13 non-synonymous polymorphism. Journal of Antimicrobial Chemotherapy, 2018, 73, 395-403.	1.3	14
575	Disrupting CD147-RAP2 interaction abrogates erythrocyte invasion by Plasmodium falciparum. Blood, 2018, 131, 1111-1121.	0.6	43
576	Drug resistance in Plasmodium. Nature Reviews Microbiology, 2018, 16, 156-170.	13.6	296
577	Closing in on the Reservoir: Proactive Case Detection in High-Risk Groups as a Strategy to Detect Plasmodium falciparum Asymptomatic Carriers in Cambodia. Clinical Infectious Diseases, 2018, 66, 1610-1617.	2.9	15
578	Remodeling of the malaria parasite and host human red cell by vesicle amplification that induces artemisinin resistance. Blood, 2018, 131, 1234-1247.	0.6	80
579	Parasite-Mediated Degradation of Synthetic Ozonide Antimalarials Impacts In Vitro Antimalarial Activity. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	17
580	Design, synthesis, and antiprotozoal evaluation of new 2,9â€bis[(substitutedâ€aminomethyl)phenyl]â€1,10â€phenanthroline derivatives. Chemical Biology and Drug Design, 2018, 91, 974-995.	1.5	20
581	Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Science, 2018, 359, 191-199.	6.0	194
582	Malaria parasite evolution in a test tube. Science, 2018, 359, 159-160.	6.0	10
583	Malariaâ€"Update on Antimalarial Resistance and Treatment Approaches. Pediatric Infectious Disease Journal, 2018, 37, 367-369.	1.1	14
584	Phytohormones, Isoprenoids, and Role of the Apicoplast in Recovery from Dihydroartemisinin-Induced Dormancy of Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	15
585	Isolation, Derivative Synthesis, and Structureâ€"Activity Relationships of Antiparasitic Bromopyrrole Alkaloids from the Marine Sponge Tedania brasiliensis. Journal of Natural Products, 2018, 81, 188-202.	1.5	40
586	Prevalence of molecular markers of artemisinin and lumefantrine resistance among patients with uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2015. Malaria Journal, 2018, 17, 84.	0.8	28
587	Profiling of the anti-malarial drug candidate SC83288 against artemisinins in Plasmodium falciparum. Malaria Journal, 2018, 17, 121.	0.8	6
588	Checks and balances? DNA replication and the cell cycle in Plasmodium. Parasites and Vectors, 2018, 11, 216.	1.0	91
589	Plasmepsin IIâ€"III copy number accounts for bimodal piperaquine resistance among Cambodian Plasmodium falciparum. Nature Communications, 2018, 9, 1769.	5.8	85

#	Article	IF	Citations
590	Synthesis and study of the antimalarial cardamom peroxide. Tetrahedron, 2018, 74, 3358-3369.	1.0	7
591	Updates on k13 mutant alleles for artemisinin resistance in Plasmodium falciparum. Journal of Microbiology, Immunology and Infection, 2018, 51, 159-165.	1.5	20
592	Drug repurposing screens and synergistic drugâ€combinations for infectious diseases. British Journal of Pharmacology, 2018, 175, 181-191.	2.7	181
593	Predictors of antimalarial self-medication in illegal gold miners in French Guiana: a pathway towards artemisinin resistance. Journal of Antimicrobial Chemotherapy, 2018, 73, 231-239.	1.3	32
594	Malaria medicines to address drug resistance and support malaria elimination efforts. Expert Review of Clinical Pharmacology, 2018, 11, 61-70.	1.3	35
595	A human microdose study of the antimalarial drug GSK3191607 in healthy volunteers. British Journal of Clinical Pharmacology, 2018, 84, 482-489.	1.1	9
596	Humanized mouse models infected with human Plasmodium species for antimalarial drug discovery. Expert Opinion on Drug Discovery, 2018, 13, 131-140.	2.5	7
597	Antiplasmodial Activity shown by Secondary Metabolites Extracted from the Seeds of Pentaclethramacrophylla Benth. IOP Conference Series: Earth and Environmental Science, 2018, 173, 012012.	0.2	1
599	Epidemiology, drug resistance, and pathophysiology ofPlasmodium vivaxmalaria. Journal of Vector Borne Diseases, 2018, 55, 1.	0.1	66
601	Plasmodium falciparum drug resistance gene status in the Horn of Africa: A systematic review. African Journal of Pharmacy and Pharmacology, 2018, 12, 361-373.	0.2	5
602	Tackling resistance: emerging antimalarials and new parasite targets in the era of elimination. F1000Research, 2018, 7, 1170.	0.8	18
603	Malaria Surveillance â€" United States, 2015. MMWR Surveillance Summaries, 2018, 67, 1-28.	18.6	207
604	Highlights on the Application of Genomics and Bioinformatics in the Fight Against Infectious Diseases: Challenges and Opportunities in Africa. Frontiers in Genetics, 2018, 9, 575.	1.1	23
605	Assessment of drug resistance associated genetic diversity in Mauritanian isolates of Plasmodium vivax reveals limited polymorphism. Malaria Journal, 2018, 17, 416.	0.8	9
606	K13-propeller gene polymorphisms in Plasmodium falciparum parasite population: a systematic review protocol of burden and associated factors. Systematic Reviews, 2018, 7, 199.	2.5	4
607	Reactive Flow in Unconsolidated Sandstone: Application to Carbon Geosequestration. , 2018, , .		1
608	Artemisinin resistance phenotypes and K13 inheritance in a Plasmodium falciparum cross and Aotus model. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12513-12518.	3.3	46
609	Emerging implications of policies on malaria treatment: genetic changes in thePfmdr-1gene affecting susceptibility to artemetherâ€"lumefantrine and artesunateâ€"amodiaquine in Africa. BMJ Global Health, 2018, 3, e000999.	2.0	58

#	Article	IF	Citations
610	Plasmodium falciparum Treated with Artemisinin-based Combined Therapy Exhibits Enhanced Mutation, Heightened Cortisol and TNF-Î± Induction. International Journal of Medical Sciences, 2018, 15, 1449-1457.	1.1	4
611	Mutations in Plasmodium falciparum actin-binding protein coronin confer reduced artemisinin susceptibility. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12799-12804.	3.3	114
612	Heterogeneous distribution of k13 mutations in Plasmodium falciparum in Laos. Malaria Journal, 2018, 17, 483.	0.8	9
613	Plasmodium falciparum artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance. Malaria Journal, 2018, 17, 463.	0.8	8
614	Genetic association between the Pfk13 gene mutation and artemisinin resistance phenotype in Plasmodium falciparum isolates from Yunnan Province, China. Malaria Journal, 2018, 17, 478.	0.8	11
615	Prevalence of molecular markers of sulfadoxineâ€“pyrimethamine and artemisinin resistance in Plasmodium falciparum from Pakistan. Malaria Journal, 2018, 17, 471.	0.8	17
616	The origins of malaria artemisinin resistance defined by a genetic and transcriptomic background. Nature Communications, 2018, 9, 5158.	5.8	41
617	Fitness Loss under Amino Acid Starvation in Artemisinin-Resistant Plasmodium falciparum Isolates from Cambodia. Scientific Reports, 2018, 8, 12622.	1.6	21
618	Altered expression of K13 disrupts DNA replication and repair in Plasmodium falciparum. BMC Genomics, 2018, 19, 849.	1.2	31
619	Alternative pathway to reduced artemisinin susceptibility in Plasmodium falciparum. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12556-12558.	3.3	9
620	Quantification of Free Ferriprotoporphyrin IX Heme and Hemozoin for Artemisinin Sensitive versus Delayed Clearance Phenotype Plasmodium falciparum Malarial Parasites. Biochemistry, 2018, 57, 6927-6934.	1.2	28
621	Dihydroartemisininâ€“Ferriprotoporphyrin IX Adduct Abundance in Plasmodium falciparum Malarial Parasites and the Relationship to Emerging Artemisinin Resistance. Biochemistry, 2018, 57, 6935-6945.	1.2	25
622	Efficacy of artemetherâ€“lumefantrine and dihydroartemisininâ€“piperaquine for the treatment of uncomplicated malaria in Papua New Guinea. Malaria Journal, 2018, 17, 350.	0.8	15
623	The structure and evolution of eukaryotic chaperonin-containing TCP-1 and its mechanism that folds actin into a protein spring. Biochemical Journal, 2018, 475, 3009-3034.	1.7	36
624	Editorial overview: Tuberculosis, malaria and schistosomiasis; understanding resistance and development of new drugs. Current Opinion in Pharmacology, 2018, 42, iv-vi.	1.7	2
625	Hemozoin inhibiting 2-phenylbenzimidazoles active against malaria parasites. European Journal of Medicinal Chemistry, 2018, 159, 243-254.	2.6	25
626	Molecular assays for antimalarial drug resistance surveillance: A target product profile. PLoS ONE, 2018, 13, e0204347.	1.1	24
627	Surveillance of Antimalarial Resistance Pfcrt, Pfmdr1, and Pfkelch13 Polymorphisms in African Plasmodium falciparum imported to Shandong Province, China. Scientific Reports, 2018, 8, 12951.	1.6	19

#	Article	IF	Citations
628	High-level artemisinin-resistance with quinine co-resistance emerges in P. falciparum malaria under in vivo artesunate pressure. BMC Medicine, 2018, 16, 181.	2.3	26
629	In Silico Investigation of the Decline in Clinical Efficacy of Artemisinin Combination Therapies Due to Increasing Artemisinin and Partner Drug Resistance. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	4
630	Malaria parasite clearance from patients following artemisinin-based combination therapy in Côte d’Ivoire. Infection and Drug Resistance, 2018, Volume 11, 2031-2038.	1.1	11
631	Gametocytes from K13 Propeller Mutant Plasmodium falciparum Clinical Isolates Demonstrate Reduced Susceptibility to Dihydroartemisinin in the Male Gamete Exflagellation Inhibition Assay. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	10
632	Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity. International Journal for Parasitology: Drugs and Drug Resistance, 2018, 8, 459-464.	1.4	61
633	Prevalence of Plasmodium falciparum infection among pregnant women at first antenatal visit in post-Ebola Monrovia, Liberia. Malaria Journal, 2018, 17, 357.	0.8	8
634	Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome. Journal of Medicinal Chemistry, 2018, 61, 10053-10066.	2.9	54
635	No polymorphisms in K13-propeller gene associated with artemisinin resistance in Plasmodium falciparum isolated from Brazzaville, Republic of Congo. BMC Infectious Diseases, 2018, 18, 538.	1.3	16
636	Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania. Malaria Journal, 2018, 17, 369.	0.8	48
637	Prevalence of Plasmodium falciparum antimalarial drug resistance genes in Southeastern Gabon from 2011 to 2014. Infection and Drug Resistance, 2018, Volume 11, 1329-1338.	1.1	30
638	Identity-by-descent analyses for measuring population dynamics and selection in recombining pathogens. PLoS Genetics, 2018, 14, e1007279.	1.5	86
639	Artemisinin kills malaria parasites by damaging proteins and inhibiting the proteasome. Nature Communications, 2018, 9, 3801.	5.8	193
640	Absence of a High Level of Duplication of the Plasmepsin II Gene in Africa. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	11
641	Intra-host dynamics of co-infecting parasite genotypes in asymptomatic malaria patients. Infection, Genetics and Evolution, 2018, 65, 414-424.	1.0	18
642	Gene copy number variation in natural populations of Plasmodium falciparum in Eastern Africa. BMC Genomics, 2018, 19, 372.	1.2	12
643	Resistance screening and trend analysis of imported falciparum malaria in NSW, Australia (2010 to) Tj ETQq1 1 0.784314 rgBT /Overl	1.1	13
644	The Artemisinin Resistance in Southeast Asia: An Imminent Global Threat to Malaria Elimination. , 0, , .		8
645	Genotyping for Plasmodium spp.: Diagnosis and Monitoring of Antimalarial Drug Resistance. , 0, , .		2

#	Article	IF	Citations
646	Malaria Transmission-Blocking Vaccines: Present Status and Future Perspectives. , 0, , .		12
647	Novel antimalarial chloroquine- and primaquine-quinoxaline 1,4-di-N-oxide hybrids: Design, synthesis, Plasmodium life cycle stage profile, and preliminary toxicity studies. European Journal of Medicinal Chemistry, 2018, 158, 68-81.	2.6	43
648	Implications of population-level immunity for the emergence of artemisinin-resistant malaria: a mathematical model. Malaria Journal, 2018, 17, 279.	0.8	26
649	Efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Nepal. Tropical Diseases, Travel Medicine and Vaccines, 2018, 4, 9.	0.9	3
650	Drugs in Development for Malaria. Drugs, 2018, 78, 861-879.	4.9	154
651	Longitudinal surveillance of drug resistance in Plasmodium falciparum isolates from the China-Myanmar border reveals persistent circulation of multidrug resistant parasites. International Journal for Parasitology: Drugs and Drug Resistance, 2018, 8, 320-328.	1.4	22
652	Routine In Vitro Culture of Plasmodium falciparum: Experimental Consequences?. Trends in Parasitology, 2018, 34, 564-575.	1.5	17
653	Consistent signatures of selection from genomic analysis of pairs of temporal and spatial Plasmodium falciparum populations from The Gambia. Scientific Reports, 2018, 8, 9687.	1.6	33
654	Genomic analysis of a pre-elimination Malaysian Plasmodium vivax population reveals selective pressures and changing transmission dynamics. Nature Communications, 2018, 9, 2585.	5.8	59
655	Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E6863-E6870.	3.3	71
656	Surveillance of Genetic Variations Associated with Antimalarial Resistance of Plasmodium falciparum Isolates from Returned Migrant Workers in Wuhan, Central China. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	12
657	Efficacy of artemisinin-based combination therapies and prevalence of molecular markers associated with artemisinin, piperaquine and sulfadoxine-pyrimethamine resistance in Sierra Leone. Acta Tropica, 2018, 185, 363-370.	0.9	13
658	An innovative diagnostic technology for the codon mutation C580Y in kelch13 of Plasmodium falciparum with MinION nanopore sequencer. Malaria Journal, 2018, 17, 217.	0.8	25
659	Artemisinin-ResistantPlasmodium falciparumwith High Survival Rates, Uganda, 2014â€“2016. Emerging Infectious Diseases, 2018, 24, 718-726.	2.0	104
660	Absence of K13 Polymorphism in Plasmodium falciparum from Brazilian Areas Where the Parasite Is Endemic. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	8
661	Phenotypic and genotypic characterization of Thai isolates of Plasmodium falciparum after an artemisinin resistance containment project. Malaria Journal, 2018, 17, 197.	0.8	5
663	Malaria Elimination in the Greater Mekong Subregion: Challenges and Prospects. , 0, , .		12
664	Malaria Elimination: Challenges and Opportunities. , 2018, , .		1

#	Article	IF	Citations
665	Introduction of F446I mutation in the K13 propeller gene leads to increased ring survival rates in Plasmodium falciparum isolates. Malaria Journal, 2018, 17, 248.	0.8	25
666	How to combat emerging artemisinin resistance: Lessons from â€œThe Three Little Pigsâ€• PLoS Pathogens, 2018, 14, e1006923.	2.1	7
667	Increasing the Strength and Production of Artemisinin and Its Derivatives. Molecules, 2018, 23, 100.	1.7	24
668	In situ loop-mediated isothermal amplification (LAMP) for identification of Plasmodium species in wide-range thin blood smears. Malaria Journal, 2018, 17, 235.	0.8	10
669	Tools for surveillance of anti-malarial drug resistance: an assessment of the current landscape. Malaria Journal, 2018, 17, 75.	0.8	57
670	Direct whole-genome sequencing of Plasmodium falciparum specimens from dried erythrocyte spots. Malaria Journal, 2018, 17, 91.	0.8	12
671	Expanding the SAR of Nontoxic Antiplasmodial Indolylâ€3â€ethanone Ethers and Thioethers. ChemMedChem, 2018, 13, 1353-1362.	1.6	11
672	Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria â€“ a proposed model-derived age-based regimen for sub-Saharan Africa. BMC Medicine, 2018, 16, 11.	2.3	10
673	Efficacy of artesunateâ€“amodiaquine, dihydroartemisininâ€“piperaquine and artemetherâ€“lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Maradi, Niger. Malaria Journal, 2018, 17, 52.	0.8	20
674	The D113N mutation in the RING E3 ubiquitin protein ligase gene is not associated with ex vivo susceptibility to common anti-malarial drugs in African Plasmodium falciparum isolates. Malaria Journal, 2018, 17, 108.	0.8	6
675	Prevalence of Plasmodium falciparum delayed clearance associated polymorphisms in adaptor protein complex 2 mu subunit (pfap2mu) and ubiquitin specific protease 1 (pfubp1) genes in Ghanaian isolates. Parasites and Vectors, 2018, 11, 175.	1.0	27
676	New endoperoxides highly active in vivo and in vitro against artemisinin-resistant Plasmodium falciparum. Malaria Journal, 2018, 17, 145.	0.8	27
677	A novel field-based molecular assay to detect validated artemisinin-resistant k13 mutants. Malaria Journal, 2018, 17, 175.	0.8	4
678	The proteasome as a target to combat malaria: hits and misses. Translational Research, 2018, 198, 40-47.	2.2	31
679	Drug targets for resistant malaria: Historic to future perspectives. Biomedicine and Pharmacotherapy, 2018, 104, 8-27.	2.5	74
680	Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine. Nature Communications, 2018, 9, 3314.	5.8	183
681	Mechanisms of resistance to the partner drugs of artemisinin in the malaria parasite. Current Opinion in Pharmacology, 2018, 42, 71-80.	1.7	22
682	Phthalimide Derivatives with Bioactivity againstPlasmodium falciparum: Synthesis, Evaluation, and Computational Studies Involvingbc1Cytochrome Inhibition. ACS Omega, 2018, 3, 9424-9430.	1.6	18

#	Article	IF	Citations
683	Defining the Determinants of Specificity of Plasmodium Proteasome Inhibitors. Journal of the American Chemical Society, 2018, 140, 11424-11437.	6.6	54
684	Imported and autochthonous malaria in West Saudi Arabia: results from a reference hospital. Malaria Journal, 2018, 17, 286.	0.8	16
685	Prevalence of chloroquine resistance alleles among Plasmodium falciparum parasites in countries affected by malaria disease since change of treatment policy: a systematic review protocol. Systematic Reviews, 2018, 7, 108.	2.5	8
686	High prevalence of Plasmodium falciparum antimalarial drug resistance markers in isolates from asymptomatic patients from the Republic of the Congo between 2010 and 2015. Journal of Global Antimicrobial Resistance, 2018, 14, 277-283.	0.9	6
687	Photo-Induced Electron Transfer Real-Time PCR for Detection of Plasmodium falciparum plasmepsin 2 Gene Copy Number. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	4
688	Model System Identifies Kinetic Driver of Hsp90 Inhibitor Activity against African Trypanosomes and Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	10
689	Artemisone and Artemiside Are Potent Panreactive Antimalarial Agents That Also Synergize Redox Imbalance in Plasmodium falciparum Transmissible Gametocyte Stages. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	39
690	Impact of treatment and re-treatment with artemether-lumefantrine and artesunate-amodiaquine on selection of Plasmodium falciparum multidrug resistance gene-1 polymorphisms in the Democratic Republic of Congo and Uganda. PLoS ONE, 2018, 13, e0191922.	1.1	20
691	Large-scale Artemisininâ€“Piperaquine Mass Drug Administration With or Without Primaquine Dramatically Reduces Malaria in a Highly Endemic Region of Africa. Clinical Infectious Diseases, 2018, 67, 1670-1676.	2.9	39
692	Fitness Costs and the Rapid Spread of kelch13 -C580Y Substitutions Conferring Artemisinin Resistance. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	56
693	Oxidative stress and protein damage responses mediate artemisinin resistance in malaria parasites. PLoS Pathogens, 2018, 14, e1006930.	2.1	129
694	Rational Structure-Based Drug Design. , 2019, , 585-600.		3
695	Molecular detection of drug resistant malaria in Southern Thailand. Malaria Journal, 2019, 18, 275.	0.8	28
696	Molecular surveillance of putative drug resistance markers of antifolate and artemisinin among imported Plasmodium falciparum in Qatar. Pathogens and Global Health, 2019, 113, 158-166.	1.0	7
697	The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. Journal of Medicinal Chemistry, 2019, 62, 10526-10562.	2.9	53
698	Proof of concept: used malaria rapid diagnostic tests applied for parallel sequencing for surveillance of molecular markers of anti-malarial resistance in Bissau, Guinea-Bissau during 2014â€“2017. Malaria Journal, 2019, 18, 252.	0.8	17
699	Malaria Molecular Epidemiology: An Evolutionary Genetics Perspective. Microbiology Spectrum, 2019, 7, .	1.2	31
700	Evolution of Plasmodium falciparum drug resistance genes following artemisinin combination therapy in Sudan. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2019, 113, 693-700.	0.7	13

#	Article	IF	Citations
701	Molecular Surveillance of Drug Resistance of Plasmodium falciparum Isolates Imported from Angola in Henan Province, China. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	8
702	Artemisinin and its derivatives; ancient tradition inspiring the latest therapeutic approaches against malaria. Future Medicinal Chemistry, 2019, 11, 1443-1459.	1.1	28
703	Genomic and biological features of Plasmodium falciparum resistance against antimalarial endoperoxide N-89. Gene, 2019, 716, 144016.	1.0	4
704	Plasmodium Genomics and Genetics: New Insights into Malaria Pathogenesis, Drug Resistance, Epidemiology, and Evolution. Clinical Microbiology Reviews, 2019, 32, .	5.7	65
705	Efficacy and Safety of Pyronaridine-Artesunate plus Single-Dose Primaquine for the Treatment of Malaria in Western Cambodia. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	12
706	Protozoan persister-like cells and drug treatment failure. Nature Reviews Microbiology, 2019, 17, 607-620.	13.6	97
707	High therapeutic efficacy of artemetherâ€“lumefantrine and dihydroartemisininâ€“piperaquine for the treatment of uncomplicated falciparum malaria in Somalia. Malaria Journal, 2019, 18, 231.	0.8	21
708	Elucidating Mechanisms of Drug-Resistant Plasmodium falciparum. Cell Host and Microbe, 2019, 26, 35-47.	5.1	85
709	Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study. Lancet Infectious Diseases, The, 2019, 19, 943-951.	4.6	219
710	Accelerated evolution and spread of multidrug-resistant Plasmodium falciparum takes down the latest first-line antimalarial drug in southeast Asia. Lancet Infectious Diseases, The, 2019, 19, 916-917.	4.6	27
711	Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infectious Diseases, The, 2019, 19, 952-961.	4.6	252
712	Comparative structural and evolutionary analyses predict functional sites in the artemisinin resistance malaria protein K13. Scientific Reports, 2019, 9, 10675.	1.6	28
713	Antimalarial drug resistance in Africa: the calm before the storm?. Lancet Infectious Diseases, The, 2019, 19, e338-e351.	4.6	167
714	Genetic diversity and drug resistance surveillance of Plasmodium falciparum for malaria elimination: is there an ideal tool for resource-limited sub-Saharan Africa?. Malaria Journal, 2019, 18, 217.	0.8	46
715	Malaria Control and Elimination. Methods in Molecular Biology, 2019, , .	0.4	2
716	An Update on Artemisinin Resistance. Methods in Molecular Biology, 2019, 2013, 141-149.	0.4	1
718	Current Malaria Situation in Asia-Oceania. Methods in Molecular Biology, 2019, 2013, 45-56.	0.4	3
719	In Vivo Assessments to Detect Antimalarial Resistance. Methods in Molecular Biology, 2019, 2013, 105-121.	0.4	1

#	Article	IF	Citations
720	Ozonide Antimalarials Alkylate Heme in the Malaria Parasite Plasmodium falciparum. ACS Infectious Diseases, 2019, 5, 2076-2086.	1.8	16
721	Stochastic Protein Alkylation by Antimalarial Peroxides. ACS Infectious Diseases, 2019, 5, 2067-2075.	1.8	23
722	Next Generation Sequencing and Bioinformatics Methodologies for Infectious Disease Research and Public Health: Approaches, Applications, and Considerations for Development of Laboratory Capacity. Journal of Infectious Diseases, 2020, 221, S292-S307.	1.9	64
723	Pairwise growth competitions identify relative fitness relationships among artemisinin resistant Plasmodium falciparum field isolates. Malaria Journal, 2019, 18, 295.	0.8	30
724	Absence of kelch13 artemisinin resistance markers but strong selection for lumefantrine-tolerance molecular markers following 18Âyears of artemisinin-based combination therapy use in Mpumalanga Province, South Africa (2001â€“2018). Malaria Journal, 2019, 18, 280.	0.8	18
725	Profiles of Kelch mutations in Plasmodium falciparum across South Asia and their implications for tracking drug resistance. International Journal for Parasitology: Drugs and Drug Resistance, 2019, 11, 49-58.	1.4	26
726	Genetic mapping of fitness determinants across the malaria parasiteÂPlasmodium falciparum life cycle. PLoS Genetics, 2019, 15, e1008453.	1.5	33
727	Imported malaria and artemisinin-based combination therapy failure in travellers returning to Belgium: A retrospective study. Travel Medicine and Infectious Disease, 2019, 32, 101505.	1.5	12
728	South African Abietane Diterpenoids and Their Analogs as Potential Antimalarials: Novel Insights from Hybrid Computational Approaches. Molecules, 2019, 24, 4036.	1.7	6
729	Artemisinin Bioactivity and Resistance in Malaria Parasites. Trends in Parasitology, 2019, 35, 953-963.	1.5	80
730	K13-propeller gene polymorphisms of Plasmodium falciparum and the therapeutic effect of artesunate among migrant workers returning to Guangxi, China (2014â€“2017). Malaria Journal, 2019, 18, 349.	0.8	7
731	Plasmodium falciparum Kelch Propeller Polymorphisms in Clinical Isolates from Ghana from 2007 to 2016. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	25
732	Validation of the protein kinase Pf CLK3 as a multistage cross-species malarial drug target. Science, 2019, 365, .	6.0	51
733	Artesunate activation by heme in an aqueous medium. Inorganica Chimica Acta, 2019, 496, 119029.	1.2	5
734	No antimalarial resistance of Plasmodium falciparum varian West Indonesia using molecular markers screening. Journal of Physics: Conference Series, 2019, 1282, 012077.	0.3	1
735	Are k13 and plasmepsin II genes, involved in Plasmodium falciparum resistance to artemisinin derivatives and piperaquine in Southeast Asia, reliable to monitor resistance surveillance in Africa?. Malaria Journal, 2019, 18, 285.	0.8	14
736	Deployment and utilization of next-generation sequencing of Plasmodium falciparum to guide anti-malarial drug policy decisions in sub-Saharan Africa: opportunities and challenges. Malaria Journal, 2019, 18, 267.	0.8	21
737	K-13 propeller gene polymorphisms isolated between 2014 and 2017 from Cameroonian Plasmodium falciparum malaria patients. PLoS ONE, 2019, 14, e0221895.	1.1	17

#	Article	IF	Citations
738	Chemical Genomic Profiling Unveils the in Vitro and in Vivo Antiplasmodial Mechanism of AÃ§aÄ±Ì• (Euterpe oleracea Mart.) Polyphenols. ACS Omega, 2019, 4, 15628-15635.	1.6	10
739	It is not just artemisinin: Artemisia sp. for treating diseases including malaria and schistosomiasis. Phytochemistry Reviews, 2019, 18, 1509-1527.	3.1	18
740	In vitro activity of ferroquine against artemisinin-based combination therapy (ACT)-resistant Plasmodium falciparum isolates from Cambodia. Journal of Antimicrobial Chemotherapy, 2019, 74, 3240-3244.	1.3	7
741	Rare mutations in Pfmdr1 gene of Plasmodium falciparum detected in clinical isolates from patients treated with anti-malarial drug in Nigeria. Malaria Journal, 2019, 18, 319.	0.8	15
742	Characterization of drug resistance and genetic diversity of Plasmodium falciparum parasites from Tripura, Northeast India. Scientific Reports, 2019, 9, 13704.	1.6	11
743	Development of pyridyl thiosemicarbazones as highly potent agents for the treatment of malaria after oral administration. Journal of Antimicrobial Chemotherapy, 2019, 74, 2965-2973.	1.3	9
744	Genetic Variations Associated with Drug Resistance Markers in Asymptomatic Plasmodium falciparum Infections in Myanmar. Genes, 2019, 10, 692.	1.0	20
745	A systematic review on anti-malarial drug discovery and antiplasmodial potential of green synthesis mediated metal nanoparticles: overview, challenges and future perspectives. Malaria Journal, 2019, 18, 337.	0.8	18
746	Genome-Wide Analysis of Genetic Diversity in Plasmodium falciparum Isolates From Chinaâ€“Myanmar Border. Frontiers in Genetics, 2019, 10, 1065.	1.1	22
747	Low polymorphisms in pfact, pfugt and pfcarl genes in African Plasmodium falciparum isolates and absence of association with susceptibility to common anti-malarial drugs. Malaria Journal, 2019, 18, 293.	0.8	1
748	Molecular characterization and mapping of glucose-6-phosphate dehydrogenase (G6PD) mutations in the Greater Mekong Subregion. Malaria Journal, 2019, 18, 20.	0.8	36
749	Association of mutations in the Plasmodium falciparum Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatmentsâ€”a WWARN individual patient data meta-analysis. BMC Medicine, 2019, 17, 1.	2.3	465
750	Susceptibility of Plasmodium falciparum to artemisinins and Plasmodium vivax to chloroquine in Phuoc Chien Commune, Ninh Thuan Province, south-central Vietnam. Malaria Journal, 2019, 18, 10.	0.8	12
751	Artemisinin Resistance in Eastern India. Clinical Infectious Diseases, 2019, 69, 1153-1155.	2.9	6
752	Artemisinin Resistance and Stage Dependency of Parasite Clearance in Falciparum Malaria. Journal of Infectious Diseases, 2019, 219, 1483-1489.	1.9	25
753	Medicinal Mushrooms as Novel Sources for New Antiparasitic Drug Development. , 2019, , 251-273.		5
754	Sequential Open-Label Study of the Safety, Tolerability, and Pharmacokinetic Interactions between Dihydroartemisinin-Piperaquine and Mefloquine in Healthy Thai Adults. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	9
755	Detection of Single-Nucleotide Polymorphism Markers of Antimalarial Drug Resistance Directly from Whole Blood. Journal of Molecular Diagnostics, 2019, 21, 623-631.	1.2	9

#	Article	IF	Citations
756	An alternative dogma on reduced artemisinin susceptibility: A new shadow from east to west. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 12611-12612.	3.3	14
757	Reply to Velavan et al.: Polymorphisms ofpfcoroninin natural populations: Implications for functional significance. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 12613-12614.	3.3	5
758	Ozonide Antimalarial Activity in the Context of Artemisinin-Resistant Malaria. Trends in Parasitology, 2019, 35, 529-543.	1.5	40
759	Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents. PLoS Pathogens, 2019, 15, e1007722.	2.1	58
760	Artemisinin-Based Antimalarial Drug Therapy: Molecular Pharmacology and Evolving Resistance. Tropical Medicine and Infectious Disease, 2019, 4, 89.	0.9	30
761	Post-Genomic Approaches to Understanding Malaria Parasite Biology: Linking Genes to Biological Functions. ACS Infectious Diseases, 2019, 5, 1269-1278.	1.8	20
762	Kelch 13 propeller gene polymorphism among Plasmodium falciparum isolates in Lagos, Nigeria: Molecular Epidemiologic Study. Tropical Medicine and International Health, 2019, 24, 1011-1017.	1.0	8
763	Bridged bicyclic 2,3-dioxabicyclo[3.3.1]nonanes as antiplasmodial agents: Synthesis, structure-activity relationships and studies on their biomimetic reaction with Fe(II). Bioorganic Chemistry, 2019, 89, 103020.	2.0	13
764	Substituted Aminoacetamides as Novel Leads for Malaria Treatment. ChemMedChem, 2019, 14, 1329-1335.	1.6	5
765	An improved nucleic acid extraction method from dried blood spots for amplification of Plasmodium falciparum kelch13 for detection of artemisinin resistance. Malaria Journal, 2019, 18, 192.	0.8	16
766	Structure-Guided Identification of Resistance Breaking Antimalarial Nâ€'Myristoyltransferase Inhibitors. Cell Chemical Biology, 2019, 26, 991-1000.e7.	2.5	26
767	Evolution and Genetic Diversity of the k13 Gene Associated with Artemisinin Delayed Parasite Clearance in Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	15
768	Contribution of Functional Antimalarial Immunity to Measures of Parasite Clearance in Therapeutic Efficacy Studies of Artemisinin Derivatives. Journal of Infectious Diseases, 2019, 220, 1178-1187.	1.9	21
769	Development of artemisinin resistance in malaria therapy. Pharmacological Research, 2019, 146, 104275.	3.1	34
770	Development and Evaluation of a Novel HNB Based Isothermal Amplification Assay for Fast Detection of Pyrimethamine Resistance (S108N) in Plasmodium falciparum. International Journal of Environmental Research and Public Health, 2019, 16, 1635.	1.2	12
771	In vitro susceptibility of Plasmodium falciparum isolates from the China-Myanmar border area to artemisinins and correlation with K13 mutations. International Journal for Parasitology: Drugs and Drug Resistance, 2019, 10, 20-27.	1.4	20
772	Investigation and Evaluation of Genetic Diversity of Plasmodium falciparum Kelch 13 Polymorphisms Imported From Southeast Asia and Africa in Southern China. Frontiers in Public Health, 2019, 7, 95.	1.3	13
773	Upregulation of gametocytogenesis in anti-malarial drug-resistant Plasmodium falciparum. Journal of Parasitic Diseases, 2019, 43, 458-463.	0.4	4

#	Article	IF	Citations
774	Polymorphisms in Plasmodium falciparum Kelch 13 and P. vivax Kelch 12 Genes in Parasites Collected from Three South Pacific Countries Prior to Extensive Exposure to Artemisinin Combination Therapies. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	5
775	Global Spread of Mutant PfCRT and Its Pleiotropic Impact on Plasmodium falciparum Multidrug Resistance and Fitness. MBio, 2019, 10, .	1.8	35
776	Analysis of Plasmodium falciparum Na+/H+ exchanger (pfnhe1) polymorphisms among imported African malaria parasites isolated in Wuhan, Central China. BMC Infectious Diseases, 2019, 19, 354.	1.3	2
777	Absence of K13 gene mutations among artesunate/sulfadoxineâ€“pyrimethamine treatment failures of Sudanese Plasmodium falciparum isolates from Damazin, southeast Sudan. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2019, 113, 428-430.	0.7	4
778	Polymorphisms in Pvkelch12 and gene amplification of Pvplasmepsin4 in Plasmodium vivax from Thailand, Lao PDR and Cambodia. Malaria Journal, 2019, 18, 114.	0.8	4
779	Two successful decades of Swiss collaborations to develop new anti-malarials. Malaria Journal, 2019, 18, 94.	0.8	8
780	Artemisinin resistance-associated markers in Plasmodium falciparum parasites from the China-Myanmar border: predicted structural stability of K13 propeller variants detected in a low-prevalence area. PLoS ONE, 2019, 14, e0213686.	1.1	18
781	Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania. Malaria Journal, 2019, 18, 88.	0.8	40
782	Drug repurposing for antimicrobial discovery. Nature Microbiology, 2019, 4, 565-577.	5.9	217
783	K13-propeller gene polymorphisms in Plasmodium falciparum parasite population in malaria affected countries: a systematic review of prevalence and risk factors. Malaria Journal, 2019, 18, 60.	0.8	32
784	More on Artemisinin-Resistant Plasmodium falciparum in Eastern India. New England Journal of Medicine, 2019, 380, e14.	13.9	3
785	Plasmodium falciparum malarial parasites from Brazil lack artemisinin resistance-associated mutations in the kelch13 gene. Revista Da Sociedade Brasileira De Medicina Tropical, 2019, 52, e20180225.	0.4	3
786	Plasmodium falciparum K13 expression associated with parasite clearance during artemisinin-based combination therapy. Journal of Antimicrobial Chemotherapy, 2019, 74, 1890-1893.	1.3	17
787	Persistence of chloroquine resistance alleles in malaria endemic countries: a systematic review of burden and risk factors. Malaria Journal, 2019, 18, 76.	0.8	51
788	African isolates show a high proportion of multiple copies of the Plasmodium falciparum plasmepsin-2 gene, a piperaquine resistance marker. Malaria Journal, 2019, 18, 126.	0.8	22
790	Clinical impact of the two ART resistance markers, K13 gene mutations and DPC3 in Vietnam. PLoS ONE, 2019, 14, e0214667.	1.1	11
791	The Challenge of Quantifying Synchrony in Malaria Parasites. Trends in Parasitology, 2019, 35, 341-355.	1.5	16
792	A small-molecule inhibitor of the DNA recombinase Rad51 from Plasmodium falciparum synergizes with the antimalarial drugs artemisinin and chloroquine. Journal of Biological Chemistry, 2019, 294, 8171-8183.	1.6	23

#	Article	IF	Citations
793	Viability Screen of LOPAC ¹²⁸⁰ Reveals Tyrosine Kinase Inhibitor Tyrphostin A9 as a Novel Partner Drug for Artesunate Combinations To Target the Plasmodium falciparum Ring Stage. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	2
794	Resistance to Artemisinin Combination Therapies (ACTs): Do Not Forget the Partner Drug!. Tropical Medicine and Infectious Disease, 2019, 4, 26.	0.9	74
795	Antiplasmodial potential and GC-MS fingerprint of endophytic fungal extracts derived from Cameroonian Annona muricata. Journal of Ethnopharmacology, 2019, 235, 111-121.	2.0	18
796	Accessibility of substituted cysteines in TM2 and TM10 transmembrane segments in the Plasmodium falciparum equilibrative nucleoside transporter PfENT1. Journal of Biological Chemistry, 2019, 294, 1924-1935.	1.6	3
797	The Adaptive Proline Response in P. falciparum Is Independent of PfeIK1 and eIF2Î± Signaling. ACS Infectious Diseases, 2019, 5, 515-520.	1.8	5
798	Targeting malaria parasite invasion of red blood cells as an antimalarial strategy. FEMS Microbiology Reviews, 2019, 43, 223-238.	3.9	56
799	2. SMALL MOLECULES: THE PAST OR THE FUTURE IN DRUG INNOVATION?. , 2019, , 17-48.		5
800	Pharmacokinetic and Pharmacodynamic Profiles of Rapid- and Slow-Acting Antimalarial Drugs. , 0, , .		3
801	The resistome and genomic reconnaissance in the age of malaria elimination. DMM Disease Models and Mechanisms, 2019, 12, .	1.2	10
802	Modification of pfap2Î¼ and pfubp1 Markedly Reduces Ring-Stage Susceptibility of Plasmodium falciparum to Artemisinin In Vitro. Antimicrobial Agents and Chemotherapy, 2019, 64, .	1.4	45
803	No Evidence of Plasmodium falciparum k13 Artemisinin Resistance-Conferring Mutations over a 24-Year Analysis in Coastal Kenya but a Near Complete Reversion to Chloroquine-Sensitive Parasites. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	26
804	The Diversity of the Plasmodium falciparum K13 Propeller Domain Did Not Increase after Implementation of Artemisinin-Based Combination Therapy in Uganda. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	9
805	New Molecular Targets and Strategies for Antimalarial Discovery. Current Medicinal Chemistry, 2019, 26, 4380-4402.	1.2	16
806	A comprehensive analysis of drug resistance molecular markers and Plasmodium falciparum genetic diversity in two malaria endemic sites in Mali. Malaria Journal, 2019, 18, 361.	0.8	25
807	Monitoring of efficacy, tolerability and safety of artemetherâ€“lumefantrine and artesunateâ€“amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in LambarÃ©nÃ©, Gabon: an open-label clinical trial. Malaria Journal, 2019, 18, 424.	0.8	18
808	8. DEVELOPING VANADIUM AS AN ANTIDIABETIC OR ANTICANCER DRUG: A CLINICAL AND HISTORICAL PERSPECTIVE. , 2019, 19, 203-230.		24
809	Rubber plantations and drug resistant malaria: a cross-sectional survey in Cambodia. Malaria Journal, 2019, 18, 379.	0.8	8
810	Decreased K13 Abundance Reduces Hemoglobin Catabolism and Proteotoxic Stress, Underpinning Artemisinin Resistance. Cell Reports, 2019, 29, 2917-2928.e5.	2.9	113

#	Article	IF	Citations
811	In vitro selection predicts malaria parasite resistance to dihydroorotate dehydrogenase inhibitors in a mouse infection model. Science Translational Medicine, 2019, 11, .	5.8	30
812	Intravenous Artesunate for Imported Severe Malaria in Children Treated in Four Tertiary Care Centers in Germany. Pediatric Infectious Disease Journal, 2019, 38, e295-e300.	1.1	7
813	Anti-malarial ozonides OZ439 and OZ609 tested at clinically relevant compound exposure parameters in a novel ring-stage survival assay. Malaria Journal, 2019, 18, 427.	0.8	13
814	Genomics and precision medicine for malaria: A dream come true?. , 2019, , 223-255.		0
815	The genomic architecture of antimalarial drug resistance. Briefings in Functional Genomics, 2019, 18, 314-328.	1.3	66
816	Malaria in North-East India: Importance and Implications in the Era of Elimination. Microorganisms, 2019, 7, 673.	1.6	30
817	Strengthening Surveillance Systems for Malaria Elimination by Integrating Molecular and Genomic Data. Tropical Medicine and Infectious Disease, 2019, 4, 139.	0.9	13
818	Genetic profiling of the Plasmodium falciparum parasite population in uncomplicated malaria from India. Malaria Journal, 2019, 18, 385.	0.8	9
819	Evolution of resistance in vitro reveals mechanisms of artemisinin activity in Toxoplasma gondii. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26881-26891.	3.3	30
820	In vitro and in vivo antimalarial activity of Nigella sativa L. extracts. Journal of Medicinal Plants Research, 2019, 13, 501-508.	0.2	1
821	Changing Molecular Markers of Antimalarial Drug Sensitivity across Uganda. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	39
822	Novel pfkelch13 Gene Polymorphism Associates With Artemisinin Resistance in Eastern India. Clinical Infectious Diseases, 2019, 69, 1144-1152.	2.9	59
823	Efficacy and Safety of Pyronaridine-Artesunate plus Single-Dose Primaquine for Treatment of Uncomplicated Plasmodium falciparum Malaria in Eastern Cambodia. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	18
824	Plasmodium genomics: an approach for learning about and ending human malaria. Parasitology Research, 2019, 118, 1-27.	0.6	45
825	To kill a piroplasm: genetic technologies to advance drug discovery and target identification in Babesia. International Journal for Parasitology, 2019, 49, 153-163.	1.3	15
826	Current scenario and future strategies to fight artemisinin resistance. Parasitology Research, 2019, 118, 29-42.	0.6	11
827	Diversity and biting patterns of Anopheles species in a malaria endemic area, Umphang Valley, Tak Province, western Thailand. Acta Tropica, 2019, 190, 183-192.	0.9	16
828	Unpacking the Pathogen Boxâ€"An Open Source Tool for Fighting Neglected Tropical Disease. ChemMedChem, 2019, 14, 386-453.	1.6	46

#	Article	IF	Citations
829	Identification of the Binding Site of Apical Membrane Antigenâ€...1 (AMA1) Inhibitors Using a Paramagnetic Probe. ChemMedChem, 2019, 14, 603-612.	1.6	9
830	Management of severe imported malaria in adults. MÃ©decine Et Maladies Infectieuses, 2020, 50, 213-225.	5.1	13
831	Importance of kelch 13 C580Y mutation in the studies of artemisinin resistance in Plasmodium falciparum in Greater Mekong Subregion. Journal of Microbiology, Immunology and Infection, 2020, 53, 676-681.	1.5	8
832	A Novel Antiparasitic Compound Kills Ring-Stage Plasmodium falciparum and Retains Activity Against Artemisinin-Resistant Parasites. Journal of Infectious Diseases, 2020, 221, 956-962.	1.9	10
833	Pyronaridine-artesunate Efficacy and Safety in Uncomplicated Plasmodium falciparum Malaria in Areas of Artemisinin-resistant Falciparum in Viet Nam (2017â€“2018). Clinical Infectious Diseases, 2020, 70, 2187-2195.	2.9	23
834	Pyronaridine-artesunate Shows Promise as an Effective and Well-tolerated Treatment for Artemisinin-resistant Plasmodium falciparum Malaria. Clinical Infectious Diseases, 2020, 70, 2196-2198.	2.9	2
835	Changes in malaria epidemiology in France and worldwide, 2000â€“2015. MÃ©decine Et Maladies Infectieuses, 2020, 50, 99-112.	5.1	19
836	Falcipain cysteine proteases of malaria parasites: An update. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2020, 1868, 140362.	1.1	32
837	Design, synthesis, and antiprotozoal evaluation of new 2,4-bis[(substituted-aminomethyl)phenyl]quinoline, 1,3-bis[(substituted-aminomethyl)phenyl]isoquinoline and 2,4-bis[(substituted-aminomethyl)phenyl]quinazoline derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 432-459.	2.5	14
838	A Kelch13-defined endocytosis pathway mediates artemisinin resistance in malaria parasites. Science, 2020, 367, 51-59.	6.0	275
839	Uncovering the ART of antimalarial resistance. Science, 2020, 367, 22-23.	6.0	7
840	Developments in drug design strategies for bromodomain protein inhibitors to target Plasmodium falciparum parasites. Expert Opinion on Drug Discovery, 2020, 15, 415-425.	2.5	11
841	Detecting sequence variants in clinically important protozoan parasites. International Journal for Parasitology, 2020, 50, 1-18.	1.3	2
842	Identification of Selective Inhibitors of Plasmodium N-Myristoyltransferase by High-Throughput Screening. Journal of Medicinal Chemistry, 2020, 63, 591-600.	2.9	17
843	Prevalence of mutations in Plasmodium falciparum genes associated with resistance to different antimalarial drugs in Nyando, Kisumu County in Kenya. Infection, Genetics and Evolution, 2020, 78, 104121.	1.0	7
844	Atovaquone-proguanil treatment failure in a case of pediatric Plasmodium falciparum infection: Malabsorption and resistance. Travel Medicine and Infectious Disease, 2020, 37, 101829.	1.5	1
845	Surveillance of molecular markers for antimalarial resistance in Zambia: Polymorphism of Pfkelch 13, Pfmdr1 and Pfdhfr/Pfdhps genes. Acta Tropica, 2020, 212, 105704.	0.9	4
846	Humanized Mice and the Rebirth of Malaria Genetic Crosses. Trends in Parasitology, 2020, 36, 850-863.	1.5	24

#	Article	IF	Citations
847	Purification and initial characterization of Plasmodium falciparum K+ channels, PfKch1 and PfKch2 produced in Saccharomyces cerevisiae. Microbial Cell Factories, 2020, 19, 183.	1.9	6
848	Resistance to Some But Not Other Dimeric Lindenane Sesquiterpenoid Esters Is Mediated by Mutations in a Plasmodium falciparum Esterase. ACS Infectious Diseases, 2020, 6, 2994-3003.	1.8	11
849	Update on malaria. Medicina ClÃnica, 2020, 155, 395-402.	0.3	39
850	Absence of association between polymorphisms in the pfcoronin and pfk13 genes and the presence of Plasmodium falciparum parasites after treatment with artemisinin derivatives in Senegal. International Journal of Antimicrobial Agents, 2020, 56, 106190.	1.1	11
851	Protecting future antimalarials from the trap of resistance: Lessons from artemisinin-based combination therapy (ACT) failures. Journal of Pharmaceutical Analysis, 2021, 11, 541-554.	2.4	8
852	Retargeting azithromycin analogues to have dual-modality antimalarial activity. BMC Biology, 2020, 18, 133.	1.7	13
853	Studying Land Cover Changes in a Malaria-Endemic Cambodian District: Considerations and Constraints. Remote Sensing, 2020, 12, 2972.	1.8	7
854	Increased Sensitivity of Plasmodium falciparum to Artesunate/Amodiaquine Despite 14 Years as First-Line Malaria Treatment, Zanzibar. Emerging Infectious Diseases, 2020, 26, 1767-1777.	2.0	11
855	Advances and roadblocks in the treatment of malaria. British Journal of Clinical Pharmacology, 2022, 88, 374-382.	1.1	36
856	Polymorphism analysis of propeller domain of k13 gene in Plasmodium ovale curtisi and Plasmodium ovale wallikeri isolates original infection from Myanmar and Africa in Yunnan Province, China. Malaria Journal, 2020, 19, 246.	0.8	5
857	K13, the Cytostome, and Artemisinin Resistance. Trends in Parasitology, 2020, 36, 533-544.	1.5	54
858	Artemisinin and artemisinin-related agents. , 2020, , 99-132.		7
859	Identification of compounds active against quiescent artemisinin-resistant Plasmodium falciparum parasites via the quiescent-stage survival assay (QSA). Journal of Antimicrobial Chemotherapy, 2020, 75, 2826-2834.	1.3	14
860	Genomic and Transcriptomic Analysis for Identification of Genes and Interlinked Pathways Mediating Artemisinin Resistance in Leishmania donovani. Genes, 2020, 11, 1362.	1.0	6
861	Plasmodium berghei K13 Mutations Mediate In Vivo Artemisinin Resistance That Is Reversed by Proteasome Inhibition. MBio, 2020, 11, .	1.8	15
862	Update on malaria. Medicina ClÃnica (English Edition), 2020, 155, 395-402.	0.1	8
863	Kelch 13-propeller polymorphisms in Plasmodium falciparum from Jazan region, southwest Saudi Arabia. Malaria Journal, 2020, 19, 397.	0.8	3
864	In vitro and in vivo Effects of Artesunate on Echinococcus granulosus Protoscoleces and Metacestodes . Drug Design, Development and Therapy, 2020, Volume 14, 4685-4694.	2.0	8

#	Article	IF	Citations
865	Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study. Lancet Infectious Diseases, The, 2020, 20, 1470-1480.	4.6	94
866	The birth of artemisinin. , 2020, 216, 107658.		150
867	K13-Mediated Reduced Susceptibility to Artemisinin in Plasmodium falciparum Is Overlaid on a Trait of Enhanced DNA Damage Repair. Cell Reports, 2020, 32, 107996.	2.9	21
868	Implementing parasite genotyping into national surveillance frameworks: feedback from control programmes and researchers in the Asiaâ€"Pacific region. Malaria Journal, 2020, 19, 271.	0.8	31
869	The Plasmodium falciparum eIK1 kinase (PfeIK1) is central for melatonin synchronization in the human malaria parasite. Melatotosil blocks melatonin action on parasite cell cycle. Journal of Pineal Research, 2020, 69, e12685.	3.4	9
870	Characterization of putative drug resistant biomarkers in Plasmodium falciparum isolated from Ghanaian blood donors. BMC Infectious Diseases, 2020, 20, 533.	1.3	11
871	Piperaquine resistant Cambodian Plasmodium falciparum clinical isolates: in vitro genotypic and phenotypic characterization. Malaria Journal, 2020, 19, 269.	0.8	25
872	Development of Potent PfCLK3 Inhibitors Based on TCMDC-135051 as a New Class of Antimalarials. Journal of Medicinal Chemistry, 2020, 63, 9300-9315.	2.9	18
873	Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nature Medicine, 2020, 26, 1602-1608.	15.2	459
874	Evaluation of antimalarial prescription pattern and susceptibility of Plasmodium falciparum isolates in Kaduna, Nigeria. International Journal of Biological and Chemical Sciences, 2020, 13, 3398-3410.	0.1	0
875	Misdiagnosis of imported falciparum malaria from African areas due to an increased prevalence of pfhrp2/pfhrp3 gene deletion: the Djibouti case. Emerging Microbes and Infections, 2020, 9, 1984-1987.	3.0	23
876	Editorial: Artemisininâ€"From Traditional Chinese Medicine to Artemisinin Combination Therapies; Four Decades of Research on the Biochemistry, Physiology, and Breeding of Artemisia annua. Frontiers in Plant Science, 2020, 11, 594565.	1.7	12
877	Genetic screens reveal a central role for heme metabolism in artemisinin susceptibility. Nature Communications, 2020, 11, 4813.	5.8	34
878	Prevalence of Plasmodium falciparum Kelch 13 (PfK13) and Ubiquitin-Specific Protease 1 () Tj ETQq1 1 0.784314 rgBT /Overlo Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	7
879	Efficacy of artemether-lumefantrine for treating uncomplicated Plasmodium falciparum cases and molecular surveillance of drug resistance genes in Western Myanmar. Malaria Journal, 2020, 19, 304.	0.8	8
880	Molecular malaria surveillance using a novel protocol for extraction and analysis of nucleic acids retained on used rapid diagnostic tests. Scientific Reports, 2020, 10, 12305.	1.6	9
881	Alkoxyamines Designed as Potential Drugs against Plasmodium and Schistosoma Parasites. Molecules, 2020, 25, 3838.	1.7	9
882	A protocol for systematic review and meta-analysis of optimizing treatment for malaria. Medicine (United States), 2020, 99, e22044.	0.4	0

#	Article	IF	Citations
883	Genomic Approaches to Drug Resistance in Malaria. Annual Review of Microbiology, 2020, 74, 761-786.	2.9	12
884	Molecular Mechanisms of Drug Resistance in Plasmodium falciparum Malaria. Annual Review of Microbiology, 2020, 74, 431-454.	2.9	123
885	Molecular surveillance for drug resistance markers in Plasmodium vivax isolates from symptomatic and asymptomatic infections at the Chinaâ€“Myanmar border. Malaria Journal, 2020, 19, 281.	0.8	15
886	Stable high frequencies of sulfadoxineâ€“pyrimethamine resistance associated mutations and absence of K13 mutations in Plasmodium falciparum 3 and 4Âyears after the introduction of artesunate plus sulfadoxineâ€“pyrimethamine in Ujjain, Madhya Pradesh, India. Malaria Journal, 2020, 19, 290.	0.8	6
887	Assessment of molecular markers of anti-malarial drug resistance among children participating in a therapeutic efficacy study in western Kenya. Malaria Journal, 2020, 19, 291.	0.8	10
888	Antimalarial drug resistance molecular makers of Plasmodium falciparum isolates from Sudan during 2015â€“2017. PLoS ONE, 2020, 15, e0235401.	1.1	18
889	Safety and parasite clearance of artemisinin-resistant Plasmodium falciparum infection: A pilot and a randomised volunteer infection study in Australia. PLoS Medicine, 2020, 17, e1003203.	3.9	26
890	The lack of K13-propeller mutations associated with artemisinin resistance in Plasmodium falciparum in Democratic Republic of Congo (DRC). PLoS ONE, 2020, 15, e0237791.	1.1	6
891	A novel multistage antiplasmodial inhibitor targeting Plasmodium falciparum histone deacetylase 1. Cell Discovery, 2020, 6, 93.	3.1	23
892	Genomic surveillance of Plasmodium falciparum and Plasmodium vivax cases at the University Hospital in Tegucigalpa, Honduras. Scientific Reports, 2020, 10, 20975.	1.6	5
893	Artemisinin resistant surveillance in African Plasmodium falciparum isolates from imported malaria cases to Italy. Journal of Travel Medicine, 2020, 28, .	1.4	4
894	Modulation of Triple Artemisinin-Based Combination Therapy Pharmacodynamics by Plasmodium falciparum Genotype. ACS Pharmacology and Translational Science, 2020, 3, 1144-1157.	2.5	8
895	The Key Glycolytic Enzyme Phosphofructokinase Is Involved in Resistance to Antiplasmodial Glycosides. MBio, 2020, 11, .	1.8	5
896	Increased prevalence of pfdhfr and pfdhps mutations associated with sulfadoxineâ€“pyrimethamine resistance in Plasmodium falciparum isolates from Jazan Region, Southwestern Saudi Arabia: important implications for malaria treatment policy. Malaria Journal, 2020, 19, 446.	0.8	8
897	Efficacy of Artemether-Lumefantrine on various Plasmodium falciparum Kelch 13 and Pfmdr1 genes isolated in Ghana. Parasite Epidemiology and Control, 2020, 11, e00190.	0.6	6
898	Chemical Composition and In Vitro Antiplasmodial Activity of the Ethanolic Extract of Cyperus articulatus var. nodosus Residue. Pathogens, 2020, 9, 889.	1.2	7
899	Transmission of Artemisinin-Resistant Malaria Parasites to Mosquitoes under Antimalarial Drug Pressure. Antimicrobial Agents and Chemotherapy, 2020, 65, .	1.4	29
900	The Plasmodium falciparum Artemisinin Susceptibility-Associated AP-2 Adaptin Î¼ Subunit is Clathrin Independent and Essential for Schizont Maturation. MBio, 2020, 11, .	1.8	27

#	Article	IF	Citations
901	Novel Endochin-Like Quinolones Exhibit Potent In Vitro Activity against Plasmodium knowlesi but Do Not Synergize with Proguanil. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	12
902	Effect of Drug Pressure on Promoting the Emergence of Antimalarial-Resistant Parasites among Pregnant Women in Ghana. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	8
903	Molecular surveillance of the Pfmdr1 N86Y allele among Congolese pregnant women with asymptomatic malaria. Malaria Journal, 2020, 19, 178.	0.8	3
904	Plasmodium falciparum Isolates Carrying pf k13 Polymorphisms Harbor the SVMNT Allele of pfcrt in Northwestern Indonesia. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	4
905	Clinical and In Vitro Resistance of Plasmodium falciparum to Artesunate-Amodiaquine in Cambodia. Clinical Infectious Diseases, 2021, 73, 406-413.	2.9	30
906	Efficacy and safety of artemisinin-based combination therapy and the implications of Pfkelch13 and Pfcoronin molecular markers in treatment failure in Senegal. Scientific Reports, 2020, 10, 8907.	1.6	29
907	Role of Plasmodium falciparum Kelch 13 Protein Mutations in P. falciparum Populations from Northeastern Myanmar in Mediating Artemisinin Resistance. MBio, 2020, 11, .	1.8	56
908	Development of copy number assays for detection and surveillance of piperaquine resistance associated plasmepsin 2/3 copy number variation in Plasmodium falciparum. Malaria Journal, 2020, 19, 181.	0.8	18
909	Molecular assessment of kelch13 non-synonymous mutations in Plasmodium falciparum isolates from Central African Republic (2017â€“2019). Malaria Journal, 2020, 19, 191.	0.8	10
910	Efficacy of dihydroartemisinin/piperaquine and artesunate monotherapy for the treatment of uncomplicated Plasmodium falciparum malaria in Central Vietnam. Journal of Antimicrobial Chemotherapy, 2020, 75, 2272-2281.	1.3	9
911	Evolution of Antimalarial Drug Resistance Markers in the Reservoir of Plasmodium falciparum Infections in the Upper East Region of Ghana. Journal of Infectious Diseases, 2020, 222, 1692-1701.	1.9	8
912	Artemisinin attenuates early renal damage on diabetic nephropathy rats through suppressing TGF-Î²1 regulator and activating the Nrf2 signaling pathway. Life Sciences, 2020, 256, 117966.	2.0	23
913	Hybrid Gold(I) NHC-Artemether Complexes to Target Falciparum Malaria Parasites. Molecules, 2020, 25, 2817.	1.7	13
914	Differential gene expression of Plasmodium homocircumflexum (lineage pCOLL4) across two experimentally infected passerine bird species. Genomics, 2020, 112, 2857-2865.	1.3	14
915	Influx of diverse, drug resistant and transmissible Plasmodium falciparum into a malaria-free setting in Qatar. BMC Infectious Diseases, 2020, 20, 413.	1.3	5
916	Protein-Protein Interactions in Malaria: Emerging Arena for Future Chemotherapeutics. , 0, , .		0
917	Surveillance of genetic markers associated with Plasmodium falciparum resistance to artemisinin-based combination therapy in Pakistan, 2018â€“2019. Malaria Journal, 2020, 19, 206.	0.8	12
918	Targeted deep amplicon sequencing of kelch 13 and cytochrome b in Plasmodium falciparum isolates from an endemic African country using the Malaria Resistance Surveillance (MaRS) protocol. Parasites and Vectors, 2020, 13, 137.	1.0	11

#	Article	IF	Citations
919	Evaluating Antiplasmodial and Antimalarial Activities of Soybean (Glycine max) Seed Extracts on P. falciparum Parasite Cultures and P. berghei-Infected Mice. Journal of Pathogens, 2020, 2020, 1-8.	0.9	8
920	Mapping the travel patterns of people with malaria in Bangladesh. BMC Medicine, 2020, 18, 45.	2.3	11
921	Lerisetron Analogues with Antimalarial Properties: Synthesis, Structureâ€“Activity Relationship Studies, and Biological Assessment. ACS Omega, 2020, 5, 6967-6982.	1.6	10
922	Synthesis of Novel G Factor or Chloroquine-Artemisinin Hybrids and Conjugates with Potent Antiplasmodial Activity. ACS Medicinal Chemistry Letters, 2020, 11, 921-927.	1.3	23
923	Are three drugs for malaria better than two?. Lancet, The, 2020, 395, 1316-1317.	6.3	12
924	CRISPR: a revolutionary tool for genome engineering in the protozoan parasites. , 2020, , 263-280.		0
925	Hydrazines in the Synthesis of Cytotoxic N-Aryl(alkyl)-N-(hexaoxazadispiroalkyl)amines. Russian Journal of Organic Chemistry, 2020, 56, 797-801.	0.3	9
926	Mining Sudanese Medicinal Plants for Antiprotozoal Agents. Frontiers in Pharmacology, 2020, 11, 865.	1.6	12
927	Identification of Mutations in Antimalarial Resistance Gene Kelch13 from Plasmodium falciparum Isolates in Kano, Nigeria. Tropical Medicine and Infectious Disease, 2020, 5, 85.	0.9	9
928	Species diversity and genome evolution of the pathogenic protozoan parasite, Neospora caninum. Infection, Genetics and Evolution, 2020, 84, 104444.	1.0	8
929	Ex-vivo Sensitivity of Plasmodium falciparum to Common Anti-malarial Drugs: The Case of KÃ©niÃ©roba, a Malaria Endemic Village in Mali. Drugs in R and D, 2020, 20, 249-255.	1.1	4
930	Different distribution of malaria parasite in left and right extremities of vertebrate hosts translates into differences in parasite transmission. Scientific Reports, 2020, 10, 10183.	1.6	2
931	Parasite clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an extended 6-day treatment of artemetherâ€“lumefantrine and a single low-dose primaquine for uncomplicated Plasmodium falciparum malaria in Bagamoyo district, Tanzania: a randomized controlled trial. Malaria Journal, 2020, 19, 216.	0.8	7
932	Altered Drug Transport by Plasmodium falciparum Chloroquine Resistance Transporter Isoforms Harboring Mutations Associated with Piperaquine Resistance. Biochemistry, 2020, 59, 2484-2493.	1.2	11
933	â€˜Artemisinin Resistanceâ€™: Something New or Old? Something of a Misnomer?. Trends in Parasitology, 2020, 36, 735-744.	1.5	20
934	Knowing oneâ€™s enemy: the Plasmodium parasite. , 2020, , 49-64.		1
935	Comparative Transcriptome Analyses of Drugâ€sensitive and Drugâ€resistant Strains of Eimeria tenella by <scp>RNA</scp>â€sequencing. Journal of Eukaryotic Microbiology, 2020, 67, 406-416.	0.8	19
936	Detection of mutations associated with artemisinin resistance at k13-propeller gene and a near complete return of chloroquine susceptible falciparum malaria in Southeast of Tanzania. Scientific Reports, 2020, 10, 3500.	1.6	70

#	Article	IF	Citations
937	Assessment of Plasmodium falciparum drug resistance molecular markers from the Blue Nile State, Southeast Sudan. Malaria Journal, 2020, 19, 78.	0.8	7
938	Optimal 10-Aminoartemisinins With Potent Transmission-Blocking Capabilities for New Artemisinin Combination Therapiesâ€"Activities Against Blood Stage P. falciparum Including PfKI3 C580Y Mutants and Liver Stage P. berghei Parasites. Frontiers in Chemistry, 2019, 7, 901.	1.8	16
939	Antimalarial Drug Resistance Profiling of Plasmodium falciparum Infections in Ghana Using Molecular Inversion Probes and Next-Generation Sequencing. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	21
940	Design, Synthesis and Efficacy of Hybrid Triclosanâ€gold Based Molecules on Artemisininâ€resistant Plasmodium falciparum and Leishmania infantum Parasites. ChemistrySelect, 2020, 5, 619-625.	0.7	7
941	New directions in antimalarial target validation. Expert Opinion on Drug Discovery, 2020, 15, 189-202.	2.5	7
942	Exploration of copy number variation in genes related to anti-malarial drug resistance in Plasmodium falciparum. Gene, 2020, 736, 144414.	1.0	11
943	Protein S-Palmitoylation Is Responsive to External Signals and Plays a Regulatory Role in Microneme Secretion in Plasmodium falciparum Merozoites. ACS Infectious Diseases, 2020, 6, 379-392.	1.8	6
945	Role of plants in the transmission of Asaia sp., which potentially inhibit the Plasmodium sporogenic cycle in Anopheles mosquitoes. Scientific Reports, 2020, 10, 7144.	1.6	26
946	Amplicon deep sequencing of kelch13 in Plasmodium falciparum isolates from Senegal. Malaria Journal, 2020, 19, 134.	0.8	10
947	Malaria in Gold Miners in the Guianas and the Amazon: Current Knowledge and Challenges. Current Tropical Medicine Reports, 2020, 7, 37-47.	1.6	38
948	Malaria Parasite Clearance: What Are We Really Measuring?. Trends in Parasitology, 2020, 36, 413-426.	1.5	21
949	A Chemically Stable Fluorescent Mimic of Dihydroartemisinin, Artemether, and Arteether with Conserved Bioactivity and Specificity Shows High Pharmacological Relevance to the Antimalarial Drugs. ACS Infectious Diseases, 2020, 6, 1532-1547.	1.8	10
950	Plasmodium falciparum Artemisinin Resistance: The Effect of Heme, Protein Damage, and Parasite Cell Stress Response. ACS Infectious Diseases, 2020, 6, 1599-1614.	1.8	34
951	Different Plasmodium falciparum clearance times in two Malian villages following artesunate monotherapy. International Journal of Infectious Diseases, 2020, 95, 399-405.	1.5	16
952	Evaluation of residual submicroscopic Plasmodium falciparum parasites 3 days after initiation of treatment with artemisinin-based combination therapy. Malaria Journal, 2020, 19, 162.	0.8	12
953	Insights into the intracellular localization, protein associations and artemisinin resistance properties of Plasmodium falciparumÂK13. PLoS Pathogens, 2020, 16, e1008482.	2.1	60
954	Sequence Analysis of the K13-Propeller Gene in Artemisinin Challenging Plasmodium falciparum Isolates from Malaria Endemic Areas of Odisha, India: A Molecular Surveillance Study. BioMed Research International, 2020, 2020, 1-6.	0.9	7
955	Supply and demandâ€"heme synthesis, salvage and utilization by Apicomplexa. FEBS Journal, 2021, 288, 382-404.	2.2	28

#	Article	IF	Citations
956	Eight-membered heterocycles with two heteroatoms in a 1,2-relationship of interest in medicinal chemistry. Advances in Heterocyclic Chemistry, 2021, , 261-317.	0.9	1
957	Antimalarial application of quinones: A recent update. European Journal of Medicinal Chemistry, 2021, 210, 113084.	2.6	53
958	A second mechanism employed by artemisinins to suppress Plasmodium falciparum hinges on inhibition of hematin crystallization. Journal of Biological Chemistry, 2021, 296, 100123.	1.6	24
959	Continued Low Efficacy of Artemether-Lumefantrine in Angola in 2019. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	35
960	Increase in Kelch 13 Polymorphisms in Plasmodium falciparum, Southern Rwanda. Emerging Infectious Diseases, 2021, 27, 294-296.	2.0	52
961	An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins. European Journal of Medicinal Chemistry, 2021, 210, 112955.	2.6	15
962	Artemisinin susceptibility in the malaria parasite Plasmodium falciparum: propellers, adaptor proteins and the need for cellular healing. FEMS Microbiology Reviews, 2021, 45, .	3.9	24
963	Spatial and molecular mapping of Pfkelch13 gene polymorphism in Africa in the era of emerging Plasmodium falciparum resistance to artemisinin: a systematic review. Lancet Infectious Diseases, The, 2021, 21, e82-e92.	4.6	42
964	Artemisinin-Ginkgo biloba extract combination therapy for Plasmodium yoelii. Parasitology International, 2021, 80, 102226.	0.6	1
965	Triple Artemisinin-Based Combination Therapies for Malaria â€“ A New Paradigm?. Trends in Parasitology, 2021, 37, 15-24.	1.5	67
966	Dormant Plasmodium falciparum Parasites in Human Infections Following Artesunate Therapy. Journal of Infectious Diseases, 2021, 223, 1631-1638.	1.9	18
967	Artemisinin Activity in Red Blood Cells from Anemic Children. American Journal of Tropical Medicine and Hygiene, 2021, 104, 271-275.	0.6	2
968	Artemisinin derivative-containing therapies and abnormal hemoglobin: Do we need to adapt the treatment?. Parasite, 2021, 28, 67.	0.8	2
969	State of Artemisinin and Partner Drug Susceptibility in Plasmodium falciparum Clinical Isolates from Colombia. American Journal of Tropical Medicine and Hygiene, 2021, 104, 263-270.	0.6	8
971	Efficacy of artemisininâ€“lumefantrine for treatment of uncomplicated malaria after more than a decade of its use in Kenya. Epidemiology and Infection, 2021, 149, e27.	1.0	4
972	Role of Anopheles stephensi Mosquitoes in Malaria Outbreak, Djibouti, 2019. Emerging Infectious Diseases, 2021, 27, 1697-1700.	2.0	37
973	Optimization of CRISPR/Cas System for Improving Genome Editing Efficiency in Plasmodium falciparum. Frontiers in Microbiology, 2020, 11, 625862.	1.5	7
974	Persistence of Markers of Chloroquine Resistance in Plasmodium falciparum in Bangladesh. American Journal of Tropical Medicine and Hygiene, 2021, 104, 276-282.	0.6	2

#	Article	IF	Citations
975	A systems-level gene regulatory network model for Plasmodium falciparum. Nucleic Acids Research, 2021, 49, 4891-4906.	6.5	2
976	New technological developments in identification and monitoring of new and emerging infections. , 2021, , .		1
978	From Metabolite to Metabolome: Metabolomics Applications in Plasmodium Research. Frontiers in Microbiology, 2020, 11, 626183.	1.5	10
979	KASP: a genotyping method to rapid identification of resistance in Plasmodium falciparum. Malaria Journal, 2021, 20, 16.	0.8	15
980	Drug resistance markers within an evolving efficacy of anti-malarial drugs in Cameroon: a systematic review and meta-analysis (1998â€“2020). Malaria Journal, 2021, 20, 32.	0.8	10
981	Mechanisms of Anti-protozoan/Helminth Drug Resistance. Updates in Clinical Dermatology, 2021, , 157-175.	0.1	0
982	Plasmodium falciparum Malaria Parasites in Ghana Show Signatures of Balancing Selection at Artemisinin Resistance Predisposing Background Genes. Evolutionary Bioinformatics, 2021, 17, 117693432199964.	0.6	4
983	Orthostericâ€“allosteric dual inhibitors of PfHT1 as selective antimalarial agents. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	17
984	Genomic Epidemiology of Antimalarial Drug Resistance in Plasmodium falciparum in Southern China. Frontiers in Cellular and Infection Microbiology, 2020, 10, 610985.	1.8	0
986	Protocol for a quasi-experimental study to assess the feasibility, acceptability and costs of multiple first-lines artemisinin-based combination therapies for uncomplicated malaria in the Kaya health district, Burkina Faso. BMJ Open, 2021, 11, e040220.	0.8	5
987	Metabolites from Marine Sponges and Their Potential to Treat Malarial Protozoan Parasites Infection: A Systematic Review. Marine Drugs, 2021, 19, 134.	2.2	10
988	Nopol-Based Quinoline Derivatives as Antiplasmodial Agents. Molecules, 2021, 26, 1008.	1.7	10
989	Three-dimensional chromatin in infectious diseaseâ€”A role for gene regulation and pathogenicity?. PLoS Pathogens, 2021, 17, e1009207.	2.1	5
990	Molecular surveillance of pfcrt, pfmdr1 and pfk13-propeller mutations in Plasmodium falciparum isolates imported from Africa to China. Malaria Journal, 2021, 20, 73.	0.8	12
992	A LAMP-SNP Assay Detecting C580Y Mutation in Pfkelch13 Gene from Clinically Dried Blood Spot Samples. Korean Journal of Parasitology, 2021, 59, 15-22.	0.5	10
993	An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples. Wellcome Open Research, 2021, 6, 42.	0.9	97
994	Antimalarial Drug Resistance and Implications for the WHO Global Technical Strategy. Current Epidemiology Reports, 2021, 8, 46-62.	1.1	38
995	Prevalence of pfk13 and pfmdr1 polymorphisms in Bounkiling, Southern Senegal. PLoS ONE, 2021, 16, e0249357.	1.1	6

#	Article	IF	Citations
996	Case Report: The First Case of Genotypically Confirmed Plasmodium falciparum Kelch 13 Propeller Mutation in Sri Lanka and Its Implications on the Elimination Status of Malaria. American Journal of Tropical Medicine and Hygiene, 2021, 104, 964-967.	0.6	1
997	In vitro growth competition experiments that suggest consequences of the substandard artemisinin epidemic that may be accelerating drug resistance in P. falciparum malaria. PLoS ONE, 2021, 16, e0248057.	1.1	7
998	Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Antiâ€malaria Activity in Humanized Mice. Angewandte Chemie - International Edition, 2021, 60, 9279-9283.	7.2	20
1000	Multidrug-Resistant Plasmodium falciparum Parasites in the Central Highlands of Vietnam Jeopardize Malaria Control and Elimination Strategies. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	4
1002	Polymorphisms in Plasmodium falciparum chloroquine resistance transporter (Pfcrt) and multidrug-resistant gene 1 (Pfmdr-1) in Nigerian children 10Âyears post-adoption of artemisinin-based combination treatments. International Journal for Parasitology, 2021, 51, 301-310.	1.3	7
1004	Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Antiâ€malaria Activity in Humanized Mice. Angewandte Chemie, 2021, 133, 9365-9369.	1.6	2
1005	Targeting Gametocytes of the Malaria Parasite Plasmodium falciparum in a Functional Genomics Era: Next Steps. Pathogens, 2021, 10, 346.	1.2	18
1006	PfMFR3: A Multidrug-Resistant Modulator in Plasmodium falciparum. ACS Infectious Diseases, 2021, 7, 811-825.	1.8	16
1007	Malaria Surveillance â€" United States, 2017. MMWR Surveillance Summaries, 2021, 70, 1-35.	18.6	45
1008	Assessment of Plasmodium falciparum anti-malarial drug resistance markers in pfk13-propeller, pfcrt and pfmdr1 genes in isolates from treatment failure patients in Democratic Republic of Congo, 2018â€"2019. Malaria Journal, 2021, 20, 144.	0.8	6
1009	In Vitro Susceptibility of Plasmodium falciparum Isolates from the China-Myanmar Border Area to Piperaquine and Association with Candidate Markers. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	9
1010	Antimalarial drug resistance markers in human immunodeficiency virus (HIV)-positive and HIV-negative adults with asymptomatic malaria infections in Port Harcourt, Nigeria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021, 115, 531-537.	0.7	3
1011	Essential Genes of the Parasitic Apicomplexa. Trends in Parasitology, 2021, 37, 304-316.	1.5	17
1012	Dissection of haplotype-specific drug response phenotypes in multiclonal malaria isolates. International Journal for Parasitology: Drugs and Drug Resistance, 2021, 15, 152-161.	1.4	2
1013	KEAP1 Is Required for Artesunate Anticancer Activity in Non-Small-Cell Lung Cancer. Cancers, 2021, 13, 1885.	1.7	7
1014	A Class of Valuable (Pro-)Activity-Based Protein Profiling Probes: Application to the Redox-Active Antiplasmodial Agent, Plasmodione. Jacs Au, 2021, 1, 669-689.	3.6	4
1015	Recrudescence of a high parasitaemia, severe Plasmodium falciparum malaria episode, treated by artesunate monotherapy. International Journal of Infectious Diseases, 2021, 105, 345-348.	1.5	6
1016	Surveillance of Antimalarial Drug-Resistance Genes in Imported Plasmodium falciparum Isolates From Nigeria in Henan, China, 2012â€"2019. Frontiers in Cellular and Infection Microbiology, 2021, 11, 644576.	1.8	6

#	Article	IF	Citations
1017	Artemisinin-based combination therapy (ACT) and drug resistance molecular markers: A systematic review of clinical studies from two malaria endemic regions â€“ India and sub-Saharan Africa. International Journal for Parasitology: Drugs and Drug Resistance, 2021, 15, 43-56.	1.4	40
1018	Absence of Association between Methylene Blue Reduced Susceptibility and Polymorphisms in 12 Genes Involved in Antimalarial Drug Resistance in African Plasmodium falciparum. Pharmaceuticals, 2021, 14, 351.	1.7	2
1020	Molecular surveillance of drug resistance: Plasmodium falciparum artemisinin resistance single nucleotide polymorphisms in Kelch protein propeller (K13) domain from Southern Pakistan. Malaria Journal, 2021, 20, 176.	0.8	8
1022	Synthesis of Mono- and Bisperoxide-Bridged Artemisinin Dimers to Elucidate the Contribution of Dimerization to Antimalarial Activity. ACS Infectious Diseases, 2021, 7, 2013-2024.	1.8	5
1023	Advances and opportunities in malaria population genomics. Nature Reviews Genetics, 2021, 22, 502-517.	7.7	61
1024	Novel molecule combinations and corresponding hybrids targeting artemisinin-resistant Plasmodium falciparum parasites. Bioorganic and Medicinal Chemistry Letters, 2021, 39, 127884.	1.0	5
1025	A randomized, double-blind, phase 2b study to investigate the efficacy, safety, tolerability and pharmacokinetics of a single-dose regimen of ferroquine with artefenomel in adults and children with uncomplicated Plasmodium falciparum malaria. Malaria Journal, 2021, 20, 222.	0.8	29
1026	Restructured Mitochondrial-Nuclear Interaction in Plasmodium falciparum Dormancy and Persister Survival after Artemisinin Exposure. MBio, 2021, 12, e0075321.	1.8	22
1027	Identification of novel inner membrane complex and apical annuli proteins of the malaria parasite <scp> Plasmodium falciparum </scp>. Cellular Microbiology, 2021, 23, e13341.	1.1	19
1028	Multi-omics approaches to improve malaria therapy. Pharmacological Research, 2021, 167, 105570.	3.1	18
1029	Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in four malaria endemic states of India. Malaria Journal, 2021, 20, 229.	0.8	6
1030	Molecular surveillance of anti-malarial resistance pfcrt, pfmdr1, and pfk13 polymorphisms in African Plasmodium falciparum imported parasites to Wuhan, China. Malaria Journal, 2021, 20, 209.	0.8	11
1031	A Proteasome Mutation Sensitizes P.Âfalciparum Cam3.II K13^{C580Y} Parasites to DHA and OZ439. ACS Infectious Diseases, 2021, 7, 1923-1931.	1.8	6
1032	Artemisinin combination therapy fails even in the absence of Plasmodium falciparum kelch13 gene polymorphism in Central India. Scientific Reports, 2021, 11, 9946.	1.6	14
1033	An integrated virtual screening and drug repurposing strategy for the discovery of new antimalarial drugs against Plasmodium falciparum phosphatidylinositol 3â€kinase. Journal of Cellular Biochemistry, 2021, 122, 1326-1336.	1.2	6
1034	Plasmodium vivax and Drug Resistance. , 0, , .		0
1035	Plasmodium malariae and Plasmodium falciparum comparative susceptibility to antimalarial drugs in Mali. Journal of Antimicrobial Chemotherapy, 2021, 76, 2079-2087.	1.3	4
1037	A Yeast-Based Drug Discovery Platform To Identify Plasmodium falciparum Type II NADH Dehydrogenase Inhibitors. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	3

#	Article	IF	Citations
1038	Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children (SchistoSAM): protocol of a proof-of-concept, open-label, two-arm, individually-randomised controlled trial. BMJ Open, 2021, 11, e047147.	0.8	4
1039	Isolation of Mutants With Reduced Susceptibility to Piperaquine From a Mutator of the Rodent Malaria Parasite Plasmodium berghei. Frontiers in Cellular and Infection Microbiology, 2021, 11, 672691.	1.8	2
1040	Therapeutic efficacy of artesunate-amodiaquine and artemether-lumefantrine and polymorphism in Plasmodium falciparum kelch13-propeller gene in Equatorial Guinea. Malaria Journal, 2021, 20, 275.	0.8	7
1041	Perceptions about malaria among Brazilian gold miners in an Amazonian border area: perspectives for malaria elimination strategies. Malaria Journal, 2021, 20, 286.	0.8	17
1043	Characterization of pfmdr1 , pfcrt , pfK13 , pfubp1 , and pfap2mu in Travelers Returning from Africa with Plasmodium falciparum Infections Reported in China from 2014 to 2018. Antimicrobial Agents and Chemotherapy, 2021, 65, e0271720.	1.4	5
1045	Selection of pfcrt K76 and pfmdr1 N86 Coding Alleles after Uncomplicated Malaria Treatment by Artemether-Lumefantrine in Mali. International Journal of Molecular Sciences, 2021, 22, 6057.	1.8	7
1046	Plasmodium falciparum phenotypic and genotypic resistance profile during the emergence of Piperaquine resistance in Northeastern Thailand. Scientific Reports, 2021, 11, 13419.	1.6	8
1047	Genomic and Genetic Approaches to Studying Antimalarial Drug Resistance and Plasmodium Biology. Trends in Parasitology, 2021, 37, 476-492.	1.5	15
1049	The power and promise of genetic mapping from Plasmodium falciparum crosses utilizing human liver-chimeric mice. Communications Biology, 2021, 4, 734.	2.0	13
1050	Targeted deep amplicon sequencing of antimalarial resistance markers in Plasmodium falciparum isolates from Cameroon. International Journal of Infectious Diseases, 2021, 107, 234-241.	1.5	12
1052	Toward New Transmission-Blocking Combination Therapies: Pharmacokinetics of 10-Amino-Artemisinins and 11-Aza-Artemisinin and Comparison with Dihydroartemisinin and Artemether. Antimicrobial Agents and Chemotherapy, 2021, 65, e0099021.	1.4	12
1053	Mapping partner drug resistance to guide antimalarial combination therapy policies in sub-Saharan Africa. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	17
1054	Persistent Submicroscopic Plasmodium falciparum Parasitemia 72 Hours after Treatment with Artemether-Lumefantrine Predicts 42-Day Treatment Failure in Mali and Burkina Faso. Antimicrobial Agents and Chemotherapy, 2021, 65, e0087321.	1.4	7
1055	Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness. ELife, 2021, 10, .	2.8	85
1057	The apicoplast link to fever-survival and artemisinin-resistance in the malaria parasite. Nature Communications, 2021, 12, 4563.	5.8	26
1058	Molecular Detection of Mutations in the Propeller Domain of Kelch 13 and pfmdr1 Copy Number Variation in Plasmodium falciparum Isolates from Thailand Collected from 2002 to 2007. American Journal of Tropical Medicine and Hygiene, 2021, , .	0.6	3
1059	Identification of Single-Nucleotide Polymorphisms in the Mitochondrial Genome and Kelch 13 Gene of Plasmodium falciparum in Different Geographical Populations. American Journal of Tropical Medicine and Hygiene, 2021, , .	0.6	1
1060	Screening for antifolate and artemisinin resistance in Plasmodium falciparum clinical isolates from three hospitals of Eritrea. F1000Research, 0, 10, 628.	0.8	0

#	Article	IF	Citations
1061	P. falciparum and Its Molecular Markers of Resistance to Antimalarial Drugs. , 0, , .		4
1062	Plasmodium falciparum kelch13 Mutations, 9 Countries in Africa, 2014â€“2018. Emerging Infectious Diseases, 2021, 27, 1902-1908.	2.0	8
1063	Pharmacotherapy for artemisinin-resistant malaria. Expert Opinion on Pharmacotherapy, 2021, 22, 2483-2493.	0.9	6
1065	Artemisinin and multidrug-resistant Plasmodium falciparum â€“ a threat for malaria control and elimination. Current Opinion in Infectious Diseases, 2021, 34, 432-439.	1.3	51
1066	High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine. Journal of Infectious Diseases, 2022, 225, 1411-1414.	1.9	54
1067	The newly discovered role of endocytosis in artemisinin resistance. Medicinal Research Reviews, 2021, 41, 2998-3022.	5.0	16
1068	An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples. Wellcome Open Research, 2021, 6, 42.	0.9	51
1070	An analysis of Plasmodium falciparum-K13 mutations in India. Journal of Parasitic Diseases, 2022, 46, 296-303.	0.4	1
1071	Artemisinin inspired synthetic endoperoxide drug candidates: Design, synthesis, and mechanism of action studies. Medicinal Research Reviews, 2021, 41, 3062-3095.	5.0	22
1072	Plasmodium falciparum resistance to ACTs: Emergence, mechanisms, and outlook. International Journal for Parasitology: Drugs and Drug Resistance, 2021, 16, 102-118.	1.4	36
1073	Efficacy of Cipargamin (KAE609) in a Randomized, Phase II Dose-Escalation Study in Adults in Sub-Saharan Africa With Uncomplicated Plasmodium falciparum Malaria. Clinical Infectious Diseases, 2022, 74, 1831-1839.	2.9	21
1074	Integration of population and functional genomics to understand mechanisms of artemisinin resistance in Plasmodium falciparum. International Journal for Parasitology: Drugs and Drug Resistance, 2021, 16, 119-128.	1.4	11
1075	The molecular basis of antimalarial drug resistance in Plasmodium vivax. International Journal for Parasitology: Drugs and Drug Resistance, 2021, 16, 23-37.	1.4	35
1076	Discrete Survival Model Analysis of Plasmodium falciparum Response to Artemisinin-Based Combination Therapies among Children in Regions of Varying Malaria Transmission in Cameroon. Pathogens, 2021, 10, 1106.	1.2	1
1077	A genetic intervention. ELife, 2021, 10, .	2.8	1
1078	Limited polymorphism in k13 gene of Plasmodium falciparum and k12 of Plasmodium vivax isolates imported from African and Asian countries between 2014 and 2019 in Hangzhou city, China. BMC Infectious Diseases, 2021, 21, 853.	1.3	4
1079	Genetic surveillance in the Greater Mekong subregion and South Asia to support malaria control and elimination. ELife, 2021, 10, .	2.8	53
1080	Surveillance of molecular markers of Plasmodium falciparum artemisinin resistance (kelch13) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf and Drug Resistance, 2021, 16, 188-193.	1.4	15

#	Article	IF	Citations
1081	Assessing risks of Plasmodium falciparum resistance to select next-generation antimalarials. Trends in Parasitology, 2021, 37, 709-721.	1.5	53
1082	A heat-shock response regulated by the PfAP2-HS transcription factor protects human malaria parasites from febrile temperatures. Nature Microbiology, 2021, 6, 1163-1174.	5.9	30
1083	Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infectious Diseases, The, 2021, 21, 1120-1128.	4.6	231
1084	Efficacy of dihydroartemisinin/piperaquine in patients with non-complicated Plasmodium falciparum malaria in YaoundÃ©, Cameroon. Journal of Antimicrobial Chemotherapy, 2021, 76, 3037-3044.	1.3	5
1086	The pharmacokinetic properties of artemether and lumefantrine in Malaysian patients with Plasmodium knowlesi malaria. British Journal of Clinical Pharmacology, 2022, 88, 691-701.	1.1	2
1087	Prevalence of Mutations in the pfcoronin Gene and Association with Ex Vivo Susceptibility to Common Quinoline Drugs against Plasmodium falciparum. Pharmaceutics, 2021, 13, 1273.	2.0	3
1088	Resistance to artemisinin in falciparum malaria parasites: A redox-mediated phenomenon. Free Radical Biology and Medicine, 2022, 179, 317-327.	1.3	24
1089	A review of the frequencies of Plasmodium falciparum Kelch 13 artemisinin resistance mutations in Africa. International Journal for Parasitology: Drugs and Drug Resistance, 2021, 16, 155-161.	1.4	42
1090	A New Thienopyrimidinone Chemotype Shows Multistage Activity against Plasmodium falciparum, Including Artemisinin-Resistant Parasites. Microbiology Spectrum, 2021, 9, e0027421.	1.2	10
1091	Single-genome sequencing reveals within-host evolution of human malaria parasites. Cell Host and Microbe, 2021, 29, 1496-1506.e3.	5.1	11
1092	Studies on Activities and Chemical Characterization of Medicinal Plants in Search for New Antimalarials: A Ten Year Review on Ethnopharmacology. Frontiers in Pharmacology, 2021, 12, 734263.	1.6	9
1093	Emerging roles of NAC transcription factor in medicinal plants: progress and prospects. 3 Biotech, 2021, 11, 425.	1.1	9
1094	Evidence of Artemisinin-Resistant Malaria in Africa. New England Journal of Medicine, 2021, 385, 1163-1171.	13.9	413
1096	Imported Malaria in Portugal: Prevalence of Polymorphisms in the Anti-Malarial Drug Resistance Genes pfmdr1 and pfk13. Microorganisms, 2021, 9, 2045.	1.6	3
1097	Single-cell genome sequencing of protozoan parasites. Trends in Parasitology, 2021, 37, 803-814.	1.5	10
1098	Are Artemisinin-Based Combination Therapies For Malaria Beginning To Fail in Africa?. American Journal of Tropical Medicine and Hygiene, 2021, 105, 857-858.	0.6	10
1099	New insights into the spread of resistance to artemisinin and its analogues. Journal of Global Antimicrobial Resistance, 2021, 27, 142-149.	0.9	16
1101	Resistance to front-line malaria drugs confirmed in Africa. Nature, 2021, 597, 604-604.	13.7	7

#	Article	IF	Citations
1102	Pyronaridine-Artesunate (Pyramax) for Treatment of Artemisinin- and Piperaquine-Resistant Plasmodium falciparum in the Central Highlands of Vietnam. Antimicrobial Agents and Chemotherapy, 2021, 65, e0027621.	1.4	8
1103	Current and emerging strategies to combat antimalarial resistance. Expert Review of Anti-Infective Therapy, 2022, 20, 353-372.	2.0	41
1104	Discovery and development of 2-aminobenzimidazoles as potent antimalarials. European Journal of Medicinal Chemistry, 2021, 221, 113518.	2.6	11
1105	Genetic surveillance for monitoring the impact of drug use on Plasmodium falciparum populations. International Journal for Parasitology: Drugs and Drug Resistance, 2021, 17, 12-22.	1.4	15
1106	Longitudinal ex vivo and molecular trends of chloroquine and piperaquine activity against Plasmodium falciparum and P. vivax before and after introduction of artemisinin-based combination therapy in Papua, Indonesia. International Journal for Parasitology: Drugs and Drug Resistance, 2021, 17, 46-56.	1.4	4
1107	Chemoprotective antimalarials identified through quantitative high-throughput screening of Plasmodium blood and liver stage parasites. Scientific Reports, 2021, 11, 2121.	1.6	14
1108	Kelch13 mutations in Plasmodium falciparum and risk of spreading in Amazon basin countries. Journal of Antimicrobial Chemotherapy, 2021, 76, 2854-2862.	1.3	7
1109	Artemisinin-resistant K13 mutations rewire Plasmodium falciparumâ€™s intra-erythrocytic metabolic program to enhance survival. Nature Communications, 2021, 12, 530.	5.8	82
1110	Phytohormones jasmonic acid, salicylic acid, gibberellins, and abscisic acid are key mediators of plant secondary metabolites. World Journal of Traditional Chinese Medicine, 2021, 7, 307.	0.9	19
1111	Host Genetic Predisposition to Malaria. , 2019, , 1-25.		2
1112	Role of the Spleen in Human Malaria. , 2015, , 1-24.		4
1113	Drug Resistance Assays for Parasitic Diseases. , 2017, , 1409-1463.		7
1114	How to defuse malariaâ€™s ticking time bomb. Nature, 2018, 559, 458-465.	13.7	10
1115	OUP accepted manuscript. Journal of Travel Medicine, 2019, 26, .	1.4	16
1135	Susceptibility Test Methods: Parasites. , 0, , 2563-2571.		2
1137	Assessing naturally acquired immune response and malaria treatment outcomes in Lagos, Nigeria. AAS Open Research, 0, 1, 6.	1.5	1
1138	Muddled mechanisms: recent progress towards antimalarial target identification. F1000Research, 2016, 5, 2514.	0.8	6
1139	Synthesis, Characterization and Biological Evaluation of Benzimidazole - Dihydroartemisinin Hybrids as Potential Dual Acting Antimalarial Agents. Mediterranean Journal of Chemistry, 2019, 9, 52-64.	0.3	3

#	Article	IF	Citations
1140	Genetic background and PfKelch13 affect artemisinin susceptibility of PfCoronin mutants in Plasmodium falciparum. PLoS Genetics, 2020, 16, e1009266.	1.5	17
1141	malERA: An updated research agenda for insecticide and drug resistance in malaria elimination and eradication. PLoS Medicine, 2017, 14, e1002450.	3.9	55
1142	malERA: An updated research agenda for basic science and enabling technologies in malaria elimination and eradication. PLoS Medicine, 2017, 14, e1002451.	3.9	29
1143	Characterization of the Commercially-Available Fluorescent Chloroquine-BODIPY Conjugate, LynxTag-CQGREEN, as a Marker for Chloroquine Resistance and Uptake in a 96-Well Plate Assay. PLoS ONE, 2014, 9, e110800.	1.1	5
1144	Novel Cross-Border Approaches to Optimise Identification of Asymptomatic and Artemisinin-Resistant Plasmodium Infection in Mobile Populations Crossing Cambodian Borders. PLoS ONE, 2015, 10, e0124300.	1.1	36
1145	Implications of Glutathione Levels in the Plasmodium berghei Response to Chloroquine and Artemisinin. PLoS ONE, 2015, 10, e0128212.	1.1	27
1146	The Genotypic and Phenotypic Stability of Plasmodium falciparum Field Isolates in Continuous In Vitro Culture. PLoS ONE, 2016, 11, e0143565.	1.1	13
1147	Artesunate-Amodiaquine and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso. PLoS ONE, 2016, 11, e0151565.	1.1	37
1148	G6PD Deficiency and Antimalarial Efficacy for Uncomplicated Malaria in Bangladesh: A Prospective Observational Study. PLoS ONE, 2016, 11, e0154015.	1.1	28
1149	Uncomplicated Clinical Malaria Features, the Efficacy of Artesunate-Amodiaquine and Their Relation with Multiplicity of Infection in the Democratic Republic of Congo. PLoS ONE, 2016, 11, e0157074.	1.1	13
1150	Genetically Determined Response to Artemisinin Treatment in Western Kenyan Plasmodium falciparum Parasites. PLoS ONE, 2016, 11, e0162524.	1.1	4
1151	Prevalence of Plasmodium falciparum Molecular Markers of Antimalarial Drug Resistance in a Residual Malaria Focus Area in Sabah, Malaysia. PLoS ONE, 2016, 11, e0165515.	1.1	9
1152	H2O2 dynamics in the malaria parasite Plasmodium falciparum. PLoS ONE, 2017, 12, e0174837.	1.1	31
1153	Molecular surveillance of Plasmodium falciparum resistance to artemisinin-based combination therapies in the Democratic Republic of Congo. PLoS ONE, 2017, 12, e0179142.	1.1	25
1154	Target-similarity search using Plasmodium falciparum proteome identifies approved drugs with anti-malarial activity and their possible targets. PLoS ONE, 2017, 12, e0186364.	1.1	16
1155	Induction of high tolerance to artemisinin by sub-lethal administration: A new in vitro model of P. falciparum. PLoS ONE, 2018, 13, e0191084.	1.1	11
1156	Effect of mass dihydroartemisininâ€“piperaquine administration in southern Mozambique on the carriage of molecular markers of antimalarial resistance. PLoS ONE, 2020, 15, e0240174.	1.1	13
1157	Identification of tyrosine kinase inhibitors that halt Plasmodium falciparum parasitemia. PLoS ONE, 2020, 15, e0242372.	1.1	13

#	Article	IF	Citations
1158	Emergence of artemisinin-resistant Plasmodium falciparum with kelch13 C580Y mutations on the island of New Guinea. PLoS Pathogens, 2020, 16, e1009133.	2.1	81
1159	Challenging Malaria Control. Juntendo Medical Journal, 2015, 61, 370-377.	0.1	2
1160	Malaria Surveillance â€" United States, 2013. MMWR Surveillance Summaries, 2016, 65, 1-22.	18.6	53
1161	Malaria Surveillance â€" United States, 2014. MMWR Surveillance Summaries, 2017, 66, 1-24.	18.6	51
1162	Malaria Surveillance â€" United States, 2016. MMWR Surveillance Summaries, 2019, 68, 1-35.	18.6	57
1163	In vitro and in vivo antimalarial activity of the volatile oil of Cyperus articulatus (Cyperaceae). Acta Amazonica, 2019, 49, 334-342.	0.3	13
1164	Malaria Elimination and Eradication. , 2017, , 315-346.		23
1165	4(1H)-Pyridone and 4(1H)-Quinolone Derivatives as Antimalarials with Erythrocytic, Exoerythrocytic, and Transmission Blocking Activities. Current Topics in Medicinal Chemistry, 2014, 14, 1693-1705.	1.0	21
1166	The Evaluation of Metal Co-ordinating Bis-Thiosemicarbazones as Potential Anti-malarial Agents. Medicinal Chemistry, 2019, 15, 51-58.	0.7	6
1167	ä¸€ç§ç"¨äºŽæ£€æµ‹æ¶²æ€§ç–Ÿå ŽŸè™«é•è'¿ç´æŠ—æ€§çš„æ–°åž‹è¡¨æ£€æµ‹æ–¹æ³•ä¸Žåº"ç"¨		
1168	Molecular Surveillance of Pfkelch13 and Pfmdr1 Mutations in Plasmodium falciparum Isolates from Southern Thailand. Korean Journal of Parasitology, 2019, 57, 369-377.	0.5	10
1169	Artemisinin resistance, some facts and opinions. Journal of Infection in Developing Countries, 2015, 9, 597-599.	0.5	5
1170	Prevalence of Malaria and Predisposing Factors to Antimalarial Drug Resistance in Southwestern Nigeria. Journal of Parasitology (Faisalabad), 2015, 10, 92-101.	0.2	19
1171	Antimalarial drug resistance: An overview. Tropical Parasitology, 2016, 6, 30.	0.2	130
1172	susceptibility of Indian isolates to different antimalarial drugs & antibiotics. Indian Journal of Medical Research, 2017, 146, 622-628.	0.4	9
1173	Sustained High Cure Rate of Artemetherâ€"Lumefantrine against Uncomplicated Plasmodium falciparum Malaria after 8 Years of Its Wide-Scale Use in Bagamoyo District, Tanzania. American Journal of Tropical Medicine and Hygiene, 2017, 97, 526-532.	0.6	12
1174	Molecular Epidemiology of Malaria in Cameroon and CÃ´te d'Ivoire. XXXI. Kelch 13 Propeller Sequences in Plasmodium falciparum Isolates before and after Implementation of Artemisinin-Based Combination Therapy. American Journal of Tropical Medicine and Hygiene, 2017, 97, 222-224.	0.6	20
1175	Country-Wide Surveillance of Molecular Markers of Antimalarial Drug Resistance in Senegal by Use of Positive Malaria Rapid Diagnostic Tests. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1593-1596.	0.6	11

#	Article	IF	Citations
1176	Prevalence of Clinical and Subclinical Plasmodium falciparum and Plasmodium vivax Malaria in Two Remote Rural Communities on the Myanmarâ€“China Border. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1524-1531.	0.6	24
1177	In Vitro Sensitivity of Pyronaridine in Thai Isolates of Plasmodium falciparum. American Journal of Tropical Medicine and Hygiene, 2018, 98, 51-56.	0.6	3
1178	Polymorphisms in the K13 Gene in Plasmodium falciparum from Different Malaria Transmission Areas of Kenya. American Journal of Tropical Medicine and Hygiene, 2018, 98, 1360-1366.	0.6	30
1179	Efficacy of Artemetherâ€“Lumefantrine for Uncomplicated Plasmodium falciparum Malaria in Cruzeiro do Sul, Brazil, 2016. American Journal of Tropical Medicine and Hygiene, 2018, 98, 88-94.	0.6	8
1180	Therapeutic Response to Dihydroartemisininâ€“Piperaquine for P. falciparum and P. vivax Nine Years after Its Introduction in Southern Papua, Indonesia. American Journal of Tropical Medicine and Hygiene, 2018, 98, 677-682.	0.6	23
1181	Impacts of Antimalarial Drugs on Plasmodium falciparum Drug Resistance Markers, Western Kenya, 2003â€“2015. American Journal of Tropical Medicine and Hygiene, 2018, 98, 692-699.	0.6	39
1182	Multiple Phenotypic and Genotypic Artemisinin Sensitivity Evaluation of Malian Plasmodium falciparum Isolates. American Journal of Tropical Medicine and Hygiene, 2018, 98, 1123-1131.	0.6	3
1183	Surveillance of Antimalarial Resistance Molecular Markers in Imported Plasmodium falciparum Malaria Cases in Anhui, China, 2012â€“2016. American Journal of Tropical Medicine and Hygiene, 2018, 98, 1132-1136.	0.6	19
1184	Gametocyte Carriage, Antimalarial Use, and Drug Resistance in Cambodia, 2008â€“2014. American Journal of Tropical Medicine and Hygiene, 2018, 99, 1145-1149.	0.6	3
1185	Prevalence of and Risk Factors Associated with Polymerase Chain Reaction-Determined Plasmodium falciparum Positivity on Day 3 after Initiation of Artemetherâ€“Lumefantrine Treatment for Uncomplicated Malaria in Bagamoyo District, Tanzania. American Journal of Tropical Medicine and Hygiene, 2019, 100, 1179-1186.	0.6	8
1186	Origin and Spread of Evolving Artemisinin-Resistant Plasmodium falciparum Malarial Parasites in Southeast Asia. American Journal of Tropical Medicine and Hygiene, 2019, 101, 1204-1211.	0.6	20
1187	Artemetherâ€“Lumefantrine and Dihydroartemisininâ€“Piperaquine Retain High Efficacy for Treatment of Uncomplicated Plasmodium falciparum Malaria in Myanmar. American Journal of Tropical Medicine and Hygiene, 2020, 102, 598-604.	0.6	6
1188	Molecular Surveillance for Polymorphisms Associated with Artemisinin-Based Combination Therapy Resistance in Plasmodium falciparum Isolates Collected in the State of Roraima, Brazil. American Journal of Tropical Medicine and Hygiene, 2020, 102, 310-312.	0.6	6
1189	Artemetherâ€“Lumefantrine Efficacy for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Choco, Colombia after 8 Years as First-Line Treatment. American Journal of Tropical Medicine and Hygiene, 2020, 102, 1056-1063.	0.6	13
1190	Efficacy and Safety of Pyronaridineâ€“Artesunate for the Treatment of Uncomplicated Plasmodium falciparum and Plasmodium vivax Malaria in Myanmar. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1088-1093.	0.6	10
1191	Molecular Surveillance and in vitro Drug Sensitivity Study of Plasmodium falciparum Isolates from the Chinaâ€“Myanmar Border. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1100-1106.	0.6	6
1192	Assessment of the risk posed to Singapore by the emergence of artemisinin-resistant malaria in the Greater Mekong Subregion. Western Pacific Surveillance and Response Journal: WPSAR, 2019, 10, 6-13.	0.3	6
1193	Genomic epidemiology of artemisinin resistant malaria. ELife, 2016, 5, .	2.8	242

#	Article	IF	Citations
1194	Deconvoluting heme biosynthesis to target blood-stage malaria parasites. ELife, 2015, 4, .	2.8	55
1195	Evolutionary genomics of epidemic visceral leishmaniasis in the Indian subcontinent. ELife, 2016, 5, .	2.8	147
1196	Local emergence in Amazonia of Plasmodium falciparum k13 C580Y mutants associated with in vitro artemisinin resistance. ELife, 2020, 9, .	2.8	102
1197	Phosphatidylinositol 3-phosphate and Hsp70 protect Plasmodium falciparum from heat-induced cell death. ELife, 2020, 9, .	2.8	20
1198	Artemisinin exposure at the ring or trophozoite stage impacts Plasmodium falciparum sexual conversion differently. ELife, 2020, 9, .	2.8	30
1199	Molecular Determinants of Artemisinin Resistance in k13 Gene of Plasmodium falciparum. British Microbiology Research Journal, 2015, 9, 1-11.	0.2	2
1200	Case Report of Attenuated-Responsiveness to CoartemÂ® in Western Kenya. International Journal of Medical and Pharmaceutical Case Reports, 2015, 2, 5-9.	0.0	1
1201	Allosteric pockets and dynamic residue network hubs of falcipain 2 in mutations including those linked to artemisinin resistance. Computational and Structural Biotechnology Journal, 2021, 19, 5647-5666.	1.9	13
1202	In vivo efficacy and safety of artemetherâ€“lumefantrine and amodiaquineâ€“artesunate for uncomplicated Plasmodium falciparum malaria in Mozambique, 2018. Malaria Journal, 2021, 20, 390.	0.8	8
1203	Molecular surveillance for polymorphisms associated with artemisinin-based combination therapy resistance in Plasmodium falciparum isolates collected in Mozambique, 2018. Malaria Journal, 2021, 20, 398.	0.8	7
1204	Increase in the proportion of Plasmodium falciparum with kelch13 C580Y mutation and decline in pfcrt and pfmdr1 mutant alleles in Papua New Guinea. Malaria Journal, 2021, 20, 410.	0.8	11
1205	Mutation in the Plasmodium falciparum BTB/POZ Domain of K13 Protein Confers Artemisinin Resistance. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0132021.	1.4	14
1206	High-Content Phenotypic Screen of a Focused TCAMS Drug Library Identifies Novel Disruptors of the Malaria Parasite Calcium Dynamics. ACS Chemical Biology, 2021, 16, 2348-2372.	1.6	4
1207	First Detection in West Africa of a Mutation That May Contribute to Artemisinin Resistance Plasmodium falciparum. Frontiers in Genetics, 2021, 12, 701750.	1.1	2
1208	Time to scale up molecular surveillance for anti-malarial drug resistance in sub-saharan Africa. Malaria Journal, 2021, 20, 401.	0.8	9
1209	Comparative Analysis of Plasmodium falciparum Genotyping via SNP Detection, Microsatellite Profiling, and Whole-Genome Sequencing. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0116321.	1.4	8
1210	Lumefantrine attenuates Plasmodium falciparum artemisinin resistance during the early ring stage. International Journal for Parasitology: Drugs and Drug Resistance, 2021, 17, 186-190.	1.4	3
1211	Resistance gene identified in malaria parasite. Nature, 0, , .	13.7	0

#	Article	IF	Citations
1212	Burden of Malaria and Prospective Challenges in South-East Asia Region: A Review. International Journal of Tropical Disease & Health, 2015, 9, 1-7.	0.1	0
1214	Mechanisms of Resistance to Antiparasitic Agents. , 0, , 2550-2562.		1
1219	Mechanisms of Antimalarial Drug Resistance. , 2017, , 629-647.		2
1220	Antimalarial Drug Resistance: Clinical Perspectives. , 2017, , 1245-1275.		0
1223	Sensitive DNA Detection and SNP Identification Using Ultrabright SERS Nanorattles and Magnetic Beads for In Vitro Diagnostics. , 2017, , 609-626.		0
1224	Capacity Development through the US Presidentâ€™s Malaria Initiativeâ€“Supported Antimalarial Resistance Monitoring in Africa Network. Emerging Infectious Diseases, 2017, 23, .	2.0	0
1227	Mode of Action of Artemisinin. , 2017, , 323-334.		0
1228	Antiplasmodial Activity of Diospyros monbuttensis and Newbouldia laevis, Two Ivorian Medicinal Plants. Journal of Parasitology (Faisalabad), 2018, 13, 57-64.	0.2	0
1229	Drug Metabolite as a Novel Tool for Measuring Antimalarial Drug Adherence. Open Public Health Journal, 2018, 11, 288-297.	0.1	1
1233	Absence of Plasmodium falciparum K13 Propeller Domain Polymorphisms among Field Isolates Collected from the Brazilian Amazon Basin between 1984 and 2011. American Journal of Tropical Medicine and Hygiene, 2018, 99, 1504-1507.	0.6	4
1234	Molecular Mechanisms of Action and Resistance of Antimalarial Drugs. , 2019, , 267-296.		3
1235	In vivo antiplasmodial potential of aqueous seed extract of Ricinus communis. Journal of HerbMed Pharmacology, 2019, 8, 133-138.	0.4	0
1239	Plasmodial enzymes in metabolic pathways as therapeutic targets and contemporary strategies to discover new antimalarial drugs: a review. Asia-Pacific Journal of Molecular Biology and Biotechnology, 0, , 38-53.	0.2	0
1241	A Comparative Review on Current and Future Drug Targets Against Bacteria & Malaria. Current Drug Targets, 2020, 21, 736-775.	1.0	1
1244	A Review: Artemisinin-Based Combination Therapies [ACTs] and K13 Polymorphism. Journal of Biomedical Research & Environmental Sciences, 2020, 1, 088-091.	0.1	0
1246	Protein abundance and folding rather than the redox state of Kelch13 determine the artemisinin susceptibility of Plasmodium falciparum. Redox Biology, 2021, 48, 102177.	3.9	7
1247	Assessment of antimalarial drug resistant markers in asymptomatic Plasmodium falciparum infections after 4 years of indoor residual spraying in Northern Ghana. PLoS ONE, 2020, 15, e0233478.	1.1	6
1248	Characterization of the erythrocyte GTPase Rac1 in relation to Plasmodium falciparum invasion. Scientific Reports, 2020, 10, 22054.	1.6	8

#	Article	IF	Citations
1249	Resistance of <i>Plasmodium falciparum</i> to Sulfadoxine-Pyrimethamine (<i>Dhfr</i> and <i>Dhps</i>) and Artemisinin and Its Derivatives (K13): A Major Challenge for Malaria Elimination in West Africa. Journal of Biosciences and Medicines, 2020, 08, 82-95.	0.1	2
1250	Ethics and Antimalarial Drug Resistance. Public Health Ethics Analysis, 2020, , 55-73.	0.1	4
1251	Mapping Partner Drug Resistance to Guide Antimalarial Combination Therapy Policies in Sub-Saharan Africa. SSRN Electronic Journal, 0, , .	0.4	0
1254	Elucidation of an essential function of the unique charged domain of Plasmodium topoisomerase III. Biochemical Journal, 2020, 477, 4745-4767.	1.7	6
1255	Last-come, best served? Mosquito biting order and Plasmodium transmission. Proceedings of the Royal Society B: Biological Sciences, 2020, 287, 20202615.	1.2	2
1256	Predicting Dihydroartemisinin Resistance in Plasmodium falciparum using Pathway Activity Inference. , 2020, , .		0
1257	Exploration of Anti-plasmodial Activity of Prunus cerasoides Buch.-Ham. ex D. Don (family: Rosaceae) and Its Wood Chromatographic Fractions. Acta Parasitologica, 2021, 66, 205-212.	0.4	2
1258	The Jeremiah Metzger lecture: new additions to the toolbox for global malaria eradication. Transactions of the American Clinical and Climatological Association, 2014, 125, 271-80.	0.9	1
1260	Pediatric Malaria. Pediatric Clinics of North America, 2022, 69, 47-64.	0.9	0
1261	Potential Emergence of Plasmodium Resistance to Artemisinin Induced by the Use of Artemisia annua for Malaria and COVID-19 Prevention in Sub-African Region. Acta Parasitologica, 2022, 67, 55-60.	0.4	13
1262	Artemisinin Binds and Inhibits the Activity of Plasmodium falciparum Ddi1, a Retroviral Aspartyl Protease. Pathogens, 2021, 10, 1465.	1.2	5
1263	Reactive Oxygen Species as the Brainbox in Malaria Treatment. Antioxidants, 2021, 10, 1872.	2.2	23
1264	Absence of Plasmodium falciparum artemisinin resistance gene mutations eleven years after the adoption of artemisinin-based combination therapy in Nigeria. Malaria Journal, 2021, 20, 434.	0.8	3
1266	The parasitophorous vacuole nutrient channel is critical for drug access in malaria parasites and modulates the artemisinin resistance fitness cost. Cell Host and Microbe, 2021, 29, 1774-1787.e9.	5.1	21
1267	Prevalence of potential mediators of artemisinin resistance in African isolates of Plasmodium falciparum. Malaria Journal, 2021, 20, 451.	0.8	15
1268	Derivatives of Dictyostelium differentiation-inducing factors suppress the growth of Plasmodium parasites in vitro and in vivo. Biochemical Pharmacology, 2021, 194, 114834.	2.0	2
1269	Simple and rapid RNA detection using cationic copolymer-chaperoned MNAzyme (ACEzyme). Translational and Regulatory Sciences, 2021, 3, 102-105.	0.2	0
1270	Clonal Expansion of Artemisinin-Resistant Plasmodium Falciparum in Uganda is Associated with Substandard Treatment Practices. SSRN Electronic Journal, 0, , .	0.4	6

#	Article	IF	Citations
1271	FIT-PNAs as RNA-Sensing Probes for Drug-Resistant Plasmodium falciparum. ACS Sensors, 2022, 7, 50-59.	4.0	4
1272	Peroxide Antimalarial Drugs Target Redox Homeostasis in Plasmodium falciparum Infected Red Blood Cells. ACS Infectious Diseases, 2022, 8, 210-226.	1.8	23
1273	Polymorphism analysis of pfmdr1 gene in Plasmodium falciparum isolates 11Âyears post-adoption of artemisinin-based combination therapy in Saudi Arabia. Scientific Reports, 2022, 12, 517.	1.6	2
1274	Co-administration effects and toxicity profile of ethyl acetate fraction of Stemonocoleus micranthus Harms and Artesunate in murine malaria model. South African Journal of Botany, 2022, 146, 715-722.	1.2	0
1275	Methods Used to Investigate the Plasmodium falciparum Digestive Vacuole. Frontiers in Cellular and Infection Microbiology, 2021, 11, 829823.	1.8	4
1276	Boosting the impact of seasonal malaria chemoprevention (SMC) through simultaneous screening and treatment of household members of children receiving SMC in Burkina Faso: a protocol for a randomized open label trial. Archives of Public Health, 2022, 80, 41.	1.0	1
1278	Molecular identification and anti-malarial drug resistance profile of Plasmodium falciparum from patients attending Kisoro Hospital, southwestern Uganda. Malaria Journal, 2022, 21, 21.	0.8	2
1280	Impact of Drug Pressure versus Limited Access to Drug in Malaria Control: The Dilemma. Medicines (Basel, Switzerland), 2022, 9, 2.	0.7	6
1281	Assessment of Plasmodium falciparum Artemisinin Resistance Independent of kelch13 Polymorphisms and with Escalating Malaria in Bangladesh. MBio, 2022, 13, e0344421.	1.8	7
1282	New insights of falcipain 2 structure from Plasmodium falciparum 3D7 strain. Biochemical and Biophysical Research Communications, 2022, 590, 145-151.	1.0	1
1283	Mapping genetic markers of artemisinin resistance in Plasmodium falciparum malaria in Asia: a systematic review and spatiotemporal analysis. Lancet Microbe, The, 2022, 3, e184-e192.	3.4	16
1284	A Phosphoinositide-Binding Protein Acts in the Trafficking Pathway of Hemoglobin in the Malaria Parasite Plasmodium falciparum. MBio, 2022, 13, e0323921.	1.8	10
1285	Plasmodium falciparum Kelch13 and its artemisininâ€resistant mutants assemble as hexamers in solution: a SAXS dataâ€driven modelling study. FEBS Journal, 2022, 289, 4935-4962.	2.2	4
1286	Long-term effects of increased adoption of artemisinin combination therapies in Burkina Faso. PLOS Global Public Health, 2022, 2, e0000111.	0.5	13
1287	Prevalence and temporal changes of mutations linked to antimalarial drug resistance in Plasmodium falciparum and Plasmodium vivax in Palawan, Philippines. International Journal of Infectious Diseases, 2022, 116, 174-181.	1.5	2
1288	Identification of polymorphisms in genes associated with drug resistance in Plasmodium falciparum isolates from school-age children in Kinshasa, Democratic Republic of Congo. Parasitology International, 2022, 88, 102541.	0.6	4
1289	Biennial surveillance of Plasmodium falciparum anti-malarial drug resistance markers in Democratic Republic of Congo, 2017 and 2019. BMC Infectious Diseases, 2022, 22, 145.	1.3	5
1290	Cross-sectional study of asymptomatic malaria and seroepidemiological surveillance of seven districts in Gia Lai province, Vietnam. Malaria Journal, 2022, 21, 40.	0.8	5

#	Article	IF	Citations
1291	Spatio-temporal distribution of antimalarial drug resistant gene mutations in a Plasmodium falciparum parasite population from Kilifi, Kenya: A 25-year retrospective study. Wellcome Open Research, 0, 7, 45.	0.9	8
1292	Machine learning for artemisinin resistance in malaria treatment across inÂvivo-inÂvitro platforms. IScience, 2022, 25, 103910.	1.9	4
1294	Characterisation of <i>pfk13</i>, <i>pfmdr1</i>, <i>pfdhfr</i>, <i>pfdhps</i> and <i>pfcrt</i> Polymorphisms in Isolates from Asymptomatic and Symptomatic School-Age Children in Kinshasa, Democratic Republic of Congo. SSRN Electronic Journal, 0, , .	0.4	0
1295	Approaches and molecular tools for targeted drug delivery in malaria infected red blood cells. , 2022, , 149-172.		1
1296	5WBF: a low-cost and straightforward whole blood filtration method suitable for whole-genome sequencing of Plasmodium falciparum clinical isolates. Malaria Journal, 2022, 21, 51.	0.8	2
1297	Current status of experimental models for the study of malaria. Parasitology, 2022, 149, 729-750.	0.7	7
1299	Molecular profiling of the artemisinin resistance Kelch 13 gene in Plasmodium falciparum from Nigeria. PLoS ONE, 2022, 17, e0264548.	1.1	8
1300	Circulation of an Artemisinin-Resistant Malaria Lineage in a Traveler Returning from East Africa to France. Clinical Infectious Diseases, 2022, 75, 1242-1244.	2.9	5
1301	Effectiveness and safety of artesunateâ€“amodiaquine versus artemetherâ€“lumefantrine for home-based treatment of uncomplicated Plasmodium falciparum malaria among children 6â€“120Âmonths in YaoundÃ©, Cameroon: a randomized trial. BMC Infectious Diseases, 2022, 22, 166.	1.3	5
1302	The Antagonizing Role of Heme in the Antimalarial Function of Artemisinin: Elevating Intracellular Free Heme Negatively Impacts Artemisinin Activity in Plasmodium falciparum. Molecules, 2022, 27, 1755.	1.7	7
1303	Synthesis, Antiplasmodial, and Antileukemia Activity of Dihydroartemisininâ€“HDAC Inhibitor Hybrids as Multitarget Drugs. Pharmaceuticals, 2022, 15, 333.	1.7	4
1305	Reduction in Plasmodium falciparum Pfk13 and pfg377 allele diversity through time in southern Vietnam. Tropical Medicine and Health, 2022, 50, 19.	1.0	0
1306	Targeted Amplicon Deep Sequencing for Monitoring Antimalarial Resistance Markers in Western Kenya. Antimicrobial Agents and Chemotherapy, 2022, 66, e0194521.	1.4	4
1307	Efficacy and safety of dihydroartemisininâ€“piperaquine for the treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax malaria in Papua and Sumatra, Indonesia. Malaria Journal, 2022, 21, 95.	0.8	5
1308	Molecular surveillance for operationally relevant genetic polymorphisms in Plasmodium falciparum in Southern Chad, 2016â€“2017. Malaria Journal, 2022, 21, 83.	0.8	5
1309	Frameshift mutation (690delG) in cpxA contributes to the extensive drug resistance of a Serratia marcescens clinical isolate. Journal of Antimicrobial Chemotherapy, 2022, 77, 1611-1616.	1.3	3
1310	Artemisinin resistance in the malaria parasite, Plasmodium falciparum, originates from its initial transcriptional response. Communications Biology, 2022, 5, 274.	2.0	33
1311	Comparative analysis of targeted next-generation sequencing for Plasmodium falciparum drug resistance markers. Scientific Reports, 2022, 12, 5563.	1.6	3

#	Article	IF	Citations
1312	Molecular Surveillance for Imported Antimicrobial Resistant Plasmodium falciparum, Ontario, Canada. Emerging Infectious Diseases, 2022, 28, 812-819.	2.0	1
1314	Identification of Co-Existing Mutations and Gene Expression Trends Associated With K13-Mediated Artemisinin Resistance in Plasmodium falciparum. Frontiers in Genetics, 2022, 13, 824483.	1.1	7
1315	Xeno-monitoring of molecular drivers of artemisinin and partner drug resistance in P. falciparum populations in malaria vectors across Cameroon. Gene, 2022, 821, 146339.	1.0	8
1316	Iloneoside, an antimalarial pregnane glycoside isolated from Gongronema latifolium leaf, potentiates the activity of chloroquine against multidrug resistant Plasmodium falciparum. Molecular and Biochemical Parasitology, 2022, 249, 111474.	0.5	1
1317	Genome instability drives epistatic adaptation in the human pathogenLeishmania. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	18
1318	Compensating P.Âfalciparum artemisinin resistance. Cell Host and Microbe, 2021, 29, 1732-1734.	5.1	1
1319	Temporal evolution of the resistance genotypes of Plasmodium falciparum in isolates from Equatorial Guinea during 20Âyears (1999 to 2019). Malaria Journal, 2021, 20, 463.	0.8	4
1320	Thienopyrimidine: A Promising Scaffold to Access Anti-Infective Agents. Pharmaceuticals, 2022, 15, 35.	1.7	15
1321	Multipurpose Drugs Active Against Both Plasmodium spp. and Microorganisms: Potential Application for New Drug Development. Frontiers in Cellular and Infection Microbiology, 2021, 11, 797509.	1.8	1
1322	Synthesis, Molecular Docking and Antiplasmodial Activities of New Tetrahydro-Î²-Carbolines. International Journal of Molecular Sciences, 2021, 22, 13569.	1.8	3
1323	Simultaneous estimation of ZY-19489 and its active metaboliteÂZY-20486 in human plasma using LCâ€“MS/MS, a novel antimalarial compound. Bioanalysis, 2021, 13, 1761-1777.	0.6	2
1324	Cooperation in Countering Artemisinin Resistance in Africa: Learning from COVID-19. American Journal of Tropical Medicine and Hygiene, 2022, , .	0.6	2
1325	Evaluations of candidate markers of dihydroartemisinin-piperaquine resistance in Plasmodium falciparum isolates from the Chinaâ€“Myanmar, Thailandâ€“Myanmar, and Thailandâ€“Cambodia borders. Parasites and Vectors, 2022, 15, 130.	1.0	7
1326	Autophagy Underlies the Proteostasis Mechanisms of Artemisinin Resistance in P. falciparum Malaria. MBio, 2022, 13, e0063022.	1.8	9
1327	Dimeric Artesunate Glycerophosphocholine Conjugate Nano-Assemblies as Slow-Release Antimalarials to Overcome Kelch 13 Mutant Artemisinin Resistance. Antimicrobial Agents and Chemotherapy, 2022, 66, e0206521.	1.4	11
1329	Design and implementation of multiplexed amplicon sequencing panels to serve genomic epidemiology of infectious disease: A malaria case study. Molecular Ecology Resources, 2022, 22, 2285-2303.	2.2	18
1330	An overview of the <scp>Plasmodium falciparum</scp> hexose transporter and its therapeutic interventions. Proteins: Structure, Function and Bioinformatics, 2022, 90, 1766-1778.	1.5	10
1353	Single-nucleotide polymorphisms of artemisinin resistance-related pfubp1 and pfap2mu genes in imported Plasmodium falciparum to Wuhan, China. Infection, Genetics and Evolution, 2022, 101, 105286.	1.0	2

#	Article	IF	Citations
1354	Leveraging genome editing to functionally evaluate Plasmodium diversity. Trends in Parasitology, 2022, , .	1.5	3
1355	Population Pharmacokinetics of Antimalarial Naphthoquine in Combination with Artemisinin in Tanzanian Children and Adults: Dose Optimization. Antimicrobial Agents and Chemotherapy, 2022, , e0169621.	1.4	0
1356	A single point mutation in the Plasmodium falciparum 3â€²â€“5â€² exonuclease does not alter piperaquine susceptibility. Malaria Journal, 2022, 21, 130.	0.8	0
1357	Polymorphisms of potential drug resistant molecular markers in Plasmodium vivax from Chinaâ€“Myanmar border during 2008â€’2017. Infectious Diseases of Poverty, 2022, 11, 43.	1.5	6
1358	An insight on drug resistance in Plasmodium vivax, a still neglected human malaria parasite. Annali Dell'Istituto Superiore Di Sanita, 2020, 56, 409-418.	0.2	0
1359	Artesunateâ€“amodiaquine and artemetherâ€“lumefantrine for the treatment of uncomplicated falciparum malaria in Liberia: in vivo efficacy and frequency of molecular markers. Malaria Journal, 2022, 21, 134.	0.8	7
1362	Worldwide Research Trends on Artemisinin: A Bibliometric Analysis From 2000 to 2021. Frontiers in Medicine, 2022, 9, .	1.2	11
1363	Pfkelch13 Plasmodium falciparum Mutations in Huambo, Angola. Pathogens, 2022, 11, 554.	1.2	1
1365	Prevalence of malaria among febrile patients and assessment of efficacy of artemether-lumefantrine and artesunate-amodiaquine for uncomplicated malaria in Dolisie, Republic of the Congo. Malaria Journal, 2022, 21, 137.	0.8	1
1366	Prevalence of arps10, fd, pfmdr-2, pfcrt and pfkelch13 gene mutations in Plasmodium falciparum parasite population in Uganda. PLoS ONE, 2022, 17, e0268095.	1.1	5
1367	Novel pfk13 polymorphisms in Plasmodium falciparum population in Ghana. Scientific Reports, 2022, 12, 7797.	1.6	6
1368	Assessing the Roles of Molecular Markers of Antimalarial Drug Resistance and the Host Pharmacogenetics in Drug-Resistant Malaria. Journal of Tropical Medicine, 2022, 2022, 1-9.	0.6	5
1369	Isolation and structure elucidation of a steroidal moiety from Withania somnifera and in silico evaluation of antimalarial efficacy against artemisinin resistance Plasmodium falciparum kelch 13 protein. Journal of Biomolecular Structure and Dynamics, 2022, , 1-14.	2.0	1
1371	A random priming amplification method for whole genome sequencing of SARS-CoV-2 virus. BMC Genomics, 2022, 23, .	1.2	6
1372	A brief history of malaria. Presse Medicale, 2022, 51, 104130.	0.8	12
1373	Low Complexity of Infection Is Associated With Molecular Persistence of Plasmodium falciparum in Kenya and Tanzania. , 2022, 2, .		3
1375	Comparison of antibody responses and parasite clearance in artemisinin therapeutic efficacy studies in Democratic Republic of Congo and Asia. Journal of Infectious Diseases, 0, , .	1.9	1
1376	Human peroxiredoxin 6 is essential for malaria parasites and provides a host-based drug target. Cell Reports, 2022, 39, 110923.	2.9	10

#	Article	IF	Citations
1377	Pd-catalyzed Câ€“C and Câ€“N cross-coupling reactions in 2-aminothieno[3,2-d]pyrimidin-4(3H)-one series for antiplasmodial pharmacomodulation. RSC Advances, 2022, 12, 20004-20021.	1.7	6
1378	Developing Molecular Surveillance Capacity for Asymptomatic and Drug-Resistant Malaria in a Resource-Limited Settingâ€”Experiences and Lessons Learned. American Journal of Tropical Medicine and Hygiene, 2022, , .	0.6	0
1379	Prospective surveillance study to detect antimalarial drug resistance, gene deletions of diagnostic relevance and genetic diversity of Plasmodium falciparum in Mozambique: protocol. BMJ Open, 2022, 12, e063456.	0.8	7
1380	Evaluation of the Effect of Gene Duplication by Genome Editing on Drug Resistance in Plasmodium falciparum. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	3
1381	Genetic Diversity of Plasmodium falciparum and Distribution of Antimalarial Drug Resistance Mutations in Symptomatic and Asymptomatic Infections. Antimicrobial Agents and Chemotherapy, 2022, 66, .	1.4	6
1382	Antiplasmodial and cytotoxic activity of lanostane type triterpenoids isolated from Leplaea mayombensis. Phytochemistry Letters, 2022, 51, 50-56.	0.6	1
1383	Malaria in 2018: Looking to the Past and Moving into the Future. Annals of the Academy of Medicine, Singapore, 2018, 47, 135-137.	0.2	1
1384	Plasmodium falciparum merozoite invasion ligands, linked antimalarial resistance loci and ex vivo responses to antimalarials in The Gambia. Journal of Antimicrobial Chemotherapy, 2022, 77, 2946-2955.	1.3	2
1385	In Vitro and In Silico Potential Inhibitory Effects of New Biflavonoids from Ochna rhizomatosa on HIV-1 Integrase and Plasmodium falciparum. Pharmaceutics, 2022, 14, 1701.	2.0	1
1389	Screening the Pathogen Box for Inhibition of Plasmodium falciparum Sporozoite Motility Reveals a Critical Role for Kinases in Transmission Stages. Antimicrobial Agents and Chemotherapy, 0, , .	1.4	4
1390	Transcriptome-module phenotype association study implicates extracellular vesicles biogenesis in Plasmodium falciparum artemisinin resistance. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	3
1391	Lumefantrine pressure selects nonsynonymous mutation in cysteine desulfurase IscS gene in the rodent malaria parasite Plasmodium berghei ANKA. , 0, 5, 27.		0
1394	Pre-existing partner-drug resistance to artemisinin combination therapies facilitates the emergence and spread of artemisinin resistance: a consensus modelling study. Lancet Microbe, The, 2022, 3, e701-e710.	3.4	22
1395	Babesia, Theileria, Plasmodium and Hemoglobin. Microorganisms, 2022, 10, 1651.	1.6	12
1396	Barcoding Genetically Distinct Plasmodium falciparum Strains for Comparative Assessment of Fitness and Antimalarial Drug Resistance. MBio, 2022, 13, .	1.8	2
1398	Bulk segregant linkage mapping for rodent and human malaria parasites. Parasitology International, 2022, 91, 102653.	0.6	2
1399	The Plasmodium falciparum Nuclear Protein Phosphatase NIF4 Is Required for Efficient Merozoite Invasion and Regulates Artemisinin Sensitivity. MBio, 2022, 13, .	1.8	1
1401	Plasmodium falciparum sexual conversion rates can be affected by artemisinin-based treatment in naturally infected malaria patients. EBioMedicine, 2022, 83, 104198.	2.7	4

#	Article	IF	Citations
1402	Naturally Acquired Kelch13 Mutations in Plasmodium falciparum Strains Modulate In Vitro Ring-Stage Artemisinin-Based Drug Tolerance and Parasite Survival in Response to Hyperoxia. Microbiology Spectrum, 2022, 10, .	1.2	4
1403	Anti-folate quintuple mutations in Plasmodium falciparum asymptomatic infections in YaoundÃ©, Cameroon. Parasitology International, 2023, 92, 102657.	0.6	0
1404	Bulk Segregant Linkage Mapping for Rodent and Human Malaria Parasites. SSRN Electronic Journal, 0, , .	0.4	0
1406	How do the mutations in PfK13 protein promote anti-malarial drug resistance?. Journal of Biomolecular Structure and Dynamics, 2023, 41, 7329-7338.	2.0	0
1407	Malaria Surveillance â€" United States, 2018. MMWR Surveillance Summaries, 2022, 71, 1-35.	18.6	26
1408	Artemisinin resistance and malaria elimination: Where are we now?. Frontiers in Pharmacology, 0, 13, .	1.6	22
1409	Exploring a Tetrahydroquinoline Antimalarial Hit from the Medicines for Malaria Pathogen Box and Identification of its Mode of Resistance as PfeEF2. ChemMedChem, 2022, 17, .	1.6	5
1410	Efficacy of three anti-malarial regimens for uncomplicated Plasmodium falciparum malaria in Cambodia, 2009â€"2011: a randomized controlled trial and brief review. Malaria Journal, 2022, 21, .	0.8	3
1411	Genome-wide SNP analysis of Plasmodium falciparum shows differentiation at drug-resistance-associated loci among malaria transmission settings in southern Mali. Frontiers in Genetics, 0, 13, .	1.1	2
1412	Drug resistance and population structure of Plasmodium falciparum and Plasmodium vivax in the Peruvian Amazon. Scientific Reports, 2022, 12, .	1.6	5
1413	Apicoplast ribosomal protein S10-V127M enhances artemisinin resistance of a Kelch13 transgenic Plasmodium falciparum. Malaria Journal, 2022, 21, .	0.8	5
1414	Genetic deletions and high diversity of Plasmodium falciparum histidine-rich proteins 2 and 3 genes in parasite populations in Ghana. , 0, 2, .		3
1415	Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and lumefantrine in northern Uganda. Nature Communications, 2022, 13, .	5.8	27
1418	Structural Modelling Prediction of Recombinant Plasmodium falciparum K13-F446I and K13-C580Y Gene by AlphaFold Method and Heterologous Expression in Spodoptera frugiperda 9 Cells. Pathogens, 2022, 11, 1271.	1.2	0
1419	In vitro susceptibility profile of Plasmodium falciparum clinical isolates from Ghana to antimalarial drugs and polymorphisms in resistance markers. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	3
1420	Multidisciplinary Investigations of Sustained Malaria Transmission in the Greater Mekong Subregion. American Journal of Tropical Medicine and Hygiene, 2022, 107, 138-151.	0.6	5
1421	Nationwide and long-term molecular epidemiologic studies of mumps viruses that circulated in Japan between 1986 and 2017. Frontiers in Microbiology, 0, 13, .	1.5	2
1422	Genome-wide functional screening of drug-resistance genes in Plasmodium falciparum. Nature Communications, 2022, 13, .	5.8	4

#	Article	IF	Citations
1423	Parasite clearance dynamics in children hospitalised with severe malaria in the Ho Teaching Hospital, Volta Region, Ghana. Parasite Epidemiology and Control, 2022, 19, e00276.	0.6	0
1424	Polymorphisms in the K13-Propeller Gene in Artemisinin-Resistant Plasmodium in Mice. Infection and Drug Resistance, 0, Volume 15, 6533-6544.	1.1	0
1426	Ring-stage growth arrest: Metabolic basis of artemisinin tolerance in Plasmodium falciparum. IScience, 2023, 26, 105725.	1.9	8
1427	Proteomic characterization of Toxoplasma gondii ME49 derived strains resistant to the artemisinin derivatives artemiside and artemisone implies potential mode of action independent of ROS formation. International Journal for Parasitology: Drugs and Drug Resistance, 2023, 21, 1-12.	1.4	4
1429	Malaria outbreak in Laos driven by a selective sweep for Plasmodium falciparum kelch13 R539T mutants: a genetic epidemiology analysis. Lancet Infectious Diseases, The, 2023, 23, 568-577.	4.6	10
1430	Drug resistance of Plasmodium falciparum and Plasmodium vivax isolates in Indonesia. Malaria Journal, 2022, 21, .	0.8	9
1431	Molecular markers of dihydroartemisinin-piperaquine resistance in northwestern Thailand. Malaria Journal, 2022, 21, .	0.8	0
1434	Molecular surveillance of anti-malarial drug resistance genes in Plasmodium falciparum isolates in Odisha, India. Malaria Journal, 2022, 21, .	0.8	5
1435	Evaluation of the Combined Effect of Artemisinin and Ferroptosis Inducer RSL3 against Toxoplasma gondii. International Journal of Molecular Sciences, 2023, 24, 229.	1.8	2
1436	Different In Vitro Drug Susceptibility Profile of Plasmodium falciparum Isolates from Two Adjacent Areas of Northeast Myanmar and Molecular Markers for Drug Resistance. Tropical Medicine and Infectious Disease, 2022, 7, 442.	0.9	1
1437	Prevalence and characterization of piperaquine, mefloquine and artemisinin derivatives triple-resistant Plasmodium falciparum in Cambodia. Journal of Antimicrobial Chemotherapy, 2023, 78, 411-417.	1.3	1
1438	Molecular surveillance of artemisinin resistance-related Pfk13 and pfcrt polymorphisms in imported Plasmodium falciparum isolates reported in eastern China from 2015 to 2019. Malaria Journal, 2022, 21, .	0.8	0
1440	Prevalence of malaria resistance-associated mutations in Plasmodium falciparum circulating in 2017â€“2018, Bo, Sierra Leone. Frontiers in Microbiology, 0, 13, .	1.5	0
1441	Novel 3-Trifluoromethyl-1,2,4-oxadiazole Analogues of Astemizole with Multi-stage Antiplasmodium Activity and In Vivo Efficacy in a Plasmodium berghei Mouse Malaria Infection Model. Journal of Medicinal Chemistry, 2022, 65, 16695-16715.	2.9	4
1442	The impact of sequestration on artemisinin-induced parasite clearance in Plasmodium falciparum malaria in Africa. Clinical Infectious Diseases, 0, , .	2.9	1
1445	Lipid peroxidation and its repair in malaria parasites. Trends in Parasitology, 2023, , .	1.5	3
1446	Protein KIC5 is a novel regulator of artemisinin stress response in the malaria parasite Plasmodium falciparum. Scientific Reports, 2023, 13, .	1.6	6
1447	Ring stage dormancy of Plasmodium falciparum tolerant to artemisinin and its analogues â€“ A genetically regulated â€œSleeping Beautyâ€• International Journal for Parasitology: Drugs and Drug Resistance, 2023, , .	1.4	0

#	Article	IF	Citations
1448	Urea and Thiourea Derivatives in the Synthesis of Hexaoxaazadispiroalkanecarboxamides. Russian Journal of Organic Chemistry, 2022, 58, 1959-1962.	0.3	0
1449	Short tandem repeat polymorphism in the promoter region of cyclophilin 19B drives its transcriptional upregulation and contributes to drug resistance in the malaria parasite Plasmodium falciparum. PLoS Pathogens, 2023, 19, e1011118.	2.1	2
1450	A Plasmodium falciparum RING Finger E3 Ubiquitin Ligase Modifies the Roles of PfMDR1 and PfCRT in Parasite Drug Responses. Antimicrobial Agents and Chemotherapy, 2023, 67, .	1.4	1
1451	FT-GPI, a highly sensitive and accurate predictor of GPI-anchored proteins, reveals the composition and evolution of the GPI proteome in Plasmodium species. Malaria Journal, 2023, 22, .	0.8	2
1453	Insight into molecular diagnosis for antimalarial drug resistance of Plasmodium falciparum parasites: A review. Acta Tropica, 2023, 241, 106870.	0.9	1
1454	A simple alkali lysis method for Plasmodium falciparum DNA extraction from filter paper blood samples. Molecular and Biochemical Parasitology, 2023, 254, 111557.	0.5	3
1455	Incorporation of Trifluoromethyltriazoline in the Side Chain of 4â€Aminoquinolines: Synthesis and Evaluation as Antiplasmodial Agents. ChemMedChem, 2023, 18, .	1.6	0
1457	Screening for antifolate and artemisinin resistance in Plasmodium falciparum clinical isolates from three hospitals of Eritrea. F1000Research, 0, 10, 628.	0.8	0
1458	Molecular surveillance of Kelch-13 gene in Plasmodium falciparum field isolates from Mayurbhanj District, Odisha, India, and in silico artemisinin-Kelch-13 protein interaction study. Parasitology Research, 2023, 122, 717-727.	0.6	1
1462	Malaria Control by Mass Drug Administration With Artemisinin Plus Piperaquine on Grande Comore Island, Union of Comoros. Open Forum Infectious Diseases, 2023, 10, .	0.4	1
1463	Assessment of artemisinin tolerance in Plasmodium falciparum clinical isolates in children with uncomplicated malaria in Ghana. Malaria Journal, 2023, 22, .	0.8	0
1464	Malaria Molecular Surveillance in the Peruvian Amazon with a Novel Highly Multiplexed Plasmodium falciparum AmpliSeq Assay. Microbiology Spectrum, 2023, 11, .	1.2	12
1465	Monitoring antimalarial drug-resistance markers in Somalia. , 2023, 61, 78-83.		1
1466	Structure-based scoring of anthocyanins and molecular modeling of PfLDH, PfDHODH, and PfDHFR reveal novel potential P. falciparum inhibitors. Informatics in Medicine Unlocked, 2023, 38, 101206.	1.9	5
1467	A world free of malaria: It is time for Africa to actively champion and take leadership of elimination and eradication strategies. African Health Sciences, 2022, 22, 627-640.	0.3	1
1468	EtcPRSMut as a molecular marker of halofuginone resistance in Eimeria tenella and Toxoplasma gondii. IScience, 2023, 26, 106334.	1.9	3
1469	Antimalarial Drug Resistance: Trends, Mechanisms, and Strategies to Combat Antimalarial Resistance. , 2023, , 43-69.		2
1470	Senna occidentalis (L.) Link root extract inhibits Plasmodium growth in vitro and in mice. BMC Complementary Medicine and Therapies, 2023, 23, .	1.2	3

#	Article	IF	Citations
1471	Amodiaquine drug pressure selects nonsynonymous mutations in pantothenate kinase 1, diacylglycerol kinase, and phosphatidylinositol-4 kinase in Plasmodium berghei ANKA. , 0, 5, 28.		0
1472	Lumefantrine pressure selects nonsynonymous mutation in cysteine desulfurase IscS gene in the rodent malaria parasite Plasmodium berghei ANKA. , 0, 5, 27.		0
1473	Novel Plasmodium falciparum k13 gene polymorphisms from Kisii County, Kenya during an era of artemisinin-based combination therapy deployment. Malaria Journal, 2023, 22, .	0.8	1
1474	Examining the Early Distribution of the Artemisinin-Resistant Plasmodium falciparum kelch13 R561H Mutation in Areas of Higher Transmission in Rwanda. Open Forum Infectious Diseases, 2023, 10, .	0.4	9
1475	Derivatives of Amaryllidaceae Alkaloid Ambelline as Selective Inhibitors of Hepatic Stage of Plasmodium berghei Infection In Vitro. Pharmaceutics, 2023, 15, 1007.	2.0	2
1476	Drug Resistance Molecular Markers of Plasmodium falciparum and Severity of Malaria in Febrile Children in the Sentinel Site for Malaria Surveillance of Melen in Gabon: Additional Data from the Plasmodium Diversity Network African Network. Tropical Medicine and Infectious Disease, 2023, 8, 184.	0.9	0
1478	In silico modeling revealed phytomolecules derived from Cymbopogon citratus (DC.) leaf extract as promising candidates for malaria therapy. Journal of Biomolecular Structure and Dynamics, 2024, 42, 101-118.	2.0	3
1479	Rational Design and Lead Optimisation of Potent Antimalarial Quinazolinediones and Their Cytotoxicity against MCF-7. Molecules, 2023, 28, 2999.	1.7	0
1480	Transcriptome profile of halofuginone resistant and sensitive strains of Eimeria tenella. Frontiers in Microbiology, 0, 14, .	1.5	0
1481	Antiplasmodial Activity of Hydroalcoholic Extract from JucÃ¡ (Libidibia ferrea) Pods. Pharmaceutics, 2023, 15, 1162.	2.0	0
1482	A duplex tetra-primer ARMS-PCR assay to discriminate three species of the Schistosoma haematobium group: Schistosoma curassoni, S. bovis, S. haematobium and their hybrids. Parasites and Vectors, 2023, 16, .	1.0	2
1483	Chemogenomic Profiling of a Plasmodium falciparum Transposon Mutant Library Reveals Shared Effects of Dihydroartemisinin and Bortezomib on Lipid Metabolism and Exported Proteins. Microbiology Spectrum, 2023, 11, .	1.2	2
1525	Antimalarial drug discovery: progress and approaches. Nature Reviews Drug Discovery, 2023, 22, 807-826.	21.5	12
1542	Diversities of Various Nanomaterials-Based Vaccines for Healthcare Applications. , 2023, , 1-21.		0
1547	Artemisinin Resistance in Plasmodium falciparum Malaria. Parasitology Research Monographs, 2023, , 267-278.	0.4	0
1568	Recent Advances in the Treatment of Parasitic Diseases: Current Status and Future. , 2023, , 249-286.		0
1569	Plant-Based Vaccines Against Human Parasitic Diseases. , 2023, , 143-156.		0
1597	Emergence, transmission dynamics and mechanisms of artemisinin partial resistance in malaria parasites in Africa. Nature Reviews Microbiology, 0, , .	13.6	0

#	Article	IF	Citations